#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Understanding marijuana’s effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A Pilot Investigation
#Text=Nearly half of patients with schizophrenia (SCZ) have co-occurring cannabis use disorder (CUD), which has been associated with decreased treatment efficacy, increased risk of psychotic relapse, and poor global functioning.
1-1	0-13	Understanding	_	
1-2	14-23	marijuana	_	
1-3	23-24	’	_	
1-4	24-25	s	_	
1-5	26-33	effects	_	
1-6	34-36	on	_	
1-7	37-47	functional	_	
1-8	48-60	connectivity	_	
1-9	61-63	of	_	
1-10	64-67	the	_	
1-11	68-75	default	_	
1-12	76-80	mode	_	
1-13	81-88	network	_	
1-14	89-91	in	_	
1-15	92-100	patients	_	
1-16	101-105	with	_	
1-17	106-119	schizophrenia	_	
1-18	120-123	and	_	
1-19	124-136	co-occurring	_	
1-20	137-145	cannabis	_	
1-21	146-149	use	_	
1-22	150-158	disorder	_	
1-23	158-159	:	_	
1-24	160-161	A	_	
1-25	162-167	Pilot	_	
1-26	168-181	Investigation	_	
1-27	182-188	Nearly	_	
1-28	189-193	half	_	
1-29	194-196	of	_	
1-30	197-205	patients	_	
1-31	206-210	with	_	
1-32	211-224	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-33	225-226	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-34	226-229	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-35	229-230	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[1]	
1-36	231-235	have	_	
1-37	236-248	co-occurring	_	
1-38	249-257	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
1-39	258-261	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
1-40	262-270	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
1-41	271-272	(	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
1-42	272-275	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
1-43	275-276	)	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[2]	
1-44	276-277	,	_	
1-45	278-283	which	_	
1-46	284-287	has	_	
1-47	288-292	been	_	
1-48	293-303	associated	_	
1-49	304-308	with	_	
1-50	309-318	decreased	_	
1-51	319-328	treatment	_	
1-52	329-337	efficacy	_	
1-53	337-338	,	_	
1-54	339-348	increased	_	
1-55	349-353	risk	_	
1-56	354-356	of	_	
1-57	357-366	psychotic	_	
1-58	367-374	relapse	_	
1-59	374-375	,	_	
1-60	376-379	and	_	
1-61	380-384	poor	_	
1-62	385-391	global	_	
1-63	392-403	functioning	_	
1-64	403-404	.	_	

#Text=While reports on the effects of cannabis on cognitive performance in patients with SCZ have been mixed, study of brain networks related to executive function may clarify the relationship between cannabis use and cognition in these dual-diagnosis patients.
2-1	405-410	While	_	
2-2	411-418	reports	_	
2-3	419-421	on	_	
2-4	422-425	the	_	
2-5	426-433	effects	_	
2-6	434-436	of	_	
2-7	437-445	cannabis	_	
2-8	446-448	on	_	
2-9	449-458	cognitive	_	
2-10	459-470	performance	_	
2-11	471-473	in	_	
2-12	474-482	patients	_	
2-13	483-487	with	_	
2-14	488-491	SCZ	_	
2-15	492-496	have	_	
2-16	497-501	been	_	
2-17	502-507	mixed	_	
2-18	507-508	,	_	
2-19	509-514	study	_	
2-20	515-517	of	_	
2-21	518-523	brain	_	
2-22	524-532	networks	_	
2-23	533-540	related	_	
2-24	541-543	to	_	
2-25	544-553	executive	_	
2-26	554-562	function	_	
2-27	563-566	may	_	
2-28	567-574	clarify	_	
2-29	575-578	the	_	
2-30	579-591	relationship	_	
2-31	592-599	between	_	
2-32	600-608	cannabis	_	
2-33	609-612	use	_	
2-34	613-616	and	_	
2-35	617-626	cognition	_	
2-36	627-629	in	_	
2-37	630-635	these	_	
2-38	636-650	dual-diagnosis	_	
2-39	651-659	patients	_	
2-40	659-660	.	_	

#Text=In the present pilot study, patients with SCZ and CUD (n=12) and healthy controls (n=12) completed two functional magnetic resonance imaging (fMRI) resting scans.
3-1	661-663	In	_	
3-2	664-667	the	_	
3-3	668-675	present	_	
3-4	676-681	pilot	_	
3-5	682-687	study	_	
3-6	687-688	,	_	
3-7	689-697	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
3-8	698-702	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
3-9	703-706	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
3-10	707-710	and	_	
3-11	711-714	CUD	_	
3-12	715-716	(	_	
3-13	716-717	n	_	
3-14	717-718	=	_	
3-15	718-720	12	_	
3-16	720-721	)	_	
3-17	722-725	and	_	
3-18	726-733	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-19	734-742	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
3-20	743-744	(	_	
3-21	744-745	n	_	
3-22	745-746	=	_	
3-23	746-748	12	_	
3-24	748-749	)	_	
3-25	750-759	completed	_	
3-26	760-763	two	_	
3-27	764-774	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-28	775-783	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-29	784-793	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-30	794-801	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-31	802-803	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-32	803-807	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-33	807-808	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	
3-34	809-816	resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]	
3-35	817-822	scans	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]	
3-36	822-823	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[5]	

#Text=Prior to the second scan, patients smoked a 3.6% tetrahydrocannabinol (THC) cannabis cigarette or ingested a 15mg delta-9-tetrahydrocannabinol (THC) pill.
4-1	824-829	Prior	_	
4-2	830-832	to	_	
4-3	833-836	the	_	
4-4	837-843	second	_	
4-5	844-848	scan	_	
4-6	848-849	,	_	
4-7	850-858	patients	_	
4-8	859-865	smoked	_	
4-9	866-867	a	_	
4-10	868-872	3.6%	_	
4-11	873-893	tetrahydrocannabinol	_	
4-12	894-895	(	_	
4-13	895-898	THC	_	
4-14	898-899	)	_	
4-15	900-908	cannabis	_	
4-16	909-918	cigarette	_	
4-17	919-921	or	_	
4-18	922-930	ingested	_	
4-19	931-932	a	_	
4-20	933-937	15mg	_	
4-21	938-943	delta	_	
4-22	943-944	-	_	
4-23	944-945	9	_	
4-24	945-946	-	_	
4-25	946-966	tetrahydrocannabinol	_	
4-26	967-968	(	_	
4-27	968-971	THC	_	
4-28	971-972	)	_	
4-29	973-977	pill	_	
4-30	977-978	.	_	

#Text=We used resting-state functional connectivity to examine the default mode network (DMN) during both scans, as connectivity/activity within this network is negatively correlated with connectivity of the network involved in executive control and shows reduced activity during task performance in normal individuals.
5-1	979-981	We	_	
5-2	982-986	used	_	
5-3	987-1000	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[7]	
5-4	1001-1011	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[7]	
5-5	1012-1024	connectivity	_	
5-6	1025-1027	to	_	
5-7	1028-1035	examine	_	
5-8	1036-1039	the	_	
5-9	1040-1047	default	_	
5-10	1048-1052	mode	_	
5-11	1053-1060	network	_	
5-12	1061-1062	(	_	
5-13	1062-1065	DMN	_	
5-14	1065-1066	)	_	
5-15	1067-1073	during	_	
5-16	1074-1078	both	_	
5-17	1079-1084	scans	_	
5-18	1084-1085	,	_	
5-19	1086-1088	as	_	
5-20	1089-1101	connectivity	_	
5-21	1101-1102	/	_	
5-22	1102-1110	activity	_	
5-23	1111-1117	within	_	
5-24	1118-1122	this	_	
5-25	1123-1130	network	_	
5-26	1131-1133	is	_	
5-27	1134-1144	negatively	_	
5-28	1145-1155	correlated	_	
5-29	1156-1160	with	_	
5-30	1161-1173	connectivity	_	
5-31	1174-1176	of	_	
5-32	1177-1180	the	_	
5-33	1181-1188	network	_	
5-34	1189-1197	involved	_	
5-35	1198-1200	in	_	
5-36	1201-1210	executive	_	
5-37	1211-1218	control	_	
5-38	1219-1222	and	_	
5-39	1223-1228	shows	_	
5-40	1229-1236	reduced	_	
5-41	1237-1245	activity	_	
5-42	1246-1252	during	_	
5-43	1253-1257	task	_	
5-44	1258-1269	performance	_	
5-45	1270-1272	in	_	
5-46	1273-1279	normal	_	
5-47	1280-1291	individuals	_	
5-48	1291-1292	.	_	

#Text=At baseline, relative to controls, patients exhibited DMN hyperconnectivity that correlated with positive symptom severity, and reduced anticorrelation between the DMN and the executive control network (ECN).
6-1	1293-1295	At	_	
6-2	1296-1304	baseline	_	
6-3	1304-1305	,	_	
6-4	1306-1314	relative	_	
6-5	1315-1317	to	_	
6-6	1318-1326	controls	_	
6-7	1326-1327	,	_	
6-8	1328-1336	patients	_	
6-9	1337-1346	exhibited	_	
6-10	1347-1350	DMN	_	
6-11	1351-1368	hyperconnectivity	_	
6-12	1369-1373	that	_	
6-13	1374-1384	correlated	_	
6-14	1385-1389	with	_	
6-15	1390-1398	positive	_	
6-16	1399-1406	symptom	_	
6-17	1407-1415	severity	_	
6-18	1415-1416	,	_	
6-19	1417-1420	and	_	
6-20	1421-1428	reduced	_	
6-21	1429-1444	anticorrelation	_	
6-22	1445-1452	between	_	
6-23	1453-1456	the	_	
6-24	1457-1460	DMN	_	
6-25	1461-1464	and	_	
6-26	1465-1468	the	_	
6-27	1469-1478	executive	_	
6-28	1479-1486	control	_	
6-29	1487-1494	network	_	
6-30	1495-1496	(	_	
6-31	1496-1499	ECN	_	
6-32	1499-1500	)	_	
6-33	1500-1501	.	_	

#Text=Cannabinoid administration reduced DMN hyperconnectivity and increased DMN-ECN anticorrelation.
7-1	1502-1513	Cannabinoid	_	
7-2	1514-1528	administration	_	
7-3	1529-1536	reduced	_	
7-4	1537-1540	DMN	_	
7-5	1541-1558	hyperconnectivity	_	
7-6	1559-1562	and	_	
7-7	1563-1572	increased	_	
7-8	1573-1580	DMN-ECN	_	
7-9	1581-1596	anticorrelation	_	
7-10	1596-1597	.	_	

#Text=Moreover, the magnitude of anticorrelation in the controls, and in the patients after cannabinoid administration, positively correlated with WM performance.
8-1	1598-1606	Moreover	_	
8-2	1606-1607	,	_	
8-3	1608-1611	the	_	
8-4	1612-1621	magnitude	_	
8-5	1622-1624	of	_	
8-6	1625-1640	anticorrelation	_	
8-7	1641-1643	in	_	
8-8	1644-1647	the	_	
8-9	1648-1656	controls	_	
8-10	1656-1657	,	_	
8-11	1658-1661	and	_	
8-12	1662-1664	in	_	
8-13	1665-1668	the	_	
8-14	1669-1677	patients	_	
8-15	1678-1683	after	_	
8-16	1684-1695	cannabinoid	_	
8-17	1696-1710	administration	_	
8-18	1710-1711	,	_	
8-19	1712-1722	positively	_	
8-20	1723-1733	correlated	_	
8-21	1734-1738	with	_	
8-22	1739-1741	WM	_	
8-23	1742-1753	performance	_	
8-24	1753-1754	.	_	

#Text=The finding that DMN brain connectivity is plastic may have implications for future pharmacotherapeutic development, as treatment efficacy could be assessed through the ability of therapies to normalize underlying circuit-level dysfunction.
9-1	1755-1758	The	_	
9-2	1759-1766	finding	_	
9-3	1767-1771	that	_	
9-4	1772-1775	DMN	_	
9-5	1776-1781	brain	_	
9-6	1782-1794	connectivity	_	
9-7	1795-1797	is	_	
9-8	1798-1805	plastic	_	
9-9	1806-1809	may	_	
9-10	1810-1814	have	_	
9-11	1815-1827	implications	_	
9-12	1828-1831	for	_	
9-13	1832-1838	future	_	
9-14	1839-1858	pharmacotherapeutic	_	
9-15	1859-1870	development	_	
9-16	1870-1871	,	_	
9-17	1872-1874	as	_	
9-18	1875-1884	treatment	_	
9-19	1885-1893	efficacy	_	
9-20	1894-1899	could	_	
9-21	1900-1902	be	_	
9-22	1903-1911	assessed	_	
9-23	1912-1919	through	_	
9-24	1920-1923	the	_	
9-25	1924-1931	ability	_	
9-26	1932-1934	of	_	
9-27	1935-1944	therapies	_	
9-28	1945-1947	to	_	
9-29	1948-1957	normalize	_	
9-30	1958-1968	underlying	_	
9-31	1969-1982	circuit-level	_	
9-32	1983-1994	dysfunction	_	
9-33	1994-1995	.	_	

#Text=Introduction
#Text=Cannabis is the most commonly used illicit drug in patients with schizophrenia (SCZ), with up to 43% of patients meeting criteria for cannabis use disorder (CUD) as compared to approximately 3% in US general population.
10-1	1996-2008	Introduction	_	
10-2	2009-2017	Cannabis	_	
10-3	2018-2020	is	_	
10-4	2021-2024	the	_	
10-5	2025-2029	most	_	
10-6	2030-2038	commonly	_	
10-7	2039-2043	used	_	
10-8	2044-2051	illicit	_	
10-9	2052-2056	drug	_	
10-10	2057-2059	in	_	
10-11	2060-2068	patients	_	
10-12	2069-2073	with	_	
10-13	2074-2087	schizophrenia	_	
10-14	2088-2089	(	_	
10-15	2089-2092	SCZ	_	
10-16	2092-2093	)	_	
10-17	2093-2094	,	_	
10-18	2095-2099	with	_	
10-19	2100-2102	up	_	
10-20	2103-2105	to	_	
10-21	2106-2109	43%	_	
10-22	2110-2112	of	_	
10-23	2113-2121	patients	_	
10-24	2122-2129	meeting	_	
10-25	2130-2138	criteria	_	
10-26	2139-2142	for	_	
10-27	2143-2151	cannabis	_	
10-28	2152-2155	use	_	
10-29	2156-2164	disorder	_	
10-30	2165-2166	(	_	
10-31	2166-2169	CUD	_	
10-32	2169-2170	)	_	
10-33	2171-2173	as	_	
10-34	2174-2182	compared	_	
10-35	2183-2185	to	_	
10-36	2186-2199	approximately	_	
10-37	2200-2202	3%	_	
10-38	2203-2205	in	_	
10-39	2206-2208	US	_	
10-40	2209-2216	general	_	
10-41	2217-2227	population	_	
10-42	2227-2228	.	_	

#Text=Long-term cannabis use substantially worsens outcomes of patients with SCZ, resulting in symptom exacerbation, increased risk of psychotic relapse, and decreased response to antipsychotic medication.
11-1	2229-2238	Long-term	_	
11-2	2239-2247	cannabis	_	
11-3	2248-2251	use	_	
11-4	2252-2265	substantially	_	
11-5	2266-2273	worsens	_	
11-6	2274-2282	outcomes	_	
11-7	2283-2285	of	_	
11-8	2286-2294	patients	_	
11-9	2295-2299	with	_	
11-10	2300-2303	SCZ	_	
11-11	2303-2304	,	_	
11-12	2305-2314	resulting	_	
11-13	2315-2317	in	_	
11-14	2318-2325	symptom	_	
11-15	2326-2338	exacerbation	_	
11-16	2338-2339	,	_	
11-17	2340-2349	increased	_	
11-18	2350-2354	risk	_	
11-19	2355-2357	of	_	
11-20	2358-2367	psychotic	_	
11-21	2368-2375	relapse	_	
11-22	2375-2376	,	_	
11-23	2377-2380	and	_	
11-24	2381-2390	decreased	_	
11-25	2391-2399	response	_	
11-26	2400-2402	to	_	
11-27	2403-2416	antipsychotic	_	
11-28	2417-2427	medication	_	
11-29	2427-2428	.	_	

#Text=While cannabis use has been associated with detrimental effects on cognition in healthy participants, its effects on cognition in SCZ are debated, and several studies and two meta analyses have shown that cannabis use in schizophrenia is associated with improved cognitive function compared to non-cannabis using patients on measures of working memory, attention, processing speed, and verbal fluency.
12-1	2429-2434	While	_	
12-2	2435-2443	cannabis	_	
12-3	2444-2447	use	_	
12-4	2448-2451	has	_	
12-5	2452-2456	been	_	
12-6	2457-2467	associated	_	
12-7	2468-2472	with	_	
12-8	2473-2484	detrimental	_	
12-9	2485-2492	effects	_	
12-10	2493-2495	on	_	
12-11	2496-2505	cognition	_	
12-12	2506-2508	in	_	
12-13	2509-2516	healthy	_	
12-14	2517-2529	participants	_	
12-15	2529-2530	,	_	
12-16	2531-2534	its	_	
12-17	2535-2542	effects	_	
12-18	2543-2545	on	_	
12-19	2546-2555	cognition	_	
12-20	2556-2558	in	_	
12-21	2559-2562	SCZ	_	
12-22	2563-2566	are	_	
12-23	2567-2574	debated	_	
12-24	2574-2575	,	_	
12-25	2576-2579	and	_	
12-26	2580-2587	several	_	
12-27	2588-2595	studies	_	
12-28	2596-2599	and	_	
12-29	2600-2603	two	_	
12-30	2604-2608	meta	_	
12-31	2609-2617	analyses	_	
12-32	2618-2622	have	_	
12-33	2623-2628	shown	_	
12-34	2629-2633	that	_	
12-35	2634-2642	cannabis	_	
12-36	2643-2646	use	_	
12-37	2647-2649	in	_	
12-38	2650-2663	schizophrenia	_	
12-39	2664-2666	is	_	
12-40	2667-2677	associated	_	
12-41	2678-2682	with	_	
12-42	2683-2691	improved	_	
12-43	2692-2701	cognitive	_	
12-44	2702-2710	function	_	
12-45	2711-2719	compared	_	
12-46	2720-2722	to	_	
12-47	2723-2735	non-cannabis	_	
12-48	2736-2741	using	_	
12-49	2742-2750	patients	_	
12-50	2751-2753	on	_	
12-51	2754-2762	measures	_	
12-52	2763-2765	of	_	
12-53	2766-2773	working	_	
12-54	2774-2780	memory	_	
12-55	2780-2781	,	_	
12-56	2782-2791	attention	_	
12-57	2791-2792	,	_	
12-58	2793-2803	processing	_	
12-59	2804-2809	speed	_	
12-60	2809-2810	,	_	
12-61	2811-2814	and	_	
12-62	2815-2821	verbal	_	
12-63	2822-2829	fluency	_	
12-64	2829-2830	.	_	

#Text=Thus, understanding the basis of cannabis’ effects on the brain in patients with SCZ could potentially lead to new treatments that decrease use and increase cognitive function in these patients.
13-1	2831-2835	Thus	_	
13-2	2835-2836	,	_	
13-3	2837-2850	understanding	_	
13-4	2851-2854	the	_	
13-5	2855-2860	basis	_	
13-6	2861-2863	of	_	
13-7	2864-2872	cannabis	_	
13-8	2872-2873	’	_	
13-9	2874-2881	effects	_	
13-10	2882-2884	on	_	
13-11	2885-2888	the	_	
13-12	2889-2894	brain	_	
13-13	2895-2897	in	_	
13-14	2898-2906	patients	_	
13-15	2907-2911	with	_	
13-16	2912-2915	SCZ	_	
13-17	2916-2921	could	_	
13-18	2922-2933	potentially	_	
13-19	2934-2938	lead	_	
13-20	2939-2941	to	_	
13-21	2942-2945	new	_	
13-22	2946-2956	treatments	_	
13-23	2957-2961	that	_	
13-24	2962-2970	decrease	_	
13-25	2971-2974	use	_	
13-26	2975-2978	and	_	
13-27	2979-2987	increase	_	
13-28	2988-2997	cognitive	_	
13-29	2998-3006	function	_	
13-30	3007-3009	in	_	
13-31	3010-3015	these	_	
13-32	3016-3024	patients	_	
13-33	3024-3025	.	_	

#Text=Resting-state functional connectivity (rs-fc) elucidates the intrinsic functional architecture of the human brain through the examination of positive and negative temporal correlations between different brain regions.
14-1	3026-3039	Resting-state	_	
14-2	3040-3050	functional	_	
14-3	3051-3063	connectivity	_	
14-4	3064-3065	(	_	
14-5	3065-3070	rs-fc	_	
14-6	3070-3071	)	_	
14-7	3072-3082	elucidates	_	
14-8	3083-3086	the	_	
14-9	3087-3096	intrinsic	_	
14-10	3097-3107	functional	_	
14-11	3108-3120	architecture	_	
14-12	3121-3123	of	_	
14-13	3124-3127	the	_	
14-14	3128-3133	human	_	
14-15	3134-3139	brain	_	
14-16	3140-3147	through	_	
14-17	3148-3151	the	_	
14-18	3152-3163	examination	_	
14-19	3164-3166	of	_	
14-20	3167-3175	positive	_	
14-21	3176-3179	and	_	
14-22	3180-3188	negative	_	
14-23	3189-3197	temporal	_	
14-24	3198-3210	correlations	_	
14-25	3211-3218	between	_	
14-26	3219-3228	different	_	
14-27	3229-3234	brain	_	
14-28	3235-3242	regions	_	
14-29	3242-3243	.	_	

#Text=It is a method that is gaining increasing focus for investigating the underlying pathophysiology of clinical disorders because it can be obtained over a short period of time, is not confounded with task performance, and has been shown to be robust and reliable.
15-1	3244-3246	It	_	
15-2	3247-3249	is	_	
15-3	3250-3251	a	_	
15-4	3252-3258	method	_	
15-5	3259-3263	that	_	
15-6	3264-3266	is	_	
15-7	3267-3274	gaining	_	
15-8	3275-3285	increasing	_	
15-9	3286-3291	focus	_	
15-10	3292-3295	for	_	
15-11	3296-3309	investigating	_	
15-12	3310-3313	the	_	
15-13	3314-3324	underlying	_	
15-14	3325-3340	pathophysiology	_	
15-15	3341-3343	of	_	
15-16	3344-3352	clinical	_	
15-17	3353-3362	disorders	_	
15-18	3363-3370	because	_	
15-19	3371-3373	it	_	
15-20	3374-3377	can	_	
15-21	3378-3380	be	_	
15-22	3381-3389	obtained	_	
15-23	3390-3394	over	_	
15-24	3395-3396	a	_	
15-25	3397-3402	short	_	
15-26	3403-3409	period	_	
15-27	3410-3412	of	_	
15-28	3413-3417	time	_	
15-29	3417-3418	,	_	
15-30	3419-3421	is	_	
15-31	3422-3425	not	_	
15-32	3426-3436	confounded	_	
15-33	3437-3441	with	_	
15-34	3442-3446	task	_	
15-35	3447-3458	performance	_	
15-36	3458-3459	,	_	
15-37	3460-3463	and	_	
15-38	3464-3467	has	_	
15-39	3468-3472	been	_	
15-40	3473-3478	shown	_	
15-41	3479-3481	to	_	
15-42	3482-3484	be	_	
15-43	3485-3491	robust	_	
15-44	3492-3495	and	_	
15-45	3496-3504	reliable	_	
15-46	3504-3505	.	_	

#Text=Through detecting functional correlation of blood oxygen level-dependent signals across the brain, rs-fc detects intrinsic functional brain networks.
16-1	3506-3513	Through	_	
16-2	3514-3523	detecting	_	
16-3	3524-3534	functional	_	
16-4	3535-3546	correlation	_	
16-5	3547-3549	of	_	
16-6	3550-3555	blood	_	
16-7	3556-3562	oxygen	_	
16-8	3563-3578	level-dependent	_	
16-9	3579-3586	signals	_	
16-10	3587-3593	across	_	
16-11	3594-3597	the	_	
16-12	3598-3603	brain	_	
16-13	3603-3604	,	_	
16-14	3605-3610	rs-fc	_	
16-15	3611-3618	detects	_	
16-16	3619-3628	intrinsic	_	
16-17	3629-3639	functional	_	
16-18	3640-3645	brain	_	
16-19	3646-3654	networks	_	
16-20	3654-3655	.	_	

#Text=One such network is the default mode network (DMN), which is comprised of brain regions typically more activated during rest than during task performance.
17-1	3656-3659	One	_	
17-2	3660-3664	such	_	
17-3	3665-3672	network	_	
17-4	3673-3675	is	_	
17-5	3676-3679	the	_	
17-6	3680-3687	default	_	
17-7	3688-3692	mode	_	
17-8	3693-3700	network	_	
17-9	3701-3702	(	_	
17-10	3702-3705	DMN	_	
17-11	3705-3706	)	_	
17-12	3706-3707	,	_	
17-13	3708-3713	which	_	
17-14	3714-3716	is	_	
17-15	3717-3726	comprised	_	
17-16	3727-3729	of	_	
17-17	3730-3735	brain	_	
17-18	3736-3743	regions	_	
17-19	3744-3753	typically	_	
17-20	3754-3758	more	_	
17-21	3759-3768	activated	_	
17-22	3769-3775	during	_	
17-23	3776-3780	rest	_	
17-24	3781-3785	than	_	
17-25	3786-3792	during	_	
17-26	3793-3797	task	_	
17-27	3798-3809	performance	_	
17-28	3809-3810	.	_	

#Text=Regions in the DMN also exhibit negative correlations (anticorrelations) with other brain regions that are activated during executive function (e.g., the executive control network [ECN]), including the dorsolateral prefrontal cortex (DLPFC).
18-1	3811-3818	Regions	_	
18-2	3819-3821	in	_	
18-3	3822-3825	the	_	
18-4	3826-3829	DMN	_	
18-5	3830-3834	also	_	
18-6	3835-3842	exhibit	_	
18-7	3843-3851	negative	_	
18-8	3852-3864	correlations	_	
18-9	3865-3866	(	_	
18-10	3866-3882	anticorrelations	_	
18-11	3882-3883	)	_	
18-12	3884-3888	with	_	
18-13	3889-3894	other	_	
18-14	3895-3900	brain	_	
18-15	3901-3908	regions	_	
18-16	3909-3913	that	_	
18-17	3914-3917	are	_	
18-18	3918-3927	activated	_	
18-19	3928-3934	during	_	
18-20	3935-3944	executive	_	
18-21	3945-3953	function	_	
18-22	3954-3955	(	_	
18-23	3955-3958	e.g	_	
18-24	3958-3959	.	_	
18-25	3959-3960	,	_	
18-26	3961-3964	the	_	
18-27	3965-3974	executive	_	
18-28	3975-3982	control	_	
18-29	3983-3990	network	_	
18-30	3991-3992	[	_	
18-31	3992-3995	ECN	_	
18-32	3995-3996	]	_	
18-33	3996-3997	)	_	
18-34	3997-3998	,	_	
18-35	3999-4008	including	_	
18-36	4009-4012	the	_	
18-37	4013-4025	dorsolateral	_	
18-38	4026-4036	prefrontal	_	
18-39	4037-4043	cortex	_	
18-40	4044-4045	(	_	
18-41	4045-4050	DLPFC	_	
18-42	4050-4051	)	_	
18-43	4051-4052	.	_	

#Text=Collectively, we refer to the positive as well as the negative (i.e., anti) correlations of a particular network as ‘functional connectivity.’
19-1	4053-4065	Collectively	_	
19-2	4065-4066	,	_	
19-3	4067-4069	we	_	
19-4	4070-4075	refer	_	
19-5	4076-4078	to	_	
19-6	4079-4082	the	_	
19-7	4083-4091	positive	_	
19-8	4092-4094	as	_	
19-9	4095-4099	well	_	
19-10	4100-4102	as	_	
19-11	4103-4106	the	_	
19-12	4107-4115	negative	_	
19-13	4116-4117	(	_	
19-14	4117-4120	i.e	_	
19-15	4120-4121	.	_	
19-16	4121-4122	,	_	
19-17	4123-4127	anti	_	
19-18	4127-4128	)	_	
19-19	4129-4141	correlations	_	
19-20	4142-4144	of	_	
19-21	4145-4146	a	_	
19-22	4147-4157	particular	_	
19-23	4158-4165	network	_	
19-24	4166-4168	as	_	
19-25	4169-4170	‘	_	
19-26	4170-4180	functional	_	
19-27	4181-4193	connectivity	_	
19-28	4193-4194	.	_	
19-29	4194-4195	’	_	

#Text=Investigating the effects of cannabis on functional connectivity of the DMN may shed light on its interaction with the ECN, as well as on the effects of cannabis use in SCZ.
20-1	4196-4209	Investigating	_	
20-2	4210-4213	the	_	
20-3	4214-4221	effects	_	
20-4	4222-4224	of	_	
20-5	4225-4233	cannabis	_	
20-6	4234-4236	on	_	
20-7	4237-4247	functional	_	
20-8	4248-4260	connectivity	_	
20-9	4261-4263	of	_	
20-10	4264-4267	the	_	
20-11	4268-4271	DMN	_	
20-12	4272-4275	may	_	
20-13	4276-4280	shed	_	
20-14	4281-4286	light	_	
20-15	4287-4289	on	_	
20-16	4290-4293	its	_	
20-17	4294-4305	interaction	_	
20-18	4306-4310	with	_	
20-19	4311-4314	the	_	
20-20	4315-4318	ECN	_	
20-21	4318-4319	,	_	
20-22	4320-4322	as	_	
20-23	4323-4327	well	_	
20-24	4328-4330	as	_	
20-25	4331-4333	on	_	
20-26	4334-4337	the	_	
20-27	4338-4345	effects	_	
20-28	4346-4348	of	_	
20-29	4349-4357	cannabis	_	
20-30	4358-4361	use	_	
20-31	4362-4364	in	_	
20-32	4365-4368	SCZ	_	
20-33	4368-4369	.	_	

#Text=The DMN, which includes the medial prefrontal cortex (MPFC), posterior cingulate cortex (PCC), and inferior parietal lobes (IPL), is associated with spontaneous task-independent mentation.
21-1	4370-4373	The	_	
21-2	4374-4377	DMN	_	
21-3	4377-4378	,	_	
21-4	4379-4384	which	_	
21-5	4385-4393	includes	_	
21-6	4394-4397	the	_	
21-7	4398-4404	medial	_	
21-8	4405-4415	prefrontal	_	
21-9	4416-4422	cortex	_	
21-10	4423-4424	(	_	
21-11	4424-4428	MPFC	_	
21-12	4428-4429	)	_	
21-13	4429-4430	,	_	
21-14	4431-4440	posterior	_	
21-15	4441-4450	cingulate	_	
21-16	4451-4457	cortex	_	
21-17	4458-4459	(	_	
21-18	4459-4462	PCC	_	
21-19	4462-4463	)	_	
21-20	4463-4464	,	_	
21-21	4465-4468	and	_	
21-22	4469-4477	inferior	_	
21-23	4478-4486	parietal	_	
21-24	4487-4492	lobes	_	
21-25	4493-4494	(	_	
21-26	4494-4497	IPL	_	
21-27	4497-4498	)	_	
21-28	4498-4499	,	_	
21-29	4500-4502	is	_	
21-30	4503-4513	associated	_	
21-31	4514-4518	with	_	
21-32	4519-4530	spontaneous	_	
21-33	4531-4547	task-independent	_	
21-34	4548-4557	mentation	_	
21-35	4557-4558	.	_	

#Text=When compared to healthy control participants, patients with SCZ as well as their first-degree relatives demonstrate DMN hyperconnectivity.
22-1	4559-4563	When	_	
22-2	4564-4572	compared	_	
22-3	4573-4575	to	_	
22-4	4576-4583	healthy	_	
22-5	4584-4591	control	_	
22-6	4592-4604	participants	_	
22-7	4604-4605	,	_	
22-8	4606-4614	patients	_	
22-9	4615-4619	with	_	
22-10	4620-4623	SCZ	_	
22-11	4624-4626	as	_	
22-12	4627-4631	well	_	
22-13	4632-4634	as	_	
22-14	4635-4640	their	_	
22-15	4641-4653	first-degree	_	
22-16	4654-4663	relatives	_	
22-17	4664-4675	demonstrate	_	
22-18	4676-4679	DMN	_	
22-19	4680-4697	hyperconnectivity	_	
22-20	4697-4698	.	_	

#Text=Hyperconnectivity of this network has been theorized to result in a blurring of boundaries between internally derived thoughts and external events, thereby contributing to altered perceptions of reality manifesting as the characteristic positive symptoms of SCZ.
23-1	4699-4716	Hyperconnectivity	_	
23-2	4717-4719	of	_	
23-3	4720-4724	this	_	
23-4	4725-4732	network	_	
23-5	4733-4736	has	_	
23-6	4737-4741	been	_	
23-7	4742-4751	theorized	_	
23-8	4752-4754	to	_	
23-9	4755-4761	result	_	
23-10	4762-4764	in	_	
23-11	4765-4766	a	_	
23-12	4767-4775	blurring	_	
23-13	4776-4778	of	_	
23-14	4779-4789	boundaries	_	
23-15	4790-4797	between	_	
23-16	4798-4808	internally	_	
23-17	4809-4816	derived	_	
23-18	4817-4825	thoughts	_	
23-19	4826-4829	and	_	
23-20	4830-4838	external	_	
23-21	4839-4845	events	_	
23-22	4845-4846	,	_	
23-23	4847-4854	thereby	_	
23-24	4855-4867	contributing	_	
23-25	4868-4870	to	_	
23-26	4871-4878	altered	_	
23-27	4879-4890	perceptions	_	
23-28	4891-4893	of	_	
23-29	4894-4901	reality	_	
23-30	4902-4913	manifesting	_	
23-31	4914-4916	as	_	
23-32	4917-4920	the	_	
23-33	4921-4935	characteristic	_	
23-34	4936-4944	positive	_	
23-35	4945-4953	symptoms	_	
23-36	4954-4956	of	_	
23-37	4957-4960	SCZ	_	
23-38	4960-4961	.	_	

#Text=Negative correlation (anticorrelation) of the DMN and the executive control network (ECN), implicated in externally focused goal-oriented attention, is thought to reflect a competitive relationship that underlies the ability to appropriately shift between internally directed thought and externally focused attention.
24-1	4962-4970	Negative	_	
24-2	4971-4982	correlation	_	
24-3	4983-4984	(	_	
24-4	4984-4999	anticorrelation	_	
24-5	4999-5000	)	_	
24-6	5001-5003	of	_	
24-7	5004-5007	the	_	
24-8	5008-5011	DMN	_	
24-9	5012-5015	and	_	
24-10	5016-5019	the	_	
24-11	5020-5029	executive	_	
24-12	5030-5037	control	_	
24-13	5038-5045	network	_	
24-14	5046-5047	(	_	
24-15	5047-5050	ECN	_	
24-16	5050-5051	)	_	
24-17	5051-5052	,	_	
24-18	5053-5063	implicated	_	
24-19	5064-5066	in	_	
24-20	5067-5077	externally	_	
24-21	5078-5085	focused	_	
24-22	5086-5099	goal-oriented	_	
24-23	5100-5109	attention	_	
24-24	5109-5110	,	_	
24-25	5111-5113	is	_	
24-26	5114-5121	thought	_	
24-27	5122-5124	to	_	
24-28	5125-5132	reflect	_	
24-29	5133-5134	a	_	
24-30	5135-5146	competitive	_	
24-31	5147-5159	relationship	_	
24-32	5160-5164	that	_	
24-33	5165-5174	underlies	_	
24-34	5175-5178	the	_	
24-35	5179-5186	ability	_	
24-36	5187-5189	to	_	
24-37	5190-5203	appropriately	_	
24-38	5204-5209	shift	_	
24-39	5210-5217	between	_	
24-40	5218-5228	internally	_	
24-41	5229-5237	directed	_	
24-42	5238-5245	thought	_	
24-43	5246-5249	and	_	
24-44	5250-5260	externally	_	
24-45	5261-5268	focused	_	
24-46	5269-5278	attention	_	
24-47	5278-5279	.	_	

#Text=Chronic as well as first-episode (medication naïve) patients with SCZ, first degree relatives and individuals with high risk for psychosis have shown reduced anticorrelation between the MPFC region of the DMN and the DLPFC component of the ECN.
25-1	5280-5287	Chronic	_	
25-2	5288-5290	as	_	
25-3	5291-5295	well	_	
25-4	5296-5298	as	_	
25-5	5299-5312	first-episode	_	
25-6	5313-5314	(	_	
25-7	5314-5324	medication	_	
25-8	5325-5330	naïve	_	
25-9	5330-5331	)	_	
25-10	5332-5340	patients	_	
25-11	5341-5345	with	_	
25-12	5346-5349	SCZ	_	
25-13	5349-5350	,	_	
25-14	5351-5356	first	_	
25-15	5357-5363	degree	_	
25-16	5364-5373	relatives	_	
25-17	5374-5377	and	_	
25-18	5378-5389	individuals	_	
25-19	5390-5394	with	_	
25-20	5395-5399	high	_	
25-21	5400-5404	risk	_	
25-22	5405-5408	for	_	
25-23	5409-5418	psychosis	_	
25-24	5419-5423	have	_	
25-25	5424-5429	shown	_	
25-26	5430-5437	reduced	_	
25-27	5438-5453	anticorrelation	_	
25-28	5454-5461	between	_	
25-29	5462-5465	the	_	
25-30	5466-5470	MPFC	_	
25-31	5471-5477	region	_	
25-32	5478-5480	of	_	
25-33	5481-5484	the	_	
25-34	5485-5488	DMN	_	
25-35	5489-5492	and	_	
25-36	5493-5496	the	_	
25-37	5497-5502	DLPFC	_	
25-38	5503-5512	component	_	
25-39	5513-5515	of	_	
25-40	5516-5519	the	_	
25-41	5520-5523	ECN	_	
25-42	5523-5524	.	_	

#Text=While its relationship to working memory has not yet been investigated in patients with SCZ, the strength of the anticorrelation between the MPFC and the DLPFC has been shown to directly correlate with working memory performance in healthy controls.
26-1	5525-5530	While	_	
26-2	5531-5534	its	_	
26-3	5535-5547	relationship	_	
26-4	5548-5550	to	_	
26-5	5551-5558	working	_	
26-6	5559-5565	memory	_	
26-7	5566-5569	has	_	
26-8	5570-5573	not	_	
26-9	5574-5577	yet	_	
26-10	5578-5582	been	_	
26-11	5583-5595	investigated	_	
26-12	5596-5598	in	_	
26-13	5599-5607	patients	_	
26-14	5608-5612	with	_	
26-15	5613-5616	SCZ	_	
26-16	5616-5617	,	_	
26-17	5618-5621	the	_	
26-18	5622-5630	strength	_	
26-19	5631-5633	of	_	
26-20	5634-5637	the	_	
26-21	5638-5653	anticorrelation	_	
26-22	5654-5661	between	_	
26-23	5662-5665	the	_	
26-24	5666-5670	MPFC	_	
26-25	5671-5674	and	_	
26-26	5675-5678	the	_	
26-27	5679-5684	DLPFC	_	
26-28	5685-5688	has	_	
26-29	5689-5693	been	_	
26-30	5694-5699	shown	_	
26-31	5700-5702	to	_	
26-32	5703-5711	directly	_	
26-33	5712-5721	correlate	_	
26-34	5722-5726	with	_	
26-35	5727-5734	working	_	
26-36	5735-5741	memory	_	
26-37	5742-5753	performance	_	
26-38	5754-5756	in	_	
26-39	5757-5764	healthy	_	
26-40	5765-5773	controls	_	
26-41	5773-5774	.	_	

#Text=In this pilot study, we assessed resting state functional connectivity of the DMN in patients with SCZ and cannabis use disorder (CUD) relative to healthy controls.
27-1	5775-5777	In	_	
27-2	5778-5782	this	_	
27-3	5783-5788	pilot	_	
27-4	5789-5794	study	_	
27-5	5794-5795	,	_	
27-6	5796-5798	we	_	
27-7	5799-5807	assessed	_	
27-8	5808-5815	resting	_	
27-9	5816-5821	state	_	
27-10	5822-5832	functional	_	
27-11	5833-5845	connectivity	_	
27-12	5846-5848	of	_	
27-13	5849-5852	the	_	
27-14	5853-5856	DMN	_	
27-15	5857-5859	in	_	
27-16	5860-5868	patients	_	
27-17	5869-5873	with	_	
27-18	5874-5877	SCZ	_	
27-19	5878-5881	and	_	
27-20	5882-5890	cannabis	_	
27-21	5891-5894	use	_	
27-22	5895-5903	disorder	_	
27-23	5904-5905	(	_	
27-24	5905-5908	CUD	_	
27-25	5908-5909	)	_	
27-26	5910-5918	relative	_	
27-27	5919-5921	to	_	
27-28	5922-5929	healthy	_	
27-29	5930-5938	controls	_	
27-30	5938-5939	.	_	

#Text=In line with previous findings in non-cannabis using patients with SCZ, we predicted that patients with SCZ and co-occurring CUD would show DMN hyperconnectivity and reduced anticorrelation with regions of the ECN.
28-1	5940-5942	In	_	
28-2	5943-5947	line	_	
28-3	5948-5952	with	_	
28-4	5953-5961	previous	_	
28-5	5962-5970	findings	_	
28-6	5971-5973	in	_	
28-7	5974-5986	non-cannabis	_	
28-8	5987-5992	using	_	
28-9	5993-6001	patients	_	
28-10	6002-6006	with	_	
28-11	6007-6010	SCZ	_	
28-12	6010-6011	,	_	
28-13	6012-6014	we	_	
28-14	6015-6024	predicted	_	
28-15	6025-6029	that	_	
28-16	6030-6038	patients	_	
28-17	6039-6043	with	_	
28-18	6044-6047	SCZ	_	
28-19	6048-6051	and	_	
28-20	6052-6064	co-occurring	_	
28-21	6065-6068	CUD	_	
28-22	6069-6074	would	_	
28-23	6075-6079	show	_	
28-24	6080-6083	DMN	_	
28-25	6084-6101	hyperconnectivity	_	
28-26	6102-6105	and	_	
28-27	6106-6113	reduced	_	
28-28	6114-6129	anticorrelation	_	
28-29	6130-6134	with	_	
28-30	6135-6142	regions	_	
28-31	6143-6145	of	_	
28-32	6146-6149	the	_	
28-33	6150-6153	ECN	_	
28-34	6153-6154	.	_	

#Text=We also explored the effects of cannabinoids, (smoked cannabis and oral delta-9-tetrahydrocannabinol [THC; the primary psychoactive constituent within cannabis]), on functional connectivity of the DMN in these patients.
29-1	6155-6157	We	_	
29-2	6158-6162	also	_	
29-3	6163-6171	explored	_	
29-4	6172-6175	the	_	
29-5	6176-6183	effects	_	
29-6	6184-6186	of	_	
29-7	6187-6199	cannabinoids	_	
29-8	6199-6200	,	_	
29-9	6201-6202	(	_	
29-10	6202-6208	smoked	_	
29-11	6209-6217	cannabis	_	
29-12	6218-6221	and	_	
29-13	6222-6226	oral	_	
29-14	6227-6232	delta	_	
29-15	6232-6233	-	_	
29-16	6233-6234	9	_	
29-17	6234-6235	-	_	
29-18	6235-6255	tetrahydrocannabinol	_	
29-19	6256-6257	[	_	
29-20	6257-6260	THC	_	
29-21	6260-6261	;	_	
29-22	6262-6265	the	_	
29-23	6266-6273	primary	_	
29-24	6274-6286	psychoactive	_	
29-25	6287-6298	constituent	_	
29-26	6299-6305	within	_	
29-27	6306-6314	cannabis	_	
29-28	6314-6315	]	_	
29-29	6315-6316	)	_	
29-30	6316-6317	,	_	
29-31	6318-6320	on	_	
29-32	6321-6331	functional	_	
29-33	6332-6344	connectivity	_	
29-34	6345-6347	of	_	
29-35	6348-6351	the	_	
29-36	6352-6355	DMN	_	
29-37	6356-6358	in	_	
29-38	6359-6364	these	_	
29-39	6365-6373	patients	_	
29-40	6373-6374	.	_	

#Text=We administered both smoked cannabis and oral THC to begin to assess whether THC per se affected the DMN in a manner consistent with that produced by smoked cannabis, given that cannabis has multiple pharmacologically active components in addition to THC.
30-1	6375-6377	We	_	
30-2	6378-6390	administered	_	
30-3	6391-6395	both	_	
30-4	6396-6402	smoked	_	
30-5	6403-6411	cannabis	_	
30-6	6412-6415	and	_	
30-7	6416-6420	oral	_	
30-8	6421-6424	THC	_	
30-9	6425-6427	to	_	
30-10	6428-6433	begin	_	
30-11	6434-6436	to	_	
30-12	6437-6443	assess	_	
30-13	6444-6451	whether	_	
30-14	6452-6455	THC	_	
30-15	6456-6459	per	_	
30-16	6460-6462	se	_	
30-17	6463-6471	affected	_	
30-18	6472-6475	the	_	
30-19	6476-6479	DMN	_	
30-20	6480-6482	in	_	
30-21	6483-6484	a	_	
30-22	6485-6491	manner	_	
30-23	6492-6502	consistent	_	
30-24	6503-6507	with	_	
30-25	6508-6512	that	_	
30-26	6513-6521	produced	_	
30-27	6522-6524	by	_	
30-28	6525-6531	smoked	_	
30-29	6532-6540	cannabis	_	
30-30	6540-6541	,	_	
30-31	6542-6547	given	_	
30-32	6548-6552	that	_	
30-33	6553-6561	cannabis	_	
30-34	6562-6565	has	_	
30-35	6566-6574	multiple	_	
30-36	6575-6592	pharmacologically	_	
30-37	6593-6599	active	_	
30-38	6600-6610	components	_	
30-39	6611-6613	in	_	
30-40	6614-6622	addition	_	
30-41	6623-6625	to	_	
30-42	6626-6629	THC	_	
30-43	6629-6630	.	_	

#Text=Lastly, we assessed the relationship between positive symptom severity and DMN hyperconnectivity, and between working memory performance and the strength of the MPFC-DLPFC anticorrelation in both patients and controls.
31-1	6631-6637	Lastly	_	
31-2	6637-6638	,	_	
31-3	6639-6641	we	_	
31-4	6642-6650	assessed	_	
31-5	6651-6654	the	_	
31-6	6655-6667	relationship	_	
31-7	6668-6675	between	_	
31-8	6676-6684	positive	_	
31-9	6685-6692	symptom	_	
31-10	6693-6701	severity	_	
31-11	6702-6705	and	_	
31-12	6706-6709	DMN	_	
31-13	6710-6727	hyperconnectivity	_	
31-14	6727-6728	,	_	
31-15	6729-6732	and	_	
31-16	6733-6740	between	_	
31-17	6741-6748	working	_	
31-18	6749-6755	memory	_	
31-19	6756-6767	performance	_	
31-20	6768-6771	and	_	
31-21	6772-6775	the	_	
31-22	6776-6784	strength	_	
31-23	6785-6787	of	_	
31-24	6788-6791	the	_	
31-25	6792-6802	MPFC-DLPFC	_	
31-26	6803-6818	anticorrelation	_	
31-27	6819-6821	in	_	
31-28	6822-6826	both	_	
31-29	6827-6835	patients	_	
31-30	6836-6839	and	_	
31-31	6840-6848	controls	_	
31-32	6848-6849	.	_	

#Text=We predicted that positive symptoms in patients would directly correlate with hyperconnectivity of the DMN, and that working memory performance would relate to strength of anticorrelation in controls and in patients after cannabinoid treatment.
32-1	6850-6852	We	_	
32-2	6853-6862	predicted	_	
32-3	6863-6867	that	_	
32-4	6868-6876	positive	_	
32-5	6877-6885	symptoms	_	
32-6	6886-6888	in	_	
32-7	6889-6897	patients	_	
32-8	6898-6903	would	_	
32-9	6904-6912	directly	_	
32-10	6913-6922	correlate	_	
32-11	6923-6927	with	_	
32-12	6928-6945	hyperconnectivity	_	
32-13	6946-6948	of	_	
32-14	6949-6952	the	_	
32-15	6953-6956	DMN	_	
32-16	6956-6957	,	_	
32-17	6958-6961	and	_	
32-18	6962-6966	that	_	
32-19	6967-6974	working	_	
32-20	6975-6981	memory	_	
32-21	6982-6993	performance	_	
32-22	6994-6999	would	_	
32-23	7000-7006	relate	_	
32-24	7007-7009	to	_	
32-25	7010-7018	strength	_	
32-26	7019-7021	of	_	
32-27	7022-7037	anticorrelation	_	
32-28	7038-7040	in	_	
32-29	7041-7049	controls	_	
32-30	7050-7053	and	_	
32-31	7054-7056	in	_	
32-32	7057-7065	patients	_	
32-33	7066-7071	after	_	
32-34	7072-7083	cannabinoid	_	
32-35	7084-7093	treatment	_	
32-36	7093-7094	.	_	

#Text=Experimental Materials and Methods
#Text=Subjects
#Text=Twelve patients with SCZ and CUD and twelve healthy control subjects participated in this study.
33-1	7095-7107	Experimental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
33-2	7108-7117	Materials	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
33-3	7118-7121	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
33-4	7122-7129	Methods	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
33-5	7130-7138	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-6	7139-7145	Twelve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-7	7146-7154	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
33-8	7155-7159	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
33-9	7160-7163	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
33-10	7164-7167	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-11	7168-7171	CUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[12]	
33-12	7172-7175	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-13	7176-7182	twelve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-14	7183-7190	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
33-15	7191-7198	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
33-16	7199-7207	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
33-17	7208-7220	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-18	7221-7223	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-19	7224-7228	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-20	7229-7234	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
33-21	7234-7235	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=As previously described in all patients were recruited from community mental health centers and met criteria for SCZ and CUD, defined as either current cannabis abuse or dependence with use within the past month prior to study enrollment, as determined by the Structured Clinical Interview for DSM-IV-TR (SCID).
34-1	7236-7238	As	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-2	7239-7249	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-3	7250-7259	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-4	7260-7262	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-5	7263-7266	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-6	7267-7275	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-7	7276-7280	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-8	7281-7290	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-9	7291-7295	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-10	7296-7305	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-11	7306-7312	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-12	7313-7319	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-13	7320-7327	centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-14	7328-7331	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-15	7332-7335	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-16	7336-7344	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-17	7345-7348	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-18	7349-7352	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
34-19	7353-7356	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-20	7357-7360	CUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-21	7360-7361	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-22	7362-7369	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-23	7370-7372	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-24	7373-7379	either	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-25	7380-7387	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-26	7388-7396	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-27	7397-7402	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-28	7403-7405	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-29	7406-7416	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-30	7417-7421	with	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-31	7422-7425	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-32	7426-7432	within	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-33	7433-7436	the	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-34	7437-7441	past	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-35	7442-7447	month	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-36	7448-7453	prior	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-37	7454-7456	to	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-38	7457-7462	study	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-39	7463-7473	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
34-40	7473-7474	,	_	
34-41	7475-7477	as	_	
34-42	7478-7488	determined	_	
34-43	7489-7491	by	_	
34-44	7492-7495	the	_	
34-45	7496-7506	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-46	7507-7515	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-47	7516-7525	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-48	7526-7529	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-49	7530-7539	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-50	7540-7541	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-51	7541-7545	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-52	7545-7546	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
34-53	7546-7547	.	_	

#Text=While a history of alcohol or substance use (other than cannabis) was permitted in the patient group, they were required to be alcohol and substance free for a minimum of seven days prior to testing and scanning.
35-1	7548-7553	While	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-2	7554-7555	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-3	7556-7563	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-4	7564-7566	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-5	7567-7574	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-6	7575-7577	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-7	7578-7587	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-8	7588-7591	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-9	7592-7593	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-10	7593-7598	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-11	7599-7603	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-12	7604-7612	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-13	7612-7613	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-14	7614-7617	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-15	7618-7627	permitted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-16	7628-7630	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-17	7631-7634	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-18	7635-7642	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-19	7643-7648	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-20	7648-7649	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-21	7650-7654	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-22	7655-7659	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-23	7660-7668	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-24	7669-7671	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-25	7672-7674	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-26	7675-7682	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-27	7683-7686	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-28	7687-7696	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-29	7697-7701	free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-30	7702-7705	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-31	7706-7707	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-32	7708-7715	minimum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-33	7716-7718	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-34	7719-7724	seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-35	7725-7729	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-36	7730-7735	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-37	7736-7738	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-38	7739-7746	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-39	7747-7750	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-40	7751-7759	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
35-41	7759-7760	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Tobacco users were included in the study, since up to 90% of patients with SCZ smoke cigarettes.
36-1	7761-7768	Tobacco	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-2	7769-7774	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-3	7775-7779	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-4	7780-7788	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-5	7789-7791	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-6	7792-7795	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-7	7796-7801	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-8	7801-7802	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-9	7803-7808	since	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-10	7809-7811	up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-11	7812-7814	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-12	7815-7818	90%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-13	7819-7821	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-14	7822-7830	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-15	7831-7835	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-16	7836-7839	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-17	7840-7845	smoke	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-18	7846-7856	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-19	7856-7857	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=All patients were on a stable dose of antipsychotic medication for a minimum of one month prior to study participation.
37-1	7858-7861	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-2	7862-7870	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-3	7871-7875	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-4	7876-7878	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-5	7879-7880	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-6	7881-7887	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-7	7888-7892	dose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-8	7893-7895	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-9	7896-7909	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-10	7910-7920	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-11	7921-7924	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-12	7925-7926	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-13	7927-7934	minimum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-14	7935-7937	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-15	7938-7941	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-16	7942-7947	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-17	7948-7953	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-18	7954-7956	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-19	7957-7962	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-20	7963-7976	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
37-21	7976-7977	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Patients taking clozapine were excluded given its proposed ability to decrease alcohol and cannabis use in patients with SCZ.
38-1	7978-7986	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-2	7987-7993	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-3	7994-8003	clozapine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-4	8004-8008	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-5	8009-8017	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-6	8018-8023	given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-7	8024-8027	its	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-8	8028-8036	proposed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-9	8037-8044	ability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-10	8045-8047	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-11	8048-8056	decrease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-12	8057-8064	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-13	8065-8068	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-14	8069-8077	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-15	8078-8081	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-16	8082-8084	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-17	8085-8093	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-18	8094-8098	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-19	8099-8102	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
38-20	8102-8103	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=Pharmacotherapies for addiction, mental retardation, a history of head injury, or factors that contraindicate the use of fMRI served as exclusion criteria.
39-1	8104-8121	Pharmacotherapies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-2	8122-8125	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-3	8126-8135	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-4	8135-8136	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-5	8137-8143	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-6	8144-8155	retardation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-7	8155-8156	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-8	8157-8158	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-9	8159-8166	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-10	8167-8169	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-11	8170-8174	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-12	8175-8181	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-13	8181-8182	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-14	8183-8185	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-15	8186-8193	factors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-16	8194-8198	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-17	8199-8213	contraindicate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-18	8214-8217	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-19	8218-8221	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-20	8222-8224	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-21	8225-8229	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-22	8230-8236	served	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-23	8237-8239	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-24	8240-8249	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-25	8250-8258	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
39-26	8258-8259	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=The healthy control group was matched to the patient sample on age, gender and handedness.
40-1	8260-8263	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
40-2	8264-8271	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
40-3	8272-8279	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
40-4	8280-8285	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
40-5	8286-8289	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-6	8290-8297	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-7	8298-8300	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-8	8301-8304	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-9	8305-8312	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-10	8313-8319	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-11	8320-8322	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-12	8323-8326	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-13	8326-8327	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-14	8328-8334	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-15	8335-8338	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-16	8339-8349	handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
40-17	8349-8350	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=In addition to the exclusion criteria noted above, controls were excluded if they had any current or history of Axis I or II disorders, including any substance use disorder.
41-1	8351-8353	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-2	8354-8362	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-3	8363-8365	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-4	8366-8369	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-5	8370-8379	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-6	8380-8388	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-7	8389-8394	noted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-8	8395-8400	above	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-9	8400-8401	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-10	8402-8410	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-11	8411-8415	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-12	8416-8424	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-13	8425-8427	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-14	8428-8432	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-15	8433-8436	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-16	8437-8440	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-17	8441-8448	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-18	8449-8451	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-19	8452-8459	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-20	8460-8462	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-21	8463-8467	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-22	8468-8469	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-23	8470-8472	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-24	8473-8475	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-25	8476-8485	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-26	8485-8486	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-27	8487-8496	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-28	8497-8500	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-29	8501-8510	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-30	8511-8514	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-31	8515-8523	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
41-32	8523-8524	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=A signed informed consent was obtained from participants prior to initiation of the study.
42-1	8525-8526	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-2	8527-8533	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-3	8534-8542	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-4	8543-8550	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-5	8551-8554	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-6	8555-8563	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-7	8564-8568	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-8	8569-8581	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-9	8582-8587	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-10	8588-8590	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-11	8591-8601	initiation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-12	8602-8604	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-13	8605-8608	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-14	8609-8614	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	
42-15	8614-8615	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]	

#Text=The protocol was approved by the Committee for the Protection of Human Subjects (IRB) at Dartmouth College.
43-1	8616-8619	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-2	8620-8628	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-3	8629-8632	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-4	8633-8641	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-5	8642-8644	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-6	8645-8648	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-7	8649-8658	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-8	8659-8662	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-9	8663-8666	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-10	8667-8677	Protection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-11	8678-8680	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-12	8681-8686	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-13	8687-8695	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-14	8696-8697	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-15	8697-8700	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-16	8700-8701	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-17	8702-8704	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-18	8705-8714	Dartmouth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-19	8715-8722	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
43-20	8722-8723	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	

#Text=Further details of the study design were reviewed in.
44-1	8724-8731	Further	_	
44-2	8732-8739	details	_	
44-3	8740-8742	of	_	
44-4	8743-8746	the	_	
44-5	8747-8752	study	_	
44-6	8753-8759	design	_	
44-7	8760-8764	were	_	
44-8	8765-8773	reviewed	_	
44-9	8774-8776	in	_	
44-10	8776-8777	.	_	

#Text=Study Design and Procedure
#Text=Participants refrained from substance use (except for tobacco or caffeine) for the duration of the study.
45-1	8778-8783	Study	http://www.case.edu/ProvCaRe/provcare#StudyMethod[27]	
45-2	8784-8790	Design	http://www.case.edu/ProvCaRe/provcare#StudyMethod[27]	
45-3	8791-8794	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[27]	
45-4	8795-8804	Procedure	http://www.case.edu/ProvCaRe/provcare#StudyMethod[27]	
45-5	8805-8817	Participants	_	
45-6	8818-8827	refrained	_	
45-7	8828-8832	from	_	
45-8	8833-8842	substance	_	
45-9	8843-8846	use	_	
45-10	8847-8848	(	_	
45-11	8848-8854	except	_	
45-12	8855-8858	for	_	
45-13	8859-8866	tobacco	_	
45-14	8867-8869	or	_	
45-15	8870-8878	caffeine	_	
45-16	8878-8879	)	_	
45-17	8880-8883	for	_	
45-18	8884-8887	the	_	
45-19	8888-8896	duration	_	
45-20	8897-8899	of	_	
45-21	8900-8903	the	_	
45-22	8904-8909	study	_	
45-23	8909-8910	.	_	

#Text=Subjects completed a ‘baseline’ session (T1), and then returned one week later for a second scan session (T2) during which patients were randomized to one of two double-blinded cannabinoid intervention groups: an oral THC group (N=6) or an active cannabis cigarette (3.6% THC) group (N=6).
46-1	8911-8919	Subjects	_	
46-2	8920-8929	completed	_	
46-3	8930-8931	a	_	
46-4	8932-8933	‘	_	
46-5	8933-8941	baseline	_	
46-6	8941-8942	’	_	
46-7	8943-8950	session	_	
46-8	8951-8952	(	_	
46-9	8952-8954	T1	_	
46-10	8954-8955	)	_	
46-11	8955-8956	,	_	
46-12	8957-8960	and	_	
46-13	8961-8965	then	_	
46-14	8966-8974	returned	_	
46-15	8975-8978	one	_	
46-16	8979-8983	week	_	
46-17	8984-8989	later	_	
46-18	8990-8993	for	_	
46-19	8994-8995	a	_	
46-20	8996-9002	second	_	
46-21	9003-9007	scan	_	
46-22	9008-9015	session	_	
46-23	9016-9017	(	_	
46-24	9017-9019	T2	_	
46-25	9019-9020	)	_	
46-26	9021-9027	during	_	
46-27	9028-9033	which	_	
46-28	9034-9042	patients	_	
46-29	9043-9047	were	_	
46-30	9048-9058	randomized	_	
46-31	9059-9061	to	_	
46-32	9062-9065	one	_	
46-33	9066-9068	of	_	
46-34	9069-9072	two	_	
46-35	9073-9087	double-blinded	_	
46-36	9088-9099	cannabinoid	_	
46-37	9100-9112	intervention	_	
46-38	9113-9119	groups	_	
46-39	9119-9120	:	_	
46-40	9121-9123	an	_	
46-41	9124-9128	oral	_	
46-42	9129-9132	THC	_	
46-43	9133-9138	group	_	
46-44	9139-9140	(	_	
46-45	9140-9141	N	_	
46-46	9141-9142	=	_	
46-47	9142-9143	6	_	
46-48	9143-9144	)	_	
46-49	9145-9147	or	_	
46-50	9148-9150	an	_	
46-51	9151-9157	active	_	
46-52	9158-9166	cannabis	_	
46-53	9167-9176	cigarette	_	
46-54	9177-9178	(	_	
46-55	9178-9182	3.6%	_	
46-56	9183-9186	THC	_	
46-57	9186-9187	)	_	
46-58	9188-9193	group	_	
46-59	9194-9195	(	_	
46-60	9195-9196	N	_	
46-61	9196-9197	=	_	
46-62	9197-9198	6	_	
46-63	9198-9199	)	_	
46-64	9199-9200	.	_	

#Text=Those in the THC group were given a 15mg THC pill (three hours prior to scanning) and then smoked a placebo cannabis cigarette immediately prior to scanning.
47-1	9201-9206	Those	_	
47-2	9207-9209	in	_	
47-3	9210-9213	the	_	
47-4	9214-9217	THC	_	
47-5	9218-9223	group	_	
47-6	9224-9228	were	_	
47-7	9229-9234	given	_	
47-8	9235-9236	a	_	
47-9	9237-9241	15mg	_	
47-10	9242-9245	THC	_	
47-11	9246-9250	pill	_	
47-12	9251-9252	(	_	
47-13	9252-9257	three	_	
47-14	9258-9263	hours	_	
47-15	9264-9269	prior	_	
47-16	9270-9272	to	_	
47-17	9273-9281	scanning	_	
47-18	9281-9282	)	_	
47-19	9283-9286	and	_	
47-20	9287-9291	then	_	
47-21	9292-9298	smoked	_	
47-22	9299-9300	a	_	
47-23	9301-9308	placebo	_	
47-24	9309-9317	cannabis	_	
47-25	9318-9327	cigarette	_	
47-26	9328-9339	immediately	_	
47-27	9340-9345	prior	_	
47-28	9346-9348	to	_	
47-29	9349-9357	scanning	_	
47-30	9357-9358	.	_	

#Text=Those in the cannabis group were given a placebo pill (3 hours prior to scanning) and then smoked an active 3.6% THC cannabis cigarette immediately before scanning.
48-1	9359-9364	Those	_	
48-2	9365-9367	in	_	
48-3	9368-9371	the	_	
48-4	9372-9380	cannabis	_	
48-5	9381-9386	group	_	
48-6	9387-9391	were	_	
48-7	9392-9397	given	_	
48-8	9398-9399	a	_	
48-9	9400-9407	placebo	_	
48-10	9408-9412	pill	_	
48-11	9413-9414	(	_	
48-12	9414-9415	3	_	
48-13	9416-9421	hours	_	
48-14	9422-9427	prior	_	
48-15	9428-9430	to	_	
48-16	9431-9439	scanning	_	
48-17	9439-9440	)	_	
48-18	9441-9444	and	_	
48-19	9445-9449	then	_	
48-20	9450-9456	smoked	_	
48-21	9457-9459	an	_	
48-22	9460-9466	active	_	
48-23	9467-9471	3.6%	_	
48-24	9472-9475	THC	_	
48-25	9476-9484	cannabis	_	
48-26	9485-9494	cigarette	_	
48-27	9495-9506	immediately	_	
48-28	9507-9513	before	_	
48-29	9514-9522	scanning	_	
48-30	9522-9523	.	_	

#Text=Smoking took place in a smoking chamber within the scanner bay, immediately prior to scanning (Figure 1a).
49-1	9524-9531	Smoking	_	
49-2	9532-9536	took	_	
49-3	9537-9542	place	_	
49-4	9543-9545	in	_	
49-5	9546-9547	a	_	
49-6	9548-9555	smoking	_	
49-7	9556-9563	chamber	_	
49-8	9564-9570	within	_	
49-9	9571-9574	the	_	
49-10	9575-9582	scanner	_	
49-11	9583-9586	bay	_	
49-12	9586-9587	,	_	
49-13	9588-9599	immediately	_	
49-14	9600-9605	prior	_	
49-15	9606-9608	to	_	
49-16	9609-9617	scanning	_	
49-17	9618-9619	(	_	
49-18	9619-9625	Figure	_	
49-19	9626-9628	1a	_	
49-20	9628-9629	)	_	
49-21	9629-9630	.	_	

#Text=Patients who were tobacco smokers were asked to smoke a cigarette 90 minutes prior to scanning, based upon pharmacokinetics of smoked tobacco.
50-1	9631-9639	Patients	_	
50-2	9640-9643	who	_	
50-3	9644-9648	were	_	
50-4	9649-9656	tobacco	_	
50-5	9657-9664	smokers	_	
50-6	9665-9669	were	_	
50-7	9670-9675	asked	_	
50-8	9676-9678	to	_	
50-9	9679-9684	smoke	_	
50-10	9685-9686	a	_	
50-11	9687-9696	cigarette	_	
50-12	9697-9699	90	_	
50-13	9700-9707	minutes	_	
50-14	9708-9713	prior	_	
50-15	9714-9716	to	_	
50-16	9717-9725	scanning	_	
50-17	9725-9726	,	_	
50-18	9727-9732	based	_	
50-19	9733-9737	upon	_	
50-20	9738-9754	pharmacokinetics	_	
50-21	9755-9757	of	_	
50-22	9758-9764	smoked	_	
50-23	9765-9772	tobacco	_	
50-24	9772-9773	.	_	

#Text=Further details can be found in.
51-1	9774-9781	Further	_	
51-2	9782-9789	details	_	
51-3	9790-9793	can	_	
51-4	9794-9796	be	_	
51-5	9797-9802	found	_	
51-6	9803-9805	in	_	
51-7	9805-9806	.	_	

#Text=Healthy control participants followed the same study protocol, but did not receive any pharmacologic intervention during T2.
52-1	9807-9814	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]	
52-2	9815-9822	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]	
52-3	9823-9835	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]	
52-4	9836-9844	followed	_	
52-5	9845-9848	the	_	
52-6	9849-9853	same	_	
52-7	9854-9859	study	_	
52-8	9860-9868	protocol	_	
52-9	9868-9869	,	_	
52-10	9870-9873	but	_	
52-11	9874-9877	did	_	
52-12	9878-9881	not	_	
52-13	9882-9889	receive	_	
52-14	9890-9893	any	_	
52-15	9894-9907	pharmacologic	_	
52-16	9908-9920	intervention	_	
52-17	9921-9927	during	_	
52-18	9928-9930	T2	_	
52-19	9930-9931	.	_	

#Text=In order to assist patients in remaining abstinent from substance use for the duration of the study, they were assessed three times in the week prior to each scan session.
53-1	9932-9934	In	_	
53-2	9935-9940	order	_	
53-3	9941-9943	to	_	
53-4	9944-9950	assist	_	
53-5	9951-9959	patients	_	
53-6	9960-9962	in	_	
53-7	9963-9972	remaining	_	
53-8	9973-9982	abstinent	_	
53-9	9983-9987	from	_	
53-10	9988-9997	substance	_	
53-11	9998-10001	use	_	
53-12	10002-10005	for	_	
53-13	10006-10009	the	_	
53-14	10010-10018	duration	_	
53-15	10019-10021	of	_	
53-16	10022-10025	the	_	
53-17	10026-10031	study	_	
53-18	10031-10032	,	_	
53-19	10033-10037	they	_	
53-20	10038-10042	were	_	
53-21	10043-10051	assessed	_	
53-22	10052-10057	three	_	
53-23	10058-10063	times	_	
53-24	10064-10066	in	_	
53-25	10067-10070	the	_	
53-26	10071-10075	week	_	
53-27	10076-10081	prior	_	
53-28	10082-10084	to	_	
53-29	10085-10089	each	_	
53-30	10090-10094	scan	_	
53-31	10095-10102	session	_	
53-32	10102-10103	.	_	

#Text=Each time, they were screened for substance use with an alcohol breathalyzer, a Timeline Follow-Back interview, and a urine toxicology screen (ToxCup Drug Screen cup; CLIAwaived, Sand Diego, CA).
54-1	10104-10108	Each	_	
54-2	10109-10113	time	_	
54-3	10113-10114	,	_	
54-4	10115-10119	they	_	
54-5	10120-10124	were	_	
54-6	10125-10133	screened	_	
54-7	10134-10137	for	_	
54-8	10138-10147	substance	_	
54-9	10148-10151	use	_	
54-10	10152-10156	with	_	
54-11	10157-10159	an	_	
54-12	10160-10167	alcohol	_	
54-13	10168-10180	breathalyzer	_	
54-14	10180-10181	,	_	
54-15	10182-10183	a	_	
54-16	10184-10192	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[29]	
54-17	10193-10204	Follow-Back	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[29]	
54-18	10205-10214	interview	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[29]	
54-19	10214-10215	,	_	
54-20	10216-10219	and	_	
54-21	10220-10221	a	_	
54-22	10222-10227	urine	_	
54-23	10228-10238	toxicology	_	
54-24	10239-10245	screen	_	
54-25	10246-10247	(	_	
54-26	10247-10253	ToxCup	_	
54-27	10254-10258	Drug	_	
54-28	10259-10265	Screen	_	
54-29	10266-10269	cup	_	
54-30	10269-10270	;	_	
54-31	10271-10281	CLIAwaived	_	
54-32	10281-10282	,	_	
54-33	10283-10287	Sand	_	
54-34	10288-10293	Diego	_	
54-35	10293-10294	,	_	
54-36	10295-10297	CA	_	
54-37	10297-10298	)	_	
54-38	10298-10299	.	_	

#Text=Patients were discontinued from the study if screening suggested substance use during study participation.
55-1	10300-10308	Patients	_	
55-2	10309-10313	were	_	
55-3	10314-10326	discontinued	_	
55-4	10327-10331	from	_	
55-5	10332-10335	the	_	
55-6	10336-10341	study	_	
55-7	10342-10344	if	_	
55-8	10345-10354	screening	_	
55-9	10355-10364	suggested	_	
55-10	10365-10374	substance	_	
55-11	10375-10378	use	_	
55-12	10379-10385	during	_	
55-13	10386-10391	study	_	
55-14	10392-10405	participation	_	
55-15	10405-10406	.	_	

#Text=THC and symptom measures
#Text=Venous blood samples were collected from patients at T1, in the morning of the T2 session, immediately prior to fMRI scanning, and before cognitive testing (Figure 1b).
56-1	10407-10410	THC	_	
56-2	10411-10414	and	_	
56-3	10415-10422	symptom	_	
56-4	10423-10431	measures	_	
56-5	10432-10438	Venous	_	
56-6	10439-10444	blood	_	
56-7	10445-10452	samples	_	
56-8	10453-10457	were	_	
56-9	10458-10467	collected	_	
56-10	10468-10472	from	_	
56-11	10473-10481	patients	_	
56-12	10482-10484	at	_	
56-13	10485-10487	T1	_	
56-14	10487-10488	,	_	
56-15	10489-10491	in	_	
56-16	10492-10495	the	_	
56-17	10496-10503	morning	_	
56-18	10504-10506	of	_	
56-19	10507-10510	the	_	
56-20	10511-10513	T2	_	
56-21	10514-10521	session	_	
56-22	10521-10522	,	_	
56-23	10523-10534	immediately	_	
56-24	10535-10540	prior	_	
56-25	10541-10543	to	_	
56-26	10544-10548	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[30]	
56-27	10549-10557	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[30]	
56-28	10557-10558	,	_	
56-29	10559-10562	and	_	
56-30	10563-10569	before	_	
56-31	10570-10579	cognitive	_	
56-32	10580-10587	testing	_	
56-33	10588-10589	(	_	
56-34	10589-10595	Figure	_	
56-35	10596-10598	1b	_	
56-36	10598-10599	)	_	
56-37	10599-10600	.	_	

#Text=The Marijuana Craving Questionnaire (MCQ), Cannabis Withdrawal Scale (CWS), and Positive and Negative Syndrome Scale (PANSS) were administered to assess for change in marijuana craving, withdrawal, and positive and negative symptoms.
57-1	10601-10604	The	_	
57-2	10605-10614	Marijuana	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[31]	
57-3	10615-10622	Craving	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[31]	
57-4	10623-10636	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[31]	
57-5	10637-10638	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[31]	
57-6	10638-10641	MCQ	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[31]	
57-7	10641-10642	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[31]	
57-8	10642-10643	,	_	
57-9	10644-10652	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[32]	
57-10	10653-10663	Withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[32]	
57-11	10664-10669	Scale	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[32]	
57-12	10670-10671	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[32]	
57-13	10671-10674	CWS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[32]	
57-14	10674-10675	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale[32]	
57-15	10675-10676	,	_	
57-16	10677-10680	and	_	
57-17	10681-10689	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-18	10690-10693	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-19	10694-10702	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-20	10703-10711	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-21	10712-10717	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-22	10718-10719	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-23	10719-10724	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-24	10724-10725	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[33]	
57-25	10726-10730	were	_	
57-26	10731-10743	administered	_	
57-27	10744-10746	to	_	
57-28	10747-10753	assess	_	
57-29	10754-10757	for	_	
57-30	10758-10764	change	_	
57-31	10765-10767	in	_	
57-32	10768-10777	marijuana	_	
57-33	10778-10785	craving	_	
57-34	10785-10786	,	_	
57-35	10787-10797	withdrawal	_	
57-36	10797-10798	,	_	
57-37	10799-10802	and	_	
57-38	10803-10811	positive	_	
57-39	10812-10815	and	_	
57-40	10816-10824	negative	_	
57-41	10825-10833	symptoms	_	
57-42	10833-10834	.	_	

#Text=Change in these measures was analyzed using repeated measures analysis of variance (ANOVA) with group as the between group factor and time as the within-subjects factor, followed by post-hoc analysis using Tukey’s LSD test for pairwise comparisons.
58-1	10835-10841	Change	_	
58-2	10842-10844	in	_	
58-3	10845-10850	these	_	
58-4	10851-10859	measures	_	
58-5	10860-10863	was	_	
58-6	10864-10872	analyzed	_	
58-7	10873-10878	using	_	
58-8	10879-10887	repeated	_	
58-9	10888-10896	measures	_	
58-10	10897-10905	analysis	_	
58-11	10906-10908	of	_	
58-12	10909-10917	variance	_	
58-13	10918-10919	(	_	
58-14	10919-10924	ANOVA	_	
58-15	10924-10925	)	_	
58-16	10926-10930	with	_	
58-17	10931-10936	group	_	
58-18	10937-10939	as	_	
58-19	10940-10943	the	_	
58-20	10944-10951	between	_	
58-21	10952-10957	group	_	
58-22	10958-10964	factor	_	
58-23	10965-10968	and	_	
58-24	10969-10973	time	_	
58-25	10974-10976	as	_	
58-26	10977-10980	the	_	
58-27	10981-10996	within-subjects	_	
58-28	10997-11003	factor	_	
58-29	11003-11004	,	_	
58-30	11005-11013	followed	_	
58-31	11014-11016	by	_	
58-32	11017-11025	post-hoc	_	
58-33	11026-11034	analysis	_	
58-34	11035-11040	using	_	
58-35	11041-11046	Tukey	_	
58-36	11046-11047	’	_	
58-37	11047-11048	s	_	
58-38	11049-11052	LSD	_	
58-39	11053-11057	test	_	
58-40	11058-11061	for	_	
58-41	11062-11070	pairwise	_	
58-42	11071-11082	comparisons	_	
58-43	11082-11083	.	_	

#Text=Working memory performance
#Text=To assess for change in working memory performance induced by cannabis and THC, the Wechsler Adult Intelligence Scale (WAIS) III Letter Number Sequencing Test was administered approximately 30 minutes after the end of the scanning sessions at T1 and T2.
59-1	11084-11091	Working	_	
59-2	11092-11098	memory	_	
59-3	11099-11110	performance	_	
59-4	11111-11113	To	_	
59-5	11114-11120	assess	_	
59-6	11121-11124	for	_	
59-7	11125-11131	change	_	
59-8	11132-11134	in	_	
59-9	11135-11142	working	_	
59-10	11143-11149	memory	_	
59-11	11150-11161	performance	_	
59-12	11162-11169	induced	_	
59-13	11170-11172	by	_	
59-14	11173-11181	cannabis	_	
59-15	11182-11185	and	_	
59-16	11186-11189	THC	_	
59-17	11189-11190	,	_	
59-18	11191-11194	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-19	11195-11203	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-20	11204-11209	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-21	11210-11222	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-22	11223-11228	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-23	11229-11230	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-24	11230-11234	WAIS	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-25	11234-11235	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-26	11236-11239	III	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-27	11240-11246	Letter	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-28	11247-11253	Number	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-29	11254-11264	Sequencing	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-30	11265-11269	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[34]	
59-31	11270-11273	was	_	
59-32	11274-11286	administered	_	
59-33	11287-11300	approximately	_	
59-34	11301-11303	30	_	
59-35	11304-11311	minutes	_	
59-36	11312-11317	after	_	
59-37	11318-11321	the	_	
59-38	11322-11325	end	_	
59-39	11326-11328	of	_	
59-40	11329-11332	the	_	
59-41	11333-11341	scanning	_	
59-42	11342-11350	sessions	_	
59-43	11351-11353	at	_	
59-44	11354-11356	T1	_	
59-45	11357-11360	and	_	
59-46	11361-11363	T2	_	
59-47	11363-11364	.	_	

#Text=This test was selected because of availability of alternate forms and thus its applicability to the repeated-measures study design.
60-1	11365-11369	This	_	
60-2	11370-11374	test	_	
60-3	11375-11378	was	_	
60-4	11379-11387	selected	_	
60-5	11388-11395	because	_	
60-6	11396-11398	of	_	
60-7	11399-11411	availability	_	
60-8	11412-11414	of	_	
60-9	11415-11424	alternate	_	
60-10	11425-11430	forms	_	
60-11	11431-11434	and	_	
60-12	11435-11439	thus	_	
60-13	11440-11443	its	_	
60-14	11444-11457	applicability	_	
60-15	11458-11460	to	_	
60-16	11461-11464	the	_	
60-17	11465-11482	repeated-measures	_	
60-18	11483-11488	study	_	
60-19	11489-11495	design	_	
60-20	11495-11496	.	_	

#Text=The change in WM performance in patients was evaluated with a repeated-measures ANOVA.
61-1	11497-11500	The	_	
61-2	11501-11507	change	_	
61-3	11508-11510	in	_	
61-4	11511-11513	WM	_	
61-5	11514-11525	performance	_	
61-6	11526-11528	in	_	
61-7	11529-11537	patients	_	
61-8	11538-11541	was	_	
61-9	11542-11551	evaluated	_	
61-10	11552-11556	with	_	
61-11	11557-11558	a	_	
61-12	11559-11576	repeated-measures	_	
61-13	11577-11582	ANOVA	_	
61-14	11582-11583	.	_	

#Text=A correlation analysis between WM performance and the magnitude of DMN-ECN anticorrelation was performed between the MPFC component of the DMN and the DLPFC component of the ECN.
#Text=fMRI data acquisition
#Text=fMRI data were obtained using a 3T Phillips Achieva fMRI scanner with an 8 channel head coil.
62-1	11584-11585	A	_	
62-2	11586-11597	correlation	_	
62-3	11598-11606	analysis	_	
62-4	11607-11614	between	_	
62-5	11615-11617	WM	_	
62-6	11618-11629	performance	_	
62-7	11630-11633	and	_	
62-8	11634-11637	the	_	
62-9	11638-11647	magnitude	_	
62-10	11648-11650	of	_	
62-11	11651-11658	DMN-ECN	_	
62-12	11659-11674	anticorrelation	_	
62-13	11675-11678	was	_	
62-14	11679-11688	performed	_	
62-15	11689-11696	between	_	
62-16	11697-11700	the	_	
62-17	11701-11705	MPFC	_	
62-18	11706-11715	component	_	
62-19	11716-11718	of	_	
62-20	11719-11722	the	_	
62-21	11723-11726	DMN	_	
62-22	11727-11730	and	_	
62-23	11731-11734	the	_	
62-24	11735-11740	DLPFC	_	
62-25	11741-11750	component	_	
62-26	11751-11753	of	_	
62-27	11754-11757	the	_	
62-28	11758-11761	ECN	_	
62-29	11761-11762	.	_	
62-30	11763-11767	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
62-31	11768-11772	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
62-32	11773-11784	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
62-33	11785-11789	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
62-34	11790-11794	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
62-35	11795-11799	were	_	
62-36	11800-11808	obtained	_	
62-37	11809-11814	using	_	
62-38	11815-11816	a	_	
62-39	11817-11819	3T	_	
62-40	11820-11828	Phillips	_	
62-41	11829-11836	Achieva	_	
62-42	11837-11841	fMRI	_	
62-43	11842-11849	scanner	_	
62-44	11850-11854	with	_	
62-45	11855-11857	an	_	
62-46	11858-11859	8	_	
62-47	11860-11867	channel	_	
62-48	11868-11872	head	_	
62-49	11873-11877	coil	_	
62-50	11877-11878	.	_	

#Text=Each subject underwent two 8-minute resting scans during the study with eyes open, one at baseline (T1), and the second during the ‘intervention’ session (T2).
63-1	11879-11883	Each	_	
63-2	11884-11891	subject	_	
63-3	11892-11901	underwent	_	
63-4	11902-11905	two	_	
63-5	11906-11907	8	_	
63-6	11907-11908	-	_	
63-7	11908-11914	minute	_	
63-8	11915-11922	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[36]	
63-9	11923-11928	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[36]	
63-10	11929-11935	during	_	
63-11	11936-11939	the	_	
63-12	11940-11945	study	_	
63-13	11946-11950	with	_	
63-14	11951-11955	eyes	_	
63-15	11956-11960	open	_	
63-16	11960-11961	,	_	
63-17	11962-11965	one	_	
63-18	11966-11968	at	_	
63-19	11969-11977	baseline	_	
63-20	11978-11979	(	_	
63-21	11979-11981	T1	_	
63-22	11981-11982	)	_	
63-23	11982-11983	,	_	
63-24	11984-11987	and	_	
63-25	11988-11991	the	_	
63-26	11992-11998	second	_	
63-27	11999-12005	during	_	
63-28	12006-12009	the	_	
63-29	12010-12011	‘	_	
63-30	12011-12023	intervention	_	
63-31	12023-12024	’	_	
63-32	12025-12032	session	_	
63-33	12033-12034	(	_	
63-34	12034-12036	T2	_	
63-35	12036-12037	)	_	
63-36	12037-12038	.	_	

#Text=Further details can be found in.
64-1	12039-12046	Further	_	
64-2	12047-12054	details	_	
64-3	12055-12058	can	_	
64-4	12059-12061	be	_	
64-5	12062-12067	found	_	
64-6	12068-12070	in	_	
64-7	12070-12071	.	_	

#Text=The resting state data were acquired transverse to the AC-PC plane, with a T2*-weighted single shot echo planar imaging (EPI) pulse sequence designed to measure whole brain BOLD contrast with optimal temporal and spatial resolution [repetition time (TR)=2000ms; echo time (TE)=30ms; Flip angle (FA)=90 degrees; field of view (FOV)=240 mm; Slice thickness=2.5 mm; Slice skip 0.5; Slice location=Pat.
65-1	12072-12075	The	_	
65-2	12076-12083	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[37]	
65-3	12084-12089	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[37]	
65-4	12090-12094	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[37]	
65-5	12095-12099	were	_	
65-6	12100-12108	acquired	_	
65-7	12109-12119	transverse	_	
65-8	12120-12122	to	_	
65-9	12123-12126	the	_	
65-10	12127-12132	AC-PC	_	
65-11	12133-12138	plane	_	
65-12	12138-12139	,	_	
65-13	12140-12144	with	_	
65-14	12145-12146	a	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[38]	
65-15	12147-12149	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[38]	
65-16	12149-12150	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[38]	
65-17	12150-12151	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[38]	
65-18	12151-12159	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[38]	
65-19	12160-12166	single	_	
65-20	12167-12171	shot	_	
65-21	12172-12176	echo	_	
65-22	12177-12183	planar	_	
65-23	12184-12191	imaging	_	
65-24	12192-12193	(	_	
65-25	12193-12196	EPI	_	
65-26	12196-12197	)	_	
65-27	12198-12203	pulse	_	
65-28	12204-12212	sequence	_	
65-29	12213-12221	designed	_	
65-30	12222-12224	to	_	
65-31	12225-12232	measure	_	
65-32	12233-12238	whole	_	
65-33	12239-12244	brain	_	
65-34	12245-12249	BOLD	_	
65-35	12250-12258	contrast	_	
65-36	12259-12263	with	_	
65-37	12264-12271	optimal	_	
65-38	12272-12280	temporal	_	
65-39	12281-12284	and	_	
65-40	12285-12292	spatial	_	
65-41	12293-12303	resolution	_	
65-42	12304-12305	[	_	
65-43	12305-12315	repetition	_	
65-44	12316-12320	time	_	
65-45	12321-12322	(	_	
65-46	12322-12324	TR	_	
65-47	12324-12325	)	_	
65-48	12325-12326	=	_	
65-49	12326-12332	2000ms	_	
65-50	12332-12333	;	_	
65-51	12334-12338	echo	_	
65-52	12339-12343	time	_	
65-53	12344-12345	(	_	
65-54	12345-12347	TE	_	
65-55	12347-12348	)	_	
65-56	12348-12349	=	_	
65-57	12349-12353	30ms	_	
65-58	12353-12354	;	_	
65-59	12355-12359	Flip	_	
65-60	12360-12365	angle	_	
65-61	12366-12367	(	_	
65-62	12367-12369	FA	_	
65-63	12369-12370	)	_	
65-64	12370-12371	=	_	
65-65	12371-12373	90	_	
65-66	12374-12381	degrees	_	
65-67	12381-12382	;	_	
65-68	12383-12388	field	_	
65-69	12389-12391	of	_	
65-70	12392-12396	view	_	
65-71	12397-12398	(	_	
65-72	12398-12401	FOV	_	
65-73	12401-12402	)	_	
65-74	12402-12403	=	_	
65-75	12403-12406	240	_	
65-76	12407-12409	mm	_	
65-77	12409-12410	;	_	
65-78	12411-12416	Slice	_	
65-79	12417-12426	thickness	_	
65-80	12426-12427	=	_	
65-81	12427-12430	2.5	_	
65-82	12431-12433	mm	_	
65-83	12433-12434	;	_	
65-84	12435-12440	Slice	_	
65-85	12441-12445	skip	_	
65-86	12446-12449	0.5	_	
65-87	12449-12450	;	_	
65-88	12451-12456	Slice	_	
65-89	12457-12465	location	_	
65-90	12465-12466	=	_	
65-91	12466-12469	Pat	_	
65-92	12469-12470	.	_	

#Text=Spec; Fat saturation=SPIR; Reps=240; NEX=1; yielding 36 contiguous transverse functional images in an 80×80 matrix with an isotropic resolution of 3.0 mm3].
66-1	12471-12475	Spec	_	
66-2	12475-12476	;	_	
66-3	12477-12480	Fat	_	
66-4	12481-12491	saturation	_	
66-5	12491-12492	=	_	
66-6	12492-12496	SPIR	_	
66-7	12496-12497	;	_	
66-8	12498-12502	Reps	_	
66-9	12502-12503	=	_	
66-10	12503-12506	240	_	
66-11	12506-12507	;	_	
66-12	12508-12511	NEX	_	
66-13	12511-12512	=	_	
66-14	12512-12513	1	_	
66-15	12513-12514	;	_	
66-16	12515-12523	yielding	_	
66-17	12524-12526	36	_	
66-18	12527-12537	contiguous	_	
66-19	12538-12548	transverse	_	
66-20	12549-12559	functional	_	
66-21	12560-12566	images	_	
66-22	12567-12569	in	_	
66-23	12570-12572	an	_	
66-24	12573-12575	80	_	
66-25	12575-12576	×	_	
66-26	12576-12578	80	_	
66-27	12579-12585	matrix	_	
66-28	12586-12590	with	_	
66-29	12591-12593	an	_	
66-30	12594-12603	isotropic	_	
66-31	12604-12614	resolution	_	
66-32	12615-12617	of	_	
66-33	12618-12621	3.0	_	
66-34	12622-12625	mm3	_	
66-35	12625-12626	]	_	
66-36	12626-12627	.	_	

#Text=T1-weighted anatomic reference images were acquired in the same planes and thickness immediately following the resting scans.
#Text=fMRI data analysis
#Text=Resting state data were analyzed using a seed driven approach (http://www.nitrc.org/projects/conn).
67-1	12628-12630	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
67-2	12630-12631	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
67-3	12631-12639	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
67-4	12640-12648	anatomic	_	
67-5	12649-12658	reference	_	
67-6	12659-12665	images	_	
67-7	12666-12670	were	_	
67-8	12671-12679	acquired	_	
67-9	12680-12682	in	_	
67-10	12683-12686	the	_	
67-11	12687-12691	same	_	
67-12	12692-12698	planes	_	
67-13	12699-12702	and	_	
67-14	12703-12712	thickness	_	
67-15	12713-12724	immediately	_	
67-16	12725-12734	following	_	
67-17	12735-12738	the	_	
67-18	12739-12746	resting	_	
67-19	12747-12752	scans	_	
67-20	12752-12753	.	_	
67-21	12754-12758	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
67-22	12759-12763	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
67-23	12764-12772	analysis	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
67-24	12773-12780	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[41]	
67-25	12781-12786	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[41]	
67-26	12787-12791	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[41]	
67-27	12792-12796	were	_	
67-28	12797-12805	analyzed	_	
67-29	12806-12811	using	_	
67-30	12812-12813	a	_	
67-31	12814-12818	seed	_	
67-32	12819-12825	driven	_	
67-33	12826-12834	approach	_	
67-34	12835-12836	(	_	
67-35	12836-12840	http	_	
67-36	12840-12841	:	_	
67-37	12841-12842	/	_	
67-38	12842-12843	/	_	
67-39	12843-12856	www.nitrc.org	_	
67-40	12856-12857	/	_	
67-41	12857-12865	projects	_	
67-42	12865-12866	/	_	
67-43	12866-12870	conn	_	
67-44	12870-12871	)	_	
67-45	12871-12872	.	_	

#Text=We used methods that minimize the influence of motion and artifact and that allow for valid identification of correlated and anticorrelated networks.
68-1	12873-12875	We	_	
68-2	12876-12880	used	_	
68-3	12881-12888	methods	_	
68-4	12889-12893	that	_	
68-5	12894-12902	minimize	_	
68-6	12903-12906	the	_	
68-7	12907-12916	influence	_	
68-8	12917-12919	of	_	
68-9	12920-12926	motion	_	
68-10	12927-12930	and	_	
68-11	12931-12939	artifact	_	
68-12	12940-12943	and	_	
68-13	12944-12948	that	_	
68-14	12949-12954	allow	_	
68-15	12955-12958	for	_	
68-16	12959-12964	valid	_	
68-17	12965-12979	identification	_	
68-18	12980-12982	of	_	
68-19	12983-12993	correlated	_	
68-20	12994-12997	and	_	
68-21	12998-13012	anticorrelated	_	
68-22	13013-13021	networks	_	
68-23	13021-13022	.	_	

#Text=Data were slice time corrected, realigned, coregistered, normalized, and spatially smoothed with a 6-mm kernel.
69-1	13023-13027	Data	_	
69-2	13028-13032	were	_	
69-3	13033-13038	slice	_	
69-4	13039-13043	time	_	
69-5	13044-13053	corrected	_	
69-6	13053-13054	,	_	
69-7	13055-13064	realigned	_	
69-8	13064-13065	,	_	
69-9	13066-13078	coregistered	_	
69-10	13078-13079	,	_	
69-11	13080-13090	normalized	_	
69-12	13090-13091	,	_	
69-13	13092-13095	and	_	
69-14	13096-13105	spatially	_	
69-15	13106-13114	smoothed	_	
69-16	13115-13119	with	_	
69-17	13120-13121	a	_	
69-18	13122-13123	6	_	
69-19	13123-13124	-	_	
69-20	13124-13126	mm	_	
69-21	13127-13133	kernel	_	
69-22	13133-13134	.	_	

#Text=To address the spurious correlations in resting-state networks caused by head motion we used quality assurance software Artifact Detection Tools (http://www.nitrc.org/projects/artifact_detect; http://www.nitrc.org/projects/conn) to identify problematic time points during the scan.
70-1	13135-13137	To	_	
70-2	13138-13145	address	_	
70-3	13146-13149	the	_	
70-4	13150-13158	spurious	_	
70-5	13159-13171	correlations	_	
70-6	13172-13174	in	_	
70-7	13175-13188	resting-state	_	
70-8	13189-13197	networks	_	
70-9	13198-13204	caused	_	
70-10	13205-13207	by	_	
70-11	13208-13212	head	_	
70-12	13213-13219	motion	_	
70-13	13220-13222	we	_	
70-14	13223-13227	used	_	
70-15	13228-13235	quality	_	
70-16	13236-13245	assurance	_	
70-17	13246-13254	software	_	
70-18	13255-13263	Artifact	_	
70-19	13264-13273	Detection	_	
70-20	13274-13279	Tools	_	
70-21	13280-13281	(	_	
70-22	13281-13285	http	_	
70-23	13285-13286	:	_	
70-24	13286-13287	/	_	
70-25	13287-13288	/	_	
70-26	13288-13301	www.nitrc.org	_	
70-27	13301-13302	/	_	
70-28	13302-13310	projects	_	
70-29	13310-13311	/	_	
70-30	13311-13326	artifact_detect	_	
70-31	13326-13327	;	_	
70-32	13328-13332	http	_	
70-33	13332-13333	:	_	
70-34	13333-13334	/	_	
70-35	13334-13335	/	_	
70-36	13335-13348	www.nitrc.org	_	
70-37	13348-13349	/	_	
70-38	13349-13357	projects	_	
70-39	13357-13358	/	_	
70-40	13358-13362	conn	_	
70-41	13362-13363	)	_	
70-42	13364-13366	to	_	
70-43	13367-13375	identify	_	
70-44	13376-13387	problematic	_	
70-45	13388-13392	time	_	
70-46	13393-13399	points	_	
70-47	13400-13406	during	_	
70-48	13407-13410	the	_	
70-49	13411-13415	scan	_	
70-50	13415-13416	.	_	

#Text=Specifically, an image was defined as an outlier if the head displacement in x, y, or z direction was greater than .5mm from the previous frame, or if the global mean intensity in the image was greater than 3 standard deviations from the mean image intensity for the entire resting scan.
71-1	13417-13429	Specifically	_	
71-2	13429-13430	,	_	
71-3	13431-13433	an	_	
71-4	13434-13439	image	_	
71-5	13440-13443	was	_	
71-6	13444-13451	defined	_	
71-7	13452-13454	as	_	
71-8	13455-13457	an	_	
71-9	13458-13465	outlier	_	
71-10	13466-13468	if	_	
71-11	13469-13472	the	_	
71-12	13473-13477	head	_	
71-13	13478-13490	displacement	_	
71-14	13491-13493	in	_	
71-15	13494-13495	x	_	
71-16	13495-13496	,	_	
71-17	13497-13498	y	_	
71-18	13498-13499	,	_	
71-19	13500-13502	or	_	
71-20	13503-13504	z	_	
71-21	13505-13514	direction	_	
71-22	13515-13518	was	_	
71-23	13519-13526	greater	_	
71-24	13527-13531	than	_	
71-25	13532-13536	.5mm	_	
71-26	13537-13541	from	_	
71-27	13542-13545	the	_	
71-28	13546-13554	previous	_	
71-29	13555-13560	frame	_	
71-30	13560-13561	,	_	
71-31	13562-13564	or	_	
71-32	13565-13567	if	_	
71-33	13568-13571	the	_	
71-34	13572-13578	global	_	
71-35	13579-13583	mean	_	
71-36	13584-13593	intensity	_	
71-37	13594-13596	in	_	
71-38	13597-13600	the	_	
71-39	13601-13606	image	_	
71-40	13607-13610	was	_	
71-41	13611-13618	greater	_	
71-42	13619-13623	than	_	
71-43	13624-13625	3	_	
71-44	13626-13634	standard	_	
71-45	13635-13645	deviations	_	
71-46	13646-13650	from	_	
71-47	13651-13654	the	_	
71-48	13655-13659	mean	_	
71-49	13660-13665	image	_	
71-50	13666-13675	intensity	_	
71-51	13676-13679	for	_	
71-52	13680-13683	the	_	
71-53	13684-13690	entire	_	
71-54	13691-13698	resting	_	
71-55	13699-13703	scan	_	
71-56	13703-13704	.	_	

#Text=A single regressor for each outlier image was included in the first level general linear model along with motion parameters and first order derivatives.
72-1	13705-13706	A	_	
72-2	13707-13713	single	_	
72-3	13714-13723	regressor	_	
72-4	13724-13727	for	_	
72-5	13728-13732	each	_	
72-6	13733-13740	outlier	_	
72-7	13741-13746	image	_	
72-8	13747-13750	was	_	
72-9	13751-13759	included	_	
72-10	13760-13762	in	_	
72-11	13763-13766	the	_	
72-12	13767-13772	first	_	
72-13	13773-13778	level	_	
72-14	13779-13786	general	_	
72-15	13787-13793	linear	_	
72-16	13794-13799	model	_	
72-17	13800-13805	along	_	
72-18	13806-13810	with	_	
72-19	13811-13817	motion	_	
72-20	13818-13828	parameters	_	
72-21	13829-13832	and	_	
72-22	13833-13838	first	_	
72-23	13839-13844	order	_	
72-24	13845-13856	derivatives	_	
72-25	13856-13857	.	_	

#Text=Physiological and other spurious sources of noise were estimated and regressed using the anatomical CompCor method (aCompCor) as opposed to global signal regression, a widely used preprocessing method known to artificially introduce negative correlations.
73-1	13858-13871	Physiological	_	
73-2	13872-13875	and	_	
73-3	13876-13881	other	_	
73-4	13882-13890	spurious	_	
73-5	13891-13898	sources	_	
73-6	13899-13901	of	_	
73-7	13902-13907	noise	_	
73-8	13908-13912	were	_	
73-9	13913-13922	estimated	_	
73-10	13923-13926	and	_	
73-11	13927-13936	regressed	_	
73-12	13937-13942	using	_	
73-13	13943-13946	the	_	
73-14	13947-13957	anatomical	_	
73-15	13958-13965	CompCor	_	
73-16	13966-13972	method	_	
73-17	13973-13974	(	_	
73-18	13974-13982	aCompCor	_	
73-19	13982-13983	)	_	
73-20	13984-13986	as	_	
73-21	13987-13994	opposed	_	
73-22	13995-13997	to	_	
73-23	13998-14004	global	_	
73-24	14005-14011	signal	_	
73-25	14012-14022	regression	_	
73-26	14022-14023	,	_	
73-27	14024-14025	a	_	
73-28	14026-14032	widely	_	
73-29	14033-14037	used	_	
73-30	14038-14051	preprocessing	_	
73-31	14052-14058	method	_	
73-32	14059-14064	known	_	
73-33	14065-14067	to	_	
73-34	14068-14080	artificially	_	
73-35	14081-14090	introduce	_	
73-36	14091-14099	negative	_	
73-37	14100-14112	correlations	_	
73-38	14112-14113	.	_	

#Text=The anatomical image for each participant was segmented into white matter, grey matter, and cerebrospinal fluid (CSF) masks using SPM8.
74-1	14114-14117	The	_	
74-2	14118-14128	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[42]	
74-3	14129-14134	image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[42]	
74-4	14135-14138	for	_	
74-5	14139-14143	each	_	
74-6	14144-14155	participant	_	
74-7	14156-14159	was	_	
74-8	14160-14169	segmented	_	
74-9	14170-14174	into	_	
74-10	14175-14180	white	_	
74-11	14181-14187	matter	_	
74-12	14187-14188	,	_	
74-13	14189-14193	grey	_	
74-14	14194-14200	matter	_	
74-15	14200-14201	,	_	
74-16	14202-14205	and	_	
74-17	14206-14219	cerebrospinal	_	
74-18	14220-14225	fluid	_	
74-19	14226-14227	(	_	
74-20	14227-14230	CSF	_	
74-21	14230-14231	)	_	
74-22	14232-14237	masks	_	
74-23	14238-14243	using	_	
74-24	14244-14248	SPM8	_	
74-25	14248-14249	.	_	

#Text=To minimize partial voluming with grey matter, the white matter and CSF masks were eroded by one voxel, which resulted in substantially smaller masks than the original segmentations.
75-1	14250-14252	To	_	
75-2	14253-14261	minimize	_	
75-3	14262-14269	partial	_	
75-4	14270-14278	voluming	_	
75-5	14279-14283	with	_	
75-6	14284-14288	grey	_	
75-7	14289-14295	matter	_	
75-8	14295-14296	,	_	
75-9	14297-14300	the	_	
75-10	14301-14306	white	_	
75-11	14307-14313	matter	_	
75-12	14314-14317	and	_	
75-13	14318-14321	CSF	_	
75-14	14322-14327	masks	_	
75-15	14328-14332	were	_	
75-16	14333-14339	eroded	_	
75-17	14340-14342	by	_	
75-18	14343-14346	one	_	
75-19	14347-14352	voxel	_	
75-20	14352-14353	,	_	
75-21	14354-14359	which	_	
75-22	14360-14368	resulted	_	
75-23	14369-14371	in	_	
75-24	14372-14385	substantially	_	
75-25	14386-14393	smaller	_	
75-26	14394-14399	masks	_	
75-27	14400-14404	than	_	
75-28	14405-14408	the	_	
75-29	14409-14417	original	_	
75-30	14418-14431	segmentations	_	
75-31	14431-14432	.	_	

#Text=The eroded white matter and CSF masks were then used as noise regions of interest (ROI).
76-1	14433-14436	The	_	
76-2	14437-14443	eroded	_	
76-3	14444-14449	white	_	
76-4	14450-14456	matter	_	
76-5	14457-14460	and	_	
76-6	14461-14464	CSF	_	
76-7	14465-14470	masks	_	
76-8	14471-14475	were	_	
76-9	14476-14480	then	_	
76-10	14481-14485	used	_	
76-11	14486-14488	as	_	
76-12	14489-14494	noise	_	
76-13	14495-14502	regions	_	
76-14	14503-14505	of	_	
76-15	14506-14514	interest	_	
76-16	14515-14516	(	_	
76-17	14516-14519	ROI	_	
76-18	14519-14520	)	_	
76-19	14520-14521	.	_	

#Text=Signals from the white matter and CSF noise ROIs were extracted from the unsmoothed functional volumes to avoid additional risk of contaminating white matter and CSF signals with grey matter signals.
77-1	14522-14529	Signals	_	
77-2	14530-14534	from	_	
77-3	14535-14538	the	_	
77-4	14539-14544	white	_	
77-5	14545-14551	matter	_	
77-6	14552-14555	and	_	
77-7	14556-14559	CSF	_	
77-8	14560-14565	noise	_	
77-9	14566-14570	ROIs	_	
77-10	14571-14575	were	_	
77-11	14576-14585	extracted	_	
77-12	14586-14590	from	_	
77-13	14591-14594	the	_	
77-14	14595-14605	unsmoothed	_	
77-15	14606-14616	functional	_	
77-16	14617-14624	volumes	_	
77-17	14625-14627	to	_	
77-18	14628-14633	avoid	_	
77-19	14634-14644	additional	_	
77-20	14645-14649	risk	_	
77-21	14650-14652	of	_	
77-22	14653-14666	contaminating	_	
77-23	14667-14672	white	_	
77-24	14673-14679	matter	_	
77-25	14680-14683	and	_	
77-26	14684-14687	CSF	_	
77-27	14688-14695	signals	_	
77-28	14696-14700	with	_	
77-29	14701-14705	grey	_	
77-30	14706-14712	matter	_	
77-31	14713-14720	signals	_	
77-32	14720-14721	.	_	

#Text=Previous results showed that aCompCor signals were considerably different from the global signal, as regressing higher order principal components of the global signal diminished both positive and negative correlations whereas regressing aCompCor signals resulted in stronger anticorrelations and eliminated spurious correlations.
78-1	14722-14730	Previous	_	
78-2	14731-14738	results	_	
78-3	14739-14745	showed	_	
78-4	14746-14750	that	_	
78-5	14751-14759	aCompCor	_	
78-6	14760-14767	signals	_	
78-7	14768-14772	were	_	
78-8	14773-14785	considerably	_	
78-9	14786-14795	different	_	
78-10	14796-14800	from	_	
78-11	14801-14804	the	_	
78-12	14805-14811	global	_	
78-13	14812-14818	signal	_	
78-14	14818-14819	,	_	
78-15	14820-14822	as	_	
78-16	14823-14833	regressing	_	
78-17	14834-14840	higher	_	
78-18	14841-14846	order	_	
78-19	14847-14856	principal	_	
78-20	14857-14867	components	_	
78-21	14868-14870	of	_	
78-22	14871-14874	the	_	
78-23	14875-14881	global	_	
78-24	14882-14888	signal	_	
78-25	14889-14899	diminished	_	
78-26	14900-14904	both	_	
78-27	14905-14913	positive	_	
78-28	14914-14917	and	_	
78-29	14918-14926	negative	_	
78-30	14927-14939	correlations	_	
78-31	14940-14947	whereas	_	
78-32	14948-14958	regressing	_	
78-33	14959-14967	aCompCor	_	
78-34	14968-14975	signals	_	
78-35	14976-14984	resulted	_	
78-36	14985-14987	in	_	
78-37	14988-14996	stronger	_	
78-38	14997-15013	anticorrelations	_	
78-39	15014-15017	and	_	
78-40	15018-15028	eliminated	_	
78-41	15029-15037	spurious	_	
78-42	15038-15050	correlations	_	
78-43	15050-15051	.	_	

#Text=Based on previous results, five principal components of the signals from white matter and CSF noise ROIs were removed with regression.
79-1	15052-15057	Based	_	
79-2	15058-15060	on	_	
79-3	15061-15069	previous	_	
79-4	15070-15077	results	_	
79-5	15077-15078	,	_	
79-6	15079-15083	five	_	
79-7	15084-15093	principal	_	
79-8	15094-15104	components	_	
79-9	15105-15107	of	_	
79-10	15108-15111	the	_	
79-11	15112-15119	signals	_	
79-12	15120-15124	from	_	
79-13	15125-15130	white	_	
79-14	15131-15137	matter	_	
79-15	15138-15141	and	_	
79-16	15142-15145	CSF	_	
79-17	15146-15151	noise	_	
79-18	15152-15156	ROIs	_	
79-19	15157-15161	were	_	
79-20	15162-15169	removed	_	
79-21	15170-15174	with	_	
79-22	15175-15185	regression	_	
79-23	15185-15186	.	_	

#Text=A temporal band-pass filter of 0.009 Hz to 0.08 Hz was applied to the time series.
80-1	15187-15188	A	_	
80-2	15189-15197	temporal	_	
80-3	15198-15207	band-pass	_	
80-4	15208-15214	filter	_	
80-5	15215-15217	of	_	
80-6	15218-15223	0.009	_	
80-7	15224-15226	Hz	_	
80-8	15227-15229	to	_	
80-9	15230-15234	0.08	_	
80-10	15235-15237	Hz	_	
80-11	15238-15241	was	_	
80-12	15242-15249	applied	_	
80-13	15250-15252	to	_	
80-14	15253-15256	the	_	
80-15	15257-15261	time	_	
80-16	15262-15268	series	_	
80-17	15268-15269	.	_	

#Text=The residual BOLD time-series was band-pass filtered over a low-frequency window of interest (0.009Hz<f<0.08Hz).
81-1	15270-15273	The	_	
81-2	15274-15282	residual	_	
81-3	15283-15287	BOLD	_	
81-4	15288-15299	time-series	_	
81-5	15300-15303	was	_	
81-6	15304-15313	band-pass	_	
81-7	15314-15322	filtered	_	
81-8	15323-15327	over	_	
81-9	15328-15329	a	_	
81-10	15330-15343	low-frequency	_	
81-11	15344-15350	window	_	
81-12	15351-15353	of	_	
81-13	15354-15362	interest	_	
81-14	15363-15364	(	_	
81-15	15364-15371	0.009Hz	_	
81-16	15371-15372	<	_	
81-17	15372-15373	f	_	
81-18	15373-15374	<	_	
81-19	15374-15380	0.08Hz	_	
81-20	15380-15381	)	_	
81-21	15381-15382	.	_	

#Text=Correlation maps were produced by extracting the residual BOLD time course from seed regions based on the literature.
82-1	15383-15394	Correlation	_	
82-2	15395-15399	maps	_	
82-3	15400-15404	were	_	
82-4	15405-15413	produced	_	
82-5	15414-15416	by	_	
82-6	15417-15427	extracting	_	
82-7	15428-15431	the	_	
82-8	15432-15440	residual	_	
82-9	15441-15445	BOLD	_	
82-10	15446-15450	time	_	
82-11	15451-15457	course	_	
82-12	15458-15462	from	_	
82-13	15463-15467	seed	_	
82-14	15468-15475	regions	_	
82-15	15476-15481	based	_	
82-16	15482-15484	on	_	
82-17	15485-15488	the	_	
82-18	15489-15499	literature	_	
82-19	15499-15500	.	_	

#Text=The DMN seed was defined using a 10 mm sphere around peak MPFC coordinates, as specified in.
83-1	15501-15504	The	_	
83-2	15505-15508	DMN	_	
83-3	15509-15513	seed	_	
83-4	15514-15517	was	_	
83-5	15518-15525	defined	_	
83-6	15526-15531	using	_	
83-7	15532-15533	a	_	
83-8	15534-15536	10	_	
83-9	15537-15539	mm	_	
83-10	15540-15546	sphere	_	
83-11	15547-15553	around	_	
83-12	15554-15558	peak	_	
83-13	15559-15563	MPFC	_	
83-14	15564-15575	coordinates	_	
83-15	15575-15576	,	_	
83-16	15577-15579	as	_	
83-17	15580-15589	specified	_	
83-18	15590-15592	in	_	
83-19	15592-15593	.	_	

#Text=Pearson’s correlation coefficients were then calculated between the DMN time course and the time course of all other voxels in the brain.
84-1	15594-15601	Pearson	_	
84-2	15601-15602	’	_	
84-3	15602-15603	s	_	
84-4	15604-15615	correlation	_	
84-5	15616-15628	coefficients	_	
84-6	15629-15633	were	_	
84-7	15634-15638	then	_	
84-8	15639-15649	calculated	_	
84-9	15650-15657	between	_	
84-10	15658-15661	the	_	
84-11	15662-15665	DMN	_	
84-12	15666-15670	time	_	
84-13	15671-15677	course	_	
84-14	15678-15681	and	_	
84-15	15682-15685	the	_	
84-16	15686-15690	time	_	
84-17	15691-15697	course	_	
84-18	15698-15700	of	_	
84-19	15701-15704	all	_	
84-20	15705-15710	other	_	
84-21	15711-15717	voxels	_	
84-22	15718-15720	in	_	
84-23	15721-15724	the	_	
84-24	15725-15730	brain	_	
84-25	15730-15731	.	_	

#Text=Correlation coefficients were converted to normally distributed scores using Fisher’s transformation to allow for second-level General Linear Model analyses.
85-1	15732-15743	Correlation	_	
85-2	15744-15756	coefficients	_	
85-3	15757-15761	were	_	
85-4	15762-15771	converted	_	
85-5	15772-15774	to	_	
85-6	15775-15783	normally	_	
85-7	15784-15795	distributed	_	
85-8	15796-15802	scores	_	
85-9	15803-15808	using	_	
85-10	15809-15815	Fisher	_	
85-11	15815-15816	’	_	
85-12	15816-15817	s	_	
85-13	15818-15832	transformation	_	
85-14	15833-15835	to	_	
85-15	15836-15841	allow	_	
85-16	15842-15845	for	_	
85-17	15846-15858	second-level	_	
85-18	15859-15866	General	_	
85-19	15867-15873	Linear	_	
85-20	15874-15879	Model	_	
85-21	15880-15888	analyses	_	
85-22	15888-15889	.	_	

#Text=Second-level within-group (one sample t-tests) and between group (ANOVA) analyses were performed on the Z-maps from the MPFC.
86-1	15890-15902	Second-level	_	
86-2	15903-15915	within-group	_	
86-3	15916-15917	(	_	
86-4	15917-15920	one	_	
86-5	15921-15927	sample	_	
86-6	15928-15935	t-tests	_	
86-7	15935-15936	)	_	
86-8	15937-15940	and	_	
86-9	15941-15948	between	_	
86-10	15949-15954	group	_	
86-11	15955-15956	(	_	
86-12	15956-15961	ANOVA	_	
86-13	15961-15962	)	_	
86-14	15963-15971	analyses	_	
86-15	15972-15976	were	_	
86-16	15977-15986	performed	_	
86-17	15987-15989	on	_	
86-18	15990-15993	the	_	
86-19	15994-16000	Z-maps	_	
86-20	16001-16005	from	_	
86-21	16006-16009	the	_	
86-22	16010-16014	MPFC	_	
86-23	16014-16015	.	_	

#Text=Correction for multiple comparisons on analyses were implemented with an FDR correction of p < 0.001.
87-1	16016-16026	Correction	_	
87-2	16027-16030	for	_	
87-3	16031-16039	multiple	_	
87-4	16040-16051	comparisons	_	
87-5	16052-16054	on	_	
87-6	16055-16063	analyses	_	
87-7	16064-16068	were	_	
87-8	16069-16080	implemented	_	
87-9	16081-16085	with	_	
87-10	16086-16088	an	_	
87-11	16089-16092	FDR	_	
87-12	16093-16103	correction	_	
87-13	16104-16106	of	_	
87-14	16107-16108	p	_	
87-15	16109-16110	<	_	
87-16	16111-16116	0.001	_	
87-17	16116-16117	.	_	

#Text=Results
#Text=Demographics
#Text=Participant demographic information is summarized in Table 1.
88-1	16118-16125	Results	_	
88-2	16126-16138	Demographics	_	
88-3	16139-16150	Participant	_	
88-4	16151-16162	demographic	_	
88-5	16163-16174	information	_	
88-6	16175-16177	is	_	
88-7	16178-16188	summarized	_	
88-8	16189-16191	in	_	
88-9	16192-16197	Table	_	
88-10	16198-16199	1	_	
88-11	16199-16200	.	_	

#Text=There were no significant group differences with respect to age [t (21) = −0.87, p = 0.39], gender [ҳ2 (1) = 0.1, p = 0.75], handedness [ҳ2 (1) = 0.1, p = 0.75], or ethnicity.
89-1	16201-16206	There	_	
89-2	16207-16211	were	_	
89-3	16212-16214	no	_	
89-4	16215-16226	significant	_	
89-5	16227-16232	group	_	
89-6	16233-16244	differences	_	
89-7	16245-16249	with	_	
89-8	16250-16257	respect	_	
89-9	16258-16260	to	_	
89-10	16261-16264	age	_	
89-11	16265-16266	[	_	
89-12	16266-16267	t	_	
89-13	16268-16269	(	_	
89-14	16269-16271	21	_	
89-15	16271-16272	)	_	
89-16	16273-16274	=	_	
89-17	16275-16276	−	_	
89-18	16276-16280	0.87	_	
89-19	16280-16281	,	_	
89-20	16282-16283	p	_	
89-21	16284-16285	=	_	
89-22	16286-16290	0.39	_	
89-23	16290-16291	]	_	
89-24	16291-16292	,	_	
89-25	16293-16299	gender	_	
89-26	16300-16301	[	_	
89-27	16301-16303	ҳ2	_	
89-28	16304-16305	(	_	
89-29	16305-16306	1	_	
89-30	16306-16307	)	_	
89-31	16308-16309	=	_	
89-32	16310-16313	0.1	_	
89-33	16313-16314	,	_	
89-34	16315-16316	p	_	
89-35	16317-16318	=	_	
89-36	16319-16323	0.75	_	
89-37	16323-16324	]	_	
89-38	16324-16325	,	_	
89-39	16326-16336	handedness	_	
89-40	16337-16338	[	_	
89-41	16338-16340	ҳ2	_	
89-42	16341-16342	(	_	
89-43	16342-16343	1	_	
89-44	16343-16344	)	_	
89-45	16345-16346	=	_	
89-46	16347-16350	0.1	_	
89-47	16350-16351	,	_	
89-48	16352-16353	p	_	
89-49	16354-16355	=	_	
89-50	16356-16360	0.75	_	
89-51	16360-16361	]	_	
89-52	16361-16362	,	_	
89-53	16363-16365	or	_	
89-54	16366-16375	ethnicity	_	
89-55	16375-16376	.	_	

#Text=Controls had significantly more years of education [t (21) = 6.98, p<0.01), but there was no significant difference in mean parental education (t (19) = 0.16, p = 0.87).
90-1	16377-16385	Controls	_	
90-2	16386-16389	had	_	
90-3	16390-16403	significantly	_	
90-4	16404-16408	more	_	
90-5	16409-16414	years	_	
90-6	16415-16417	of	_	
90-7	16418-16427	education	_	
90-8	16428-16429	[	_	
90-9	16429-16430	t	_	
90-10	16431-16432	(	_	
90-11	16432-16434	21	_	
90-12	16434-16435	)	_	
90-13	16436-16437	=	_	
90-14	16438-16442	6.98	_	
90-15	16442-16443	,	_	
90-16	16444-16445	p	_	
90-17	16445-16446	<	_	
90-18	16446-16450	0.01	_	
90-19	16450-16451	)	_	
90-20	16451-16452	,	_	
90-21	16453-16456	but	_	
90-22	16457-16462	there	_	
90-23	16463-16466	was	_	
90-24	16467-16469	no	_	
90-25	16470-16481	significant	_	
90-26	16482-16492	difference	_	
90-27	16493-16495	in	_	
90-28	16496-16500	mean	_	
90-29	16501-16509	parental	_	
90-30	16510-16519	education	_	
90-31	16520-16521	(	_	
90-32	16521-16522	t	_	
90-33	16523-16524	(	_	
90-34	16524-16526	19	_	
90-35	16526-16527	)	_	
90-36	16528-16529	=	_	
90-37	16530-16534	0.16	_	
90-38	16534-16535	,	_	
90-39	16536-16537	p	_	
90-40	16538-16539	=	_	
90-41	16540-16544	0.87	_	
90-42	16544-16545	)	_	
90-43	16545-16546	.	_	

#Text=All patients met criteria for current diagnosis of CUD, which included both cannabis abuse (n=2) and dependence (n=10), with an average use of 1.8 ± 1.2 joints per week.
91-1	16547-16550	All	_	
91-2	16551-16559	patients	_	
91-3	16560-16563	met	_	
91-4	16564-16572	criteria	_	
91-5	16573-16576	for	_	
91-6	16577-16584	current	_	
91-7	16585-16594	diagnosis	_	
91-8	16595-16597	of	_	
91-9	16598-16601	CUD	_	
91-10	16601-16602	,	_	
91-11	16603-16608	which	_	
91-12	16609-16617	included	_	
91-13	16618-16622	both	_	
91-14	16623-16631	cannabis	_	
91-15	16632-16637	abuse	_	
91-16	16638-16639	(	_	
91-17	16639-16640	n	_	
91-18	16640-16641	=	_	
91-19	16641-16642	2	_	
91-20	16642-16643	)	_	
91-21	16644-16647	and	_	
91-22	16648-16658	dependence	_	
91-23	16659-16660	(	_	
91-24	16660-16661	n	_	
91-25	16661-16662	=	_	
91-26	16662-16664	10	_	
91-27	16664-16665	)	_	
91-28	16665-16666	,	_	
91-29	16667-16671	with	_	
91-30	16672-16674	an	_	
91-31	16675-16682	average	_	
91-32	16683-16686	use	_	
91-33	16687-16689	of	_	
91-34	16690-16693	1.8	_	
91-35	16694-16695	±	_	
91-36	16696-16699	1.2	_	
91-37	16700-16706	joints	_	
91-38	16707-16710	per	_	
91-39	16711-16715	week	_	
91-40	16715-16716	.	_	

#Text=All except one patient smoked tobacco cigarettes (average use of 18.15 ± 10.7 cigarettes per day).
92-1	16717-16720	All	_	
92-2	16721-16727	except	_	
92-3	16728-16731	one	_	
92-4	16732-16739	patient	_	
92-5	16740-16746	smoked	_	
92-6	16747-16754	tobacco	_	
92-7	16755-16765	cigarettes	_	
92-8	16766-16767	(	_	
92-9	16767-16774	average	_	
92-10	16775-16778	use	_	
92-11	16779-16781	of	_	
92-12	16782-16787	18.15	_	
92-13	16788-16789	±	_	
92-14	16790-16794	10.7	_	
92-15	16795-16805	cigarettes	_	
92-16	16806-16809	per	_	
92-17	16810-16813	day	_	
92-18	16813-16814	)	_	
92-19	16814-16815	.	_	

#Text=The cannabis and THC patient subgroups did not significantly differ with respect to cannabis use, tobacco use, or any of the demographic variables listed in Table 1.
93-1	16816-16819	The	_	
93-2	16820-16828	cannabis	_	
93-3	16829-16832	and	_	
93-4	16833-16836	THC	_	
93-5	16837-16844	patient	_	
93-6	16845-16854	subgroups	_	
93-7	16855-16858	did	_	
93-8	16859-16862	not	_	
93-9	16863-16876	significantly	_	
93-10	16877-16883	differ	_	
93-11	16884-16888	with	_	
93-12	16889-16896	respect	_	
93-13	16897-16899	to	_	
93-14	16900-16908	cannabis	_	
93-15	16909-16912	use	_	
93-16	16912-16913	,	_	
93-17	16914-16921	tobacco	_	
93-18	16922-16925	use	_	
93-19	16925-16926	,	_	
93-20	16927-16929	or	_	
93-21	16930-16933	any	_	
93-22	16934-16936	of	_	
93-23	16937-16940	the	_	
93-24	16941-16952	demographic	_	
93-25	16953-16962	variables	_	
93-26	16963-16969	listed	_	
93-27	16970-16972	in	_	
93-28	16973-16978	Table	_	
93-29	16979-16980	1	_	
93-30	16980-16981	.	_	

#Text=All patients were taking a stable dose of one of the following antipsychotic medications: aripiprazole (n=2), haloperidol (n=2), olanzapine (n=1), paliperidone (n=4), or risperidone (n=3).
94-1	16982-16985	All	_	
94-2	16986-16994	patients	_	
94-3	16995-16999	were	_	
94-4	17000-17006	taking	_	
94-5	17007-17008	a	_	
94-6	17009-17015	stable	_	
94-7	17016-17020	dose	_	
94-8	17021-17023	of	_	
94-9	17024-17027	one	_	
94-10	17028-17030	of	_	
94-11	17031-17034	the	_	
94-12	17035-17044	following	_	
94-13	17045-17058	antipsychotic	_	
94-14	17059-17070	medications	_	
94-15	17070-17071	:	_	
94-16	17072-17084	aripiprazole	_	
94-17	17085-17086	(	_	
94-18	17086-17087	n	_	
94-19	17087-17088	=	_	
94-20	17088-17089	2	_	
94-21	17089-17090	)	_	
94-22	17090-17091	,	_	
94-23	17092-17103	haloperidol	_	
94-24	17104-17105	(	_	
94-25	17105-17106	n	_	
94-26	17106-17107	=	_	
94-27	17107-17108	2	_	
94-28	17108-17109	)	_	
94-29	17109-17110	,	_	
94-30	17111-17121	olanzapine	_	
94-31	17122-17123	(	_	
94-32	17123-17124	n	_	
94-33	17124-17125	=	_	
94-34	17125-17126	1	_	
94-35	17126-17127	)	_	
94-36	17127-17128	,	_	
94-37	17129-17141	paliperidone	_	
94-38	17142-17143	(	_	
94-39	17143-17144	n	_	
94-40	17144-17145	=	_	
94-41	17145-17146	4	_	
94-42	17146-17147	)	_	
94-43	17147-17148	,	_	
94-44	17149-17151	or	_	
94-45	17152-17163	risperidone	_	
94-46	17164-17165	(	_	
94-47	17165-17166	n	_	
94-48	17166-17167	=	_	
94-49	17167-17168	3	_	
94-50	17168-17169	)	_	
94-51	17169-17170	.	_	

#Text=The mean chlorpromazine equivalent dose for the patient group was of 300 ± 261 mg/day, with no significant difference in dose between patients in the cannabis and THC groups (p=0.1).
95-1	17171-17174	The	_	
95-2	17175-17179	mean	_	
95-3	17180-17194	chlorpromazine	_	
95-4	17195-17205	equivalent	_	
95-5	17206-17210	dose	_	
95-6	17211-17214	for	_	
95-7	17215-17218	the	_	
95-8	17219-17226	patient	_	
95-9	17227-17232	group	_	
95-10	17233-17236	was	_	
95-11	17237-17239	of	_	
95-12	17240-17243	300	_	
95-13	17244-17245	±	_	
95-14	17246-17249	261	_	
95-15	17250-17252	mg	_	
95-16	17252-17253	/	_	
95-17	17253-17256	day	_	
95-18	17256-17257	,	_	
95-19	17258-17262	with	_	
95-20	17263-17265	no	_	
95-21	17266-17277	significant	_	
95-22	17278-17288	difference	_	
95-23	17289-17291	in	_	
95-24	17292-17296	dose	_	
95-25	17297-17304	between	_	
95-26	17305-17313	patients	_	
95-27	17314-17316	in	_	
95-28	17317-17320	the	_	
95-29	17321-17329	cannabis	_	
95-30	17330-17333	and	_	
95-31	17334-17337	THC	_	
95-32	17338-17344	groups	_	
95-33	17345-17346	(	_	
95-34	17346-17347	p	_	
95-35	17347-17348	=	_	
95-36	17348-17351	0.1	_	
95-37	17351-17352	)	_	
95-38	17352-17353	.	_	

#Text=The average symptoms severity at T1 on the positive PANSS scale was 14.27 ± 3.38.
96-1	17354-17357	The	_	
96-2	17358-17365	average	_	
96-3	17366-17374	symptoms	_	
96-4	17375-17383	severity	_	
96-5	17384-17386	at	_	
96-6	17387-17389	T1	_	
96-7	17390-17392	on	_	
96-8	17393-17396	the	_	
96-9	17397-17405	positive	_	
96-10	17406-17411	PANSS	_	
96-11	17412-17417	scale	_	
96-12	17418-17421	was	_	
96-13	17422-17427	14.27	_	
96-14	17428-17429	±	_	
96-15	17430-17434	3.38	_	
96-16	17434-17435	.	_	

#Text=Patients with a prior history of substance (other than cannabis) or alcohol use disorder (n = 9) were counterbalanced into the cannabis and THC groups.
97-1	17436-17444	Patients	_	
97-2	17445-17449	with	_	
97-3	17450-17451	a	_	
97-4	17452-17457	prior	_	
97-5	17458-17465	history	_	
97-6	17466-17468	of	_	
97-7	17469-17478	substance	_	
97-8	17479-17480	(	_	
97-9	17480-17485	other	_	
97-10	17486-17490	than	_	
97-11	17491-17499	cannabis	_	
97-12	17499-17500	)	_	
97-13	17501-17503	or	_	
97-14	17504-17511	alcohol	_	
97-15	17512-17515	use	_	
97-16	17516-17524	disorder	_	
97-17	17525-17526	(	_	
97-18	17526-17527	n	_	
97-19	17528-17529	=	_	
97-20	17530-17531	9	_	
97-21	17531-17532	)	_	
97-22	17533-17537	were	_	
97-23	17538-17553	counterbalanced	_	
97-24	17554-17558	into	_	
97-25	17559-17562	the	_	
97-26	17563-17571	cannabis	_	
97-27	17572-17575	and	_	
97-28	17576-17579	THC	_	
97-29	17580-17586	groups	_	
97-30	17586-17587	.	_	

#Text=On average, patients were abstinent from cannabis 13.73 ± 8.36 days prior to T1.
98-1	17588-17590	On	_	
98-2	17591-17598	average	_	
98-3	17598-17599	,	_	
98-4	17600-17608	patients	_	
98-5	17609-17613	were	_	
98-6	17614-17623	abstinent	_	
98-7	17624-17628	from	_	
98-8	17629-17637	cannabis	_	
98-9	17638-17643	13.73	_	
98-10	17644-17645	±	_	
98-11	17646-17650	8.36	_	
98-12	17651-17655	days	_	
98-13	17656-17661	prior	_	
98-14	17662-17664	to	_	
98-15	17665-17667	T1	_	
98-16	17667-17668	.	_	

#Text=Artifact Motion Correction
#Text=There was no significant difference (p = 0.37) between the total number of outliers in motion and global signal intensity in patients with SCZ/CUD (5.39 ± 7.8) as compared to healthy control subjects (4.6 ± 3.5).
99-1	17669-17677	Artifact	_	
99-2	17678-17684	Motion	_	
99-3	17685-17695	Correction	_	
99-4	17696-17701	There	_	
99-5	17702-17705	was	_	
99-6	17706-17708	no	_	
99-7	17709-17720	significant	_	
99-8	17721-17731	difference	_	
99-9	17732-17733	(	_	
99-10	17733-17734	p	_	
99-11	17735-17736	=	_	
99-12	17737-17741	0.37	_	
99-13	17741-17742	)	_	
99-14	17743-17750	between	_	
99-15	17751-17754	the	_	
99-16	17755-17760	total	_	
99-17	17761-17767	number	_	
99-18	17768-17770	of	_	
99-19	17771-17779	outliers	_	
99-20	17780-17782	in	_	
99-21	17783-17789	motion	_	
99-22	17790-17793	and	_	
99-23	17794-17800	global	_	
99-24	17801-17807	signal	_	
99-25	17808-17817	intensity	_	
99-26	17818-17820	in	_	
99-27	17821-17829	patients	_	
99-28	17830-17834	with	_	
99-29	17835-17838	SCZ	_	
99-30	17838-17839	/	_	
99-31	17839-17842	CUD	_	
99-32	17843-17844	(	_	
99-33	17844-17848	5.39	_	
99-34	17849-17850	±	_	
99-35	17851-17854	7.8	_	
99-36	17854-17855	)	_	
99-37	17856-17858	as	_	
99-38	17859-17867	compared	_	
99-39	17868-17870	to	_	
99-40	17871-17878	healthy	_	
99-41	17879-17886	control	_	
99-42	17887-17895	subjects	_	
99-43	17896-17897	(	_	
99-44	17897-17900	4.6	_	
99-45	17901-17902	±	_	
99-46	17903-17906	3.5	_	
99-47	17906-17907	)	_	
99-48	17907-17908	.	_	

#Text=There was also no significant difference in number of artifactual time points within-groups when compared across sessions (p = 0.42).
100-1	17909-17914	There	_	
100-2	17915-17918	was	_	
100-3	17919-17923	also	_	
100-4	17924-17926	no	_	
100-5	17927-17938	significant	_	
100-6	17939-17949	difference	_	
100-7	17950-17952	in	_	
100-8	17953-17959	number	_	
100-9	17960-17962	of	_	
100-10	17963-17974	artifactual	_	
100-11	17975-17979	time	_	
100-12	17980-17986	points	_	
100-13	17987-18000	within-groups	_	
100-14	18001-18005	when	_	
100-15	18006-18014	compared	_	
100-16	18015-18021	across	_	
100-17	18022-18030	sessions	_	
100-18	18031-18032	(	_	
100-19	18032-18033	p	_	
100-20	18034-18035	=	_	
100-21	18036-18040	0.42	_	
100-22	18040-18041	)	_	
100-23	18041-18042	.	_	

#Text=In addition, there were no significant between group or between session differences in the framewise displacement in motion as measured by DVARS.
101-1	18043-18045	In	_	
101-2	18046-18054	addition	_	
101-3	18054-18055	,	_	
101-4	18056-18061	there	_	
101-5	18062-18066	were	_	
101-6	18067-18069	no	_	
101-7	18070-18081	significant	_	
101-8	18082-18089	between	_	
101-9	18090-18095	group	_	
101-10	18096-18098	or	_	
101-11	18099-18106	between	_	
101-12	18107-18114	session	_	
101-13	18115-18126	differences	_	
101-14	18127-18129	in	_	
101-15	18130-18133	the	_	
101-16	18134-18143	framewise	_	
101-17	18144-18156	displacement	_	
101-18	18157-18159	in	_	
101-19	18160-18166	motion	_	
101-20	18167-18169	as	_	
101-21	18170-18178	measured	_	
101-22	18179-18181	by	_	
101-23	18182-18187	DVARS	_	
101-24	18187-18188	.	_	

#Text=DVARS (D referring to temporal derivative of timecourses, VARS referring to root mean square (RMS) variance over voxels) indexes the rate of change of BOLD signal across the entire brain at each frame of data.
102-1	18189-18194	DVARS	_	
102-2	18195-18196	(	_	
102-3	18196-18197	D	_	
102-4	18198-18207	referring	_	
102-5	18208-18210	to	_	
102-6	18211-18219	temporal	_	
102-7	18220-18230	derivative	_	
102-8	18231-18233	of	_	
102-9	18234-18245	timecourses	_	
102-10	18245-18246	,	_	
102-11	18247-18251	VARS	_	
102-12	18252-18261	referring	_	
102-13	18262-18264	to	_	
102-14	18265-18269	root	_	
102-15	18270-18274	mean	_	
102-16	18275-18281	square	_	
102-17	18282-18283	(	_	
102-18	18283-18286	RMS	_	
102-19	18286-18287	)	_	
102-20	18288-18296	variance	_	
102-21	18297-18301	over	_	
102-22	18302-18308	voxels	_	
102-23	18308-18309	)	_	
102-24	18310-18317	indexes	_	
102-25	18318-18321	the	_	
102-26	18322-18326	rate	_	
102-27	18327-18329	of	_	
102-28	18330-18336	change	_	
102-29	18337-18339	of	_	
102-30	18340-18344	BOLD	_	
102-31	18345-18351	signal	_	
102-32	18352-18358	across	_	
102-33	18359-18362	the	_	
102-34	18363-18369	entire	_	
102-35	18370-18375	brain	_	
102-36	18376-18378	at	_	
102-37	18379-18383	each	_	
102-38	18384-18389	frame	_	
102-39	18390-18392	of	_	
102-40	18393-18397	data	_	
102-41	18397-18398	.	_	

#Text=Plasma THC and symptom measures
#Text=Plasma measures of THC at T1 in the patient group (15.9 ± 19.37 mg/ml) did not significantly differ from THC measures at T2 prior to pharmacologic intervention (17.2 ± 16.58 ng/ml; p>0.1, ηp2 = 0.044), suggesting that patients had remained abstinent in the interval between scans at T1 and T2.
103-1	18399-18405	Plasma	_	
103-2	18406-18409	THC	_	
103-3	18410-18413	and	_	
103-4	18414-18421	symptom	_	
103-5	18422-18430	measures	_	
103-6	18431-18437	Plasma	_	
103-7	18438-18446	measures	_	
103-8	18447-18449	of	_	
103-9	18450-18453	THC	_	
103-10	18454-18456	at	_	
103-11	18457-18459	T1	_	
103-12	18460-18462	in	_	
103-13	18463-18466	the	_	
103-14	18467-18474	patient	_	
103-15	18475-18480	group	_	
103-16	18481-18482	(	_	
103-17	18482-18486	15.9	_	
103-18	18487-18488	±	_	
103-19	18489-18494	19.37	_	
103-20	18495-18497	mg	_	
103-21	18497-18498	/	_	
103-22	18498-18500	ml	_	
103-23	18500-18501	)	_	
103-24	18502-18505	did	_	
103-25	18506-18509	not	_	
103-26	18510-18523	significantly	_	
103-27	18524-18530	differ	_	
103-28	18531-18535	from	_	
103-29	18536-18539	THC	_	
103-30	18540-18548	measures	_	
103-31	18549-18551	at	_	
103-32	18552-18554	T2	_	
103-33	18555-18560	prior	_	
103-34	18561-18563	to	_	
103-35	18564-18577	pharmacologic	_	
103-36	18578-18590	intervention	_	
103-37	18591-18592	(	_	
103-38	18592-18596	17.2	_	
103-39	18597-18598	±	_	
103-40	18599-18604	16.58	_	
103-41	18605-18607	ng	_	
103-42	18607-18608	/	_	
103-43	18608-18610	ml	_	
103-44	18610-18611	;	_	
103-45	18612-18613	p	_	
103-46	18613-18614	>	_	
103-47	18614-18617	0.1	_	
103-48	18617-18618	,	_	
103-49	18619-18622	ηp2	_	
103-50	18623-18624	=	_	
103-51	18625-18630	0.044	_	
103-52	18630-18631	)	_	
103-53	18631-18632	,	_	
103-54	18633-18643	suggesting	_	
103-55	18644-18648	that	_	
103-56	18649-18657	patients	_	
103-57	18658-18661	had	_	
103-58	18662-18670	remained	_	
103-59	18671-18680	abstinent	_	
103-60	18681-18683	in	_	
103-61	18684-18687	the	_	
103-62	18688-18696	interval	_	
103-63	18697-18704	between	_	
103-64	18705-18710	scans	_	
103-65	18711-18713	at	_	
103-66	18714-18716	T1	_	
103-67	18717-18720	and	_	
103-68	18721-18723	T2	_	
103-69	18723-18724	.	_	

#Text=(Note: The T2 scan of one of the patients within the cannabis group was excluded from the data analysis because of an elevated plasma THC level prior to intervention, suggesting recent use of cannabis).
104-1	18725-18726	(	_	
104-2	18726-18730	Note	_	
104-3	18730-18731	:	_	
104-4	18732-18735	The	_	
104-5	18736-18738	T2	_	
104-6	18739-18743	scan	_	
104-7	18744-18746	of	_	
104-8	18747-18750	one	_	
104-9	18751-18753	of	_	
104-10	18754-18757	the	_	
104-11	18758-18766	patients	_	
104-12	18767-18773	within	_	
104-13	18774-18777	the	_	
104-14	18778-18786	cannabis	_	
104-15	18787-18792	group	_	
104-16	18793-18796	was	_	
104-17	18797-18805	excluded	_	
104-18	18806-18810	from	_	
104-19	18811-18814	the	_	
104-20	18815-18819	data	_	
104-21	18820-18828	analysis	_	
104-22	18829-18836	because	_	
104-23	18837-18839	of	_	
104-24	18840-18842	an	_	
104-25	18843-18851	elevated	_	
104-26	18852-18858	plasma	_	
104-27	18859-18862	THC	_	
104-28	18863-18868	level	_	
104-29	18869-18874	prior	_	
104-30	18875-18877	to	_	
104-31	18878-18890	intervention	_	
104-32	18890-18891	,	_	
104-33	18892-18902	suggesting	_	
104-34	18903-18909	recent	_	
104-35	18910-18913	use	_	
104-36	18914-18916	of	_	
104-37	18917-18925	cannabis	_	
104-38	18925-18926	)	_	
104-39	18926-18927	.	_	

#Text=Following pharmacologic intervention, there was a significant increase in THC plasma levels obtained immediately prior to fMRI scanning (increased to 37.1 ± 23.0 ng/ml and 44.8 ± 12.16 ng/ml for the THC and cannabis groups, respectively; p<0.01, ηp2 = 0.81).
105-1	18928-18937	Following	_	
105-2	18938-18951	pharmacologic	_	
105-3	18952-18964	intervention	_	
105-4	18964-18965	,	_	
105-5	18966-18971	there	_	
105-6	18972-18975	was	_	
105-7	18976-18977	a	_	
105-8	18978-18989	significant	_	
105-9	18990-18998	increase	_	
105-10	18999-19001	in	_	
105-11	19002-19005	THC	_	
105-12	19006-19012	plasma	_	
105-13	19013-19019	levels	_	
105-14	19020-19028	obtained	_	
105-15	19029-19040	immediately	_	
105-16	19041-19046	prior	_	
105-17	19047-19049	to	_	
105-18	19050-19054	fMRI	_	
105-19	19055-19063	scanning	_	
105-20	19064-19065	(	_	
105-21	19065-19074	increased	_	
105-22	19075-19077	to	_	
105-23	19078-19082	37.1	_	
105-24	19083-19084	±	_	
105-25	19085-19089	23.0	_	
105-26	19090-19092	ng	_	
105-27	19092-19093	/	_	
105-28	19093-19095	ml	_	
105-29	19096-19099	and	_	
105-30	19100-19104	44.8	_	
105-31	19105-19106	±	_	
105-32	19107-19112	12.16	_	
105-33	19113-19115	ng	_	
105-34	19115-19116	/	_	
105-35	19116-19118	ml	_	
105-36	19119-19122	for	_	
105-37	19123-19126	the	_	
105-38	19127-19130	THC	_	
105-39	19131-19134	and	_	
105-40	19135-19143	cannabis	_	
105-41	19144-19150	groups	_	
105-42	19150-19151	,	_	
105-43	19152-19164	respectively	_	
105-44	19164-19165	;	_	
105-45	19166-19167	p	_	
105-46	19167-19168	<	_	
105-47	19168-19172	0.01	_	
105-48	19172-19173	,	_	
105-49	19174-19177	ηp2	_	
105-50	19178-19179	=	_	
105-51	19180-19184	0.81	_	
105-52	19184-19185	)	_	
105-53	19185-19186	.	_	

#Text=Study participants completed cognitive assessments approximately 30 minutes post scanning.
106-1	19187-19192	Study	_	
106-2	19193-19205	participants	_	
106-3	19206-19215	completed	_	
106-4	19216-19225	cognitive	_	
106-5	19226-19237	assessments	_	
106-6	19238-19251	approximately	_	
106-7	19252-19254	30	_	
106-8	19255-19262	minutes	_	
106-9	19263-19267	post	_	
106-10	19268-19276	scanning	_	
106-11	19276-19277	.	_	

#Text=The plasma THC levels obtained immediately prior to WM testing were 21.1 ± 15.54 ng/ml and 24.1 ± 19.80 ng/ml for the THC and cannabis groups, respectively.
107-1	19278-19281	The	_	
107-2	19282-19288	plasma	_	
107-3	19289-19292	THC	_	
107-4	19293-19299	levels	_	
107-5	19300-19308	obtained	_	
107-6	19309-19320	immediately	_	
107-7	19321-19326	prior	_	
107-8	19327-19329	to	_	
107-9	19330-19332	WM	_	
107-10	19333-19340	testing	_	
107-11	19341-19345	were	_	
107-12	19346-19350	21.1	_	
107-13	19351-19352	±	_	
107-14	19353-19358	15.54	_	
107-15	19359-19361	ng	_	
107-16	19361-19362	/	_	
107-17	19362-19364	ml	_	
107-18	19365-19368	and	_	
107-19	19369-19373	24.1	_	
107-20	19374-19375	±	_	
107-21	19376-19381	19.80	_	
107-22	19382-19384	ng	_	
107-23	19384-19385	/	_	
107-24	19385-19387	ml	_	
107-25	19388-19391	for	_	
107-26	19392-19395	the	_	
107-27	19396-19399	THC	_	
107-28	19400-19403	and	_	
107-29	19404-19412	cannabis	_	
107-30	19413-19419	groups	_	
107-31	19419-19420	,	_	
107-32	19421-19433	respectively	_	
107-33	19433-19434	.	_	

#Text=These values were higher than at baseline (p = 0.053 as compared to baseline; ηp2 = 0.325), but showed a significant decline from immediately post-intervention (p<0.01; ηp2 = 0.732).
108-1	19435-19440	These	_	
108-2	19441-19447	values	_	
108-3	19448-19452	were	_	
108-4	19453-19459	higher	_	
108-5	19460-19464	than	_	
108-6	19465-19467	at	_	
108-7	19468-19476	baseline	_	
108-8	19477-19478	(	_	
108-9	19478-19479	p	_	
108-10	19480-19481	=	_	
108-11	19482-19487	0.053	_	
108-12	19488-19490	as	_	
108-13	19491-19499	compared	_	
108-14	19500-19502	to	_	
108-15	19503-19511	baseline	_	
108-16	19511-19512	;	_	
108-17	19513-19516	ηp2	_	
108-18	19517-19518	=	_	
108-19	19519-19524	0.325	_	
108-20	19524-19525	)	_	
108-21	19525-19526	,	_	
108-22	19527-19530	but	_	
108-23	19531-19537	showed	_	
108-24	19538-19539	a	_	
108-25	19540-19551	significant	_	
108-26	19552-19559	decline	_	
108-27	19560-19564	from	_	
108-28	19565-19576	immediately	_	
108-29	19577-19594	post-intervention	_	
108-30	19595-19596	(	_	
108-31	19596-19597	p	_	
108-32	19597-19598	<	_	
108-33	19598-19602	0.01	_	
108-34	19602-19603	;	_	
108-35	19604-19607	ηp2	_	
108-36	19608-19609	=	_	
108-37	19610-19615	0.732	_	
108-38	19615-19616	)	_	
108-39	19616-19617	.	_	

#Text=No significant differences were found on measures of craving (average MCQ T1: 48.18 ± 13.63; T2: 43.64 +/− 16.59), withdrawal (average CWS T1: 3.10 ± 3.78; T2: 2.70 +/− 2.91) or symptom severity (average positive PANSS T1: 13.82 ± 3.19; T2: 12.91 ± 3.21) following cannabis or THC intervention as compared to baseline T2 (prior to the intervention) and T1 measures (p>0.1; ηp2 = 0.140 for MCQ; ηp2 = 0.087 for CWS; ηp2 = 0.248 for positive PANSS scores).
109-1	19618-19620	No	_	
109-2	19621-19632	significant	_	
109-3	19633-19644	differences	_	
109-4	19645-19649	were	_	
109-5	19650-19655	found	_	
109-6	19656-19658	on	_	
109-7	19659-19667	measures	_	
109-8	19668-19670	of	_	
109-9	19671-19678	craving	_	
109-10	19679-19680	(	_	
109-11	19680-19687	average	_	
109-12	19688-19691	MCQ	_	
109-13	19692-19694	T1	_	
109-14	19694-19695	:	_	
109-15	19696-19701	48.18	_	
109-16	19702-19703	±	_	
109-17	19704-19709	13.63	_	
109-18	19709-19710	;	_	
109-19	19711-19713	T2	_	
109-20	19713-19714	:	_	
109-21	19715-19720	43.64	_	
109-22	19721-19722	+	_	
109-23	19722-19723	/	_	
109-24	19723-19724	−	_	
109-25	19725-19730	16.59	_	
109-26	19730-19731	)	_	
109-27	19731-19732	,	_	
109-28	19733-19743	withdrawal	_	
109-29	19744-19745	(	_	
109-30	19745-19752	average	_	
109-31	19753-19756	CWS	_	
109-32	19757-19759	T1	_	
109-33	19759-19760	:	_	
109-34	19761-19765	3.10	_	
109-35	19766-19767	±	_	
109-36	19768-19772	3.78	_	
109-37	19772-19773	;	_	
109-38	19774-19776	T2	_	
109-39	19776-19777	:	_	
109-40	19778-19782	2.70	_	
109-41	19783-19784	+	_	
109-42	19784-19785	/	_	
109-43	19785-19786	−	_	
109-44	19787-19791	2.91	_	
109-45	19791-19792	)	_	
109-46	19793-19795	or	_	
109-47	19796-19803	symptom	_	
109-48	19804-19812	severity	_	
109-49	19813-19814	(	_	
109-50	19814-19821	average	_	
109-51	19822-19830	positive	_	
109-52	19831-19836	PANSS	_	
109-53	19837-19839	T1	_	
109-54	19839-19840	:	_	
109-55	19841-19846	13.82	_	
109-56	19847-19848	±	_	
109-57	19849-19853	3.19	_	
109-58	19853-19854	;	_	
109-59	19855-19857	T2	_	
109-60	19857-19858	:	_	
109-61	19859-19864	12.91	_	
109-62	19865-19866	±	_	
109-63	19867-19871	3.21	_	
109-64	19871-19872	)	_	
109-65	19873-19882	following	_	
109-66	19883-19891	cannabis	_	
109-67	19892-19894	or	_	
109-68	19895-19898	THC	_	
109-69	19899-19911	intervention	_	
109-70	19912-19914	as	_	
109-71	19915-19923	compared	_	
109-72	19924-19926	to	_	
109-73	19927-19935	baseline	_	
109-74	19936-19938	T2	_	
109-75	19939-19940	(	_	
109-76	19940-19945	prior	_	
109-77	19946-19948	to	_	
109-78	19949-19952	the	_	
109-79	19953-19965	intervention	_	
109-80	19965-19966	)	_	
109-81	19967-19970	and	_	
109-82	19971-19973	T1	_	
109-83	19974-19982	measures	_	
109-84	19983-19984	(	_	
109-85	19984-19985	p	_	
109-86	19985-19986	>	_	
109-87	19986-19989	0.1	_	
109-88	19989-19990	;	_	
109-89	19991-19994	ηp2	_	
109-90	19995-19996	=	_	
109-91	19997-20002	0.140	_	
109-92	20003-20006	for	_	
109-93	20007-20010	MCQ	_	
109-94	20010-20011	;	_	
109-95	20012-20015	ηp2	_	
109-96	20016-20017	=	_	
109-97	20018-20023	0.087	_	
109-98	20024-20027	for	_	
109-99	20028-20031	CWS	_	
109-100	20031-20032	;	_	
109-101	20033-20036	ηp2	_	
109-102	20037-20038	=	_	
109-103	20039-20044	0.248	_	
109-104	20045-20048	for	_	
109-105	20049-20057	positive	_	
109-106	20058-20063	PANSS	_	
109-107	20064-20070	scores	_	
109-108	20070-20071	)	_	
109-109	20071-20072	.	_	

#Text=Given the similarity in plasma THC levels as well as symptom measures, and no significant DMN connectivity differences between subgroups, patients receiving THC and cannabis were combined as one patient group.
110-1	20073-20078	Given	_	
110-2	20079-20082	the	_	
110-3	20083-20093	similarity	_	
110-4	20094-20096	in	_	
110-5	20097-20103	plasma	_	
110-6	20104-20107	THC	_	
110-7	20108-20114	levels	_	
110-8	20115-20117	as	_	
110-9	20118-20122	well	_	
110-10	20123-20125	as	_	
110-11	20126-20133	symptom	_	
110-12	20134-20142	measures	_	
110-13	20142-20143	,	_	
110-14	20144-20147	and	_	
110-15	20148-20150	no	_	
110-16	20151-20162	significant	_	
110-17	20163-20166	DMN	_	
110-18	20167-20179	connectivity	_	
110-19	20180-20191	differences	_	
110-20	20192-20199	between	_	
110-21	20200-20209	subgroups	_	
110-22	20209-20210	,	_	
110-23	20211-20219	patients	_	
110-24	20220-20229	receiving	_	
110-25	20230-20233	THC	_	
110-26	20234-20237	and	_	
110-27	20238-20246	cannabis	_	
110-28	20247-20251	were	_	
110-29	20252-20260	combined	_	
110-30	20261-20263	as	_	
110-31	20264-20267	one	_	
110-32	20268-20275	patient	_	
110-33	20276-20281	group	_	
110-34	20281-20282	.	_	

#Text=Further detail on symptom measures can be found in.
111-1	20283-20290	Further	_	
111-2	20291-20297	detail	_	
111-3	20298-20300	on	_	
111-4	20301-20308	symptom	_	
111-5	20309-20317	measures	_	
111-6	20318-20321	can	_	
111-7	20322-20324	be	_	
111-8	20325-20330	found	_	
111-9	20331-20333	in	_	
111-10	20333-20334	.	_	

#Text=DMN Functional Connectivity at T1
#Text=Within-group whole brain seed-to-voxel analysis (using the MPFC seed) revealed significant rs-fc between the MPFC, posterior cingulate cortex (PCC) and bilateral inferior parietal lobe (IPL) regions of the DMN in both the control and patient groups (p<0.001, whole brain FDR-corrected).
112-1	20335-20338	DMN	_	
112-2	20339-20349	Functional	_	
112-3	20350-20362	Connectivity	_	
112-4	20363-20365	at	_	
112-5	20366-20368	T1	_	
112-6	20369-20381	Within-group	_	
112-7	20382-20387	whole	_	
112-8	20388-20393	brain	_	
112-9	20394-20407	seed-to-voxel	_	
112-10	20408-20416	analysis	_	
112-11	20417-20418	(	_	
112-12	20418-20423	using	_	
112-13	20424-20427	the	_	
112-14	20428-20432	MPFC	_	
112-15	20433-20437	seed	_	
112-16	20437-20438	)	_	
112-17	20439-20447	revealed	_	
112-18	20448-20459	significant	_	
112-19	20460-20465	rs-fc	_	
112-20	20466-20473	between	_	
112-21	20474-20477	the	_	
112-22	20478-20482	MPFC	_	
112-23	20482-20483	,	_	
112-24	20484-20493	posterior	_	
112-25	20494-20503	cingulate	_	
112-26	20504-20510	cortex	_	
112-27	20511-20512	(	_	
112-28	20512-20515	PCC	_	
112-29	20515-20516	)	_	
112-30	20517-20520	and	_	
112-31	20521-20530	bilateral	_	
112-32	20531-20539	inferior	_	
112-33	20540-20548	parietal	_	
112-34	20549-20553	lobe	_	
112-35	20554-20555	(	_	
112-36	20555-20558	IPL	_	
112-37	20558-20559	)	_	
112-38	20560-20567	regions	_	
112-39	20568-20570	of	_	
112-40	20571-20574	the	_	
112-41	20575-20578	DMN	_	
112-42	20579-20581	in	_	
112-43	20582-20586	both	_	
112-44	20587-20590	the	_	
112-45	20591-20598	control	_	
112-46	20599-20602	and	_	
112-47	20603-20610	patient	_	
112-48	20611-20617	groups	_	
112-49	20618-20619	(	_	
112-50	20619-20620	p	_	
112-51	20620-20621	<	_	
112-52	20621-20626	0.001	_	
112-53	20626-20627	,	_	
112-54	20628-20633	whole	_	
112-55	20634-20639	brain	_	
112-56	20640-20653	FDR-corrected	_	
112-57	20653-20654	)	_	
112-58	20654-20655	.	_	

#Text=Between-group comparison showed hyperconnectivity of the DMN in patients with SCZ and CUD as compared to controls at T1, p<0.001 whole brain FDR-corrected as shown in Fig. 2a.
113-1	20656-20669	Between-group	_	
113-2	20670-20680	comparison	_	
113-3	20681-20687	showed	_	
113-4	20688-20705	hyperconnectivity	_	
113-5	20706-20708	of	_	
113-6	20709-20712	the	_	
113-7	20713-20716	DMN	_	
113-8	20717-20719	in	_	
113-9	20720-20728	patients	_	
113-10	20729-20733	with	_	
113-11	20734-20737	SCZ	_	
113-12	20738-20741	and	_	
113-13	20742-20745	CUD	_	
113-14	20746-20748	as	_	
113-15	20749-20757	compared	_	
113-16	20758-20760	to	_	
113-17	20761-20769	controls	_	
113-18	20770-20772	at	_	
113-19	20773-20775	T1	_	
113-20	20775-20776	,	_	
113-21	20777-20778	p	_	
113-22	20778-20779	<	_	
113-23	20779-20784	0.001	_	
113-24	20785-20790	whole	_	
113-25	20791-20796	brain	_	
113-26	20797-20810	FDR-corrected	_	
113-27	20811-20813	as	_	
113-28	20814-20819	shown	_	
113-29	20820-20822	in	_	
113-30	20823-20826	Fig	_	
113-31	20826-20827	.	_	
113-32	20828-20830	2a	_	
113-33	20830-20831	.	_	

#Text=The degree of MPFC-precuneus resting state functional connectivity positively correlated with positive symptom severity on the PANSS (r = 0.65, p=0.04; Fig. 3).
114-1	20832-20835	The	_	
114-2	20836-20842	degree	_	
114-3	20843-20845	of	_	
114-4	20846-20860	MPFC-precuneus	_	
114-5	20861-20868	resting	_	
114-6	20869-20874	state	_	
114-7	20875-20885	functional	_	
114-8	20886-20898	connectivity	_	
114-9	20899-20909	positively	_	
114-10	20910-20920	correlated	_	
114-11	20921-20925	with	_	
114-12	20926-20934	positive	_	
114-13	20935-20942	symptom	_	
114-14	20943-20951	severity	_	
114-15	20952-20954	on	_	
114-16	20955-20958	the	_	
114-17	20959-20964	PANSS	_	
114-18	20965-20966	(	_	
114-19	20966-20967	r	_	
114-20	20968-20969	=	_	
114-21	20970-20974	0.65	_	
114-22	20974-20975	,	_	
114-23	20976-20977	p	_	
114-24	20977-20978	=	_	
114-25	20978-20982	0.04	_	
114-26	20982-20983	;	_	
114-27	20984-20987	Fig	_	
114-28	20987-20988	.	_	
114-29	20989-20990	3	_	
114-30	20990-20991	)	_	
114-31	20991-20992	.	_	

#Text=Significant anticorrelation between the MPFC (DMN seed) and the right DLPFC component of the ECN was found in the control but not the patient group.
115-1	20993-21004	Significant	_	
115-2	21005-21020	anticorrelation	_	
115-3	21021-21028	between	_	
115-4	21029-21032	the	_	
115-5	21033-21037	MPFC	_	
115-6	21038-21039	(	_	
115-7	21039-21042	DMN	_	
115-8	21043-21047	seed	_	
115-9	21047-21048	)	_	
115-10	21049-21052	and	_	
115-11	21053-21056	the	_	
115-12	21057-21062	right	_	
115-13	21063-21068	DLPFC	_	
115-14	21069-21078	component	_	
115-15	21079-21081	of	_	
115-16	21082-21085	the	_	
115-17	21086-21089	ECN	_	
115-18	21090-21093	was	_	
115-19	21094-21099	found	_	
115-20	21100-21102	in	_	
115-21	21103-21106	the	_	
115-22	21107-21114	control	_	
115-23	21115-21118	but	_	
115-24	21119-21122	not	_	
115-25	21123-21126	the	_	
115-26	21127-21134	patient	_	
115-27	21135-21140	group	_	
115-28	21140-21141	.	_	

#Text=Correspondingly, the between group comparison revealed significantly greater MPFC-DLPFC anticorrelation in controls relative to patients, (p<0.001, FDR corrected Fig. 2b).
116-1	21142-21157	Correspondingly	_	
116-2	21157-21158	,	_	
116-3	21159-21162	the	_	
116-4	21163-21170	between	_	
116-5	21171-21176	group	_	
116-6	21177-21187	comparison	_	
116-7	21188-21196	revealed	_	
116-8	21197-21210	significantly	_	
116-9	21211-21218	greater	_	
116-10	21219-21229	MPFC-DLPFC	_	
116-11	21230-21245	anticorrelation	_	
116-12	21246-21248	in	_	
116-13	21249-21257	controls	_	
116-14	21258-21266	relative	_	
116-15	21267-21269	to	_	
116-16	21270-21278	patients	_	
116-17	21278-21279	,	_	
116-18	21280-21281	(	_	
116-19	21281-21282	p	_	
116-20	21282-21283	<	_	
116-21	21283-21288	0.001	_	
116-22	21288-21289	,	_	
116-23	21290-21293	FDR	_	
116-24	21294-21303	corrected	_	
116-25	21304-21307	Fig	_	
116-26	21307-21308	.	_	
116-27	21309-21311	2b	_	
116-28	21311-21312	)	_	
116-29	21312-21313	.	_	

#Text=Effects of Cannabinoids on Functional Connectivity at T2
#Text=Cannabinoid administration produced a reduction in DMN hyperconnectivity, (p<0.001, FDR corrected Fig. 4), with no significant difference found between cannabis and THC groups.
117-1	21314-21321	Effects	_	
117-2	21322-21324	of	_	
117-3	21325-21337	Cannabinoids	_	
117-4	21338-21340	on	_	
117-5	21341-21351	Functional	_	
117-6	21352-21364	Connectivity	_	
117-7	21365-21367	at	_	
117-8	21368-21370	T2	_	
117-9	21371-21382	Cannabinoid	_	
117-10	21383-21397	administration	_	
117-11	21398-21406	produced	_	
117-12	21407-21408	a	_	
117-13	21409-21418	reduction	_	
117-14	21419-21421	in	_	
117-15	21422-21425	DMN	_	
117-16	21426-21443	hyperconnectivity	_	
117-17	21443-21444	,	_	
117-18	21445-21446	(	_	
117-19	21446-21447	p	_	
117-20	21447-21448	<	_	
117-21	21448-21453	0.001	_	
117-22	21453-21454	,	_	
117-23	21455-21458	FDR	_	
117-24	21459-21468	corrected	_	
117-25	21469-21472	Fig	_	
117-26	21472-21473	.	_	
117-27	21474-21475	4	_	
117-28	21475-21476	)	_	
117-29	21476-21477	,	_	
117-30	21478-21482	with	_	
117-31	21483-21485	no	_	
117-32	21486-21497	significant	_	
117-33	21498-21508	difference	_	
117-34	21509-21514	found	_	
117-35	21515-21522	between	_	
117-36	21523-21531	cannabis	_	
117-37	21532-21535	and	_	
117-38	21536-21539	THC	_	
117-39	21540-21546	groups	_	
117-40	21546-21547	.	_	

#Text=Post intervention, the strength of DMN connectivity no longer correlated with positive symptom severity on the PANSS, although overall positive symptom severity did not significantly differ from baseline [F(1,10) = 3.38; p = 0.096], with mean symptom severity remaining in the mild to moderate range.
118-1	21548-21552	Post	_	
118-2	21553-21565	intervention	_	
118-3	21565-21566	,	_	
118-4	21567-21570	the	_	
118-5	21571-21579	strength	_	
118-6	21580-21582	of	_	
118-7	21583-21586	DMN	_	
118-8	21587-21599	connectivity	_	
118-9	21600-21602	no	_	
118-10	21603-21609	longer	_	
118-11	21610-21620	correlated	_	
118-12	21621-21625	with	_	
118-13	21626-21634	positive	_	
118-14	21635-21642	symptom	_	
118-15	21643-21651	severity	_	
118-16	21652-21654	on	_	
118-17	21655-21658	the	_	
118-18	21659-21664	PANSS	_	
118-19	21664-21665	,	_	
118-20	21666-21674	although	_	
118-21	21675-21682	overall	_	
118-22	21683-21691	positive	_	
118-23	21692-21699	symptom	_	
118-24	21700-21708	severity	_	
118-25	21709-21712	did	_	
118-26	21713-21716	not	_	
118-27	21717-21730	significantly	_	
118-28	21731-21737	differ	_	
118-29	21738-21742	from	_	
118-30	21743-21751	baseline	_	
118-31	21752-21753	[	_	
118-32	21753-21754	F	_	
118-33	21754-21755	(	_	
118-34	21755-21759	1,10	_	
118-35	21759-21760	)	_	
118-36	21761-21762	=	_	
118-37	21763-21767	3.38	_	
118-38	21767-21768	;	_	
118-39	21769-21770	p	_	
118-40	21771-21772	=	_	
118-41	21773-21778	0.096	_	
118-42	21778-21779	]	_	
118-43	21779-21780	,	_	
118-44	21781-21785	with	_	
118-45	21786-21790	mean	_	
118-46	21791-21798	symptom	_	
118-47	21799-21807	severity	_	
118-48	21808-21817	remaining	_	
118-49	21818-21820	in	_	
118-50	21821-21824	the	_	
118-51	21825-21829	mild	_	
118-52	21830-21832	to	_	
118-53	21833-21841	moderate	_	
118-54	21842-21847	range	_	
118-55	21847-21848	.	_	

#Text=Cannabinoid administration, both cannabis and THC, significantly increased the strength of anticorrelation between the MPFC and DLPFC (Fig. 4), and a significant difference could no longer be found between the combined patient and control groups (Fig. 4).
119-1	21849-21860	Cannabinoid	_	
119-2	21861-21875	administration	_	
119-3	21875-21876	,	_	
119-4	21877-21881	both	_	
119-5	21882-21890	cannabis	_	
119-6	21891-21894	and	_	
119-7	21895-21898	THC	_	
119-8	21898-21899	,	_	
119-9	21900-21913	significantly	_	
119-10	21914-21923	increased	_	
119-11	21924-21927	the	_	
119-12	21928-21936	strength	_	
119-13	21937-21939	of	_	
119-14	21940-21955	anticorrelation	_	
119-15	21956-21963	between	_	
119-16	21964-21967	the	_	
119-17	21968-21972	MPFC	_	
119-18	21973-21976	and	_	
119-19	21977-21982	DLPFC	_	
119-20	21983-21984	(	_	
119-21	21984-21987	Fig	_	
119-22	21987-21988	.	_	
119-23	21989-21990	4	_	
119-24	21990-21991	)	_	
119-25	21991-21992	,	_	
119-26	21993-21996	and	_	
119-27	21997-21998	a	_	
119-28	21999-22010	significant	_	
119-29	22011-22021	difference	_	
119-30	22022-22027	could	_	
119-31	22028-22030	no	_	
119-32	22031-22037	longer	_	
119-33	22038-22040	be	_	
119-34	22041-22046	found	_	
119-35	22047-22054	between	_	
119-36	22055-22058	the	_	
119-37	22059-22067	combined	_	
119-38	22068-22075	patient	_	
119-39	22076-22079	and	_	
119-40	22080-22087	control	_	
119-41	22088-22094	groups	_	
119-42	22095-22096	(	_	
119-43	22096-22099	Fig	_	
119-44	22099-22100	.	_	
119-45	22101-22102	4	_	
119-46	22102-22103	)	_	
119-47	22103-22104	.	_	

#Text=Working Memory Performance
#Text=At T1, controls performed significantly better than patients (p < .01; ηp2 = 0.31) with average age-scaled scores of 12.1 ± 2.75 and 8.9 ± 2.96, respectively on the WAIS-III-Letter-Number Sequencing Test.
120-1	22105-22112	Working	_	
120-2	22113-22119	Memory	_	
120-3	22120-22131	Performance	_	
120-4	22132-22134	At	_	
120-5	22135-22137	T1	_	
120-6	22137-22138	,	_	
120-7	22139-22147	controls	_	
120-8	22148-22157	performed	_	
120-9	22158-22171	significantly	_	
120-10	22172-22178	better	_	
120-11	22179-22183	than	_	
120-12	22184-22192	patients	_	
120-13	22193-22194	(	_	
120-14	22194-22195	p	_	
120-15	22196-22197	<	_	
120-16	22198-22201	.01	_	
120-17	22201-22202	;	_	
120-18	22203-22206	ηp2	_	
120-19	22207-22208	=	_	
120-20	22209-22213	0.31	_	
120-21	22213-22214	)	_	
120-22	22215-22219	with	_	
120-23	22220-22227	average	_	
120-24	22228-22238	age-scaled	_	
120-25	22239-22245	scores	_	
120-26	22246-22248	of	_	
120-27	22249-22253	12.1	_	
120-28	22254-22255	±	_	
120-29	22256-22260	2.75	_	
120-30	22261-22264	and	_	
120-31	22265-22268	8.9	_	
120-32	22269-22270	±	_	
120-33	22271-22275	2.96	_	
120-34	22275-22276	,	_	
120-35	22277-22289	respectively	_	
120-36	22290-22292	on	_	
120-37	22293-22296	the	_	
120-38	22297-22319	WAIS-III-Letter-Number	_	
120-39	22320-22330	Sequencing	_	
120-40	22331-22335	Test	_	
120-41	22335-22336	.	_	

#Text=A significant association was found between the strength of the MPFC and DLPFC anticorrelation (quantified as z scores) and WM performance in the control (r = −0.65, p<0.05) but not the patient group at T1.
121-1	22337-22338	A	_	
121-2	22339-22350	significant	_	
121-3	22351-22362	association	_	
121-4	22363-22366	was	_	
121-5	22367-22372	found	_	
121-6	22373-22380	between	_	
121-7	22381-22384	the	_	
121-8	22385-22393	strength	_	
121-9	22394-22396	of	_	
121-10	22397-22400	the	_	
121-11	22401-22405	MPFC	_	
121-12	22406-22409	and	_	
121-13	22410-22415	DLPFC	_	
121-14	22416-22431	anticorrelation	_	
121-15	22432-22433	(	_	
121-16	22433-22443	quantified	_	
121-17	22444-22446	as	_	
121-18	22447-22448	z	_	
121-19	22449-22455	scores	_	
121-20	22455-22456	)	_	
121-21	22457-22460	and	_	
121-22	22461-22463	WM	_	
121-23	22464-22475	performance	_	
121-24	22476-22478	in	_	
121-25	22479-22482	the	_	
121-26	22483-22490	control	_	
121-27	22491-22492	(	_	
121-28	22492-22493	r	_	
121-29	22494-22495	=	_	
121-30	22496-22497	−	_	
121-31	22497-22501	0.65	_	
121-32	22501-22502	,	_	
121-33	22503-22504	p	_	
121-34	22504-22505	<	_	
121-35	22505-22509	0.05	_	
121-36	22509-22510	)	_	
121-37	22511-22514	but	_	
121-38	22515-22518	not	_	
121-39	22519-22522	the	_	
121-40	22523-22530	patient	_	
121-41	22531-22536	group	_	
121-42	22537-22539	at	_	
121-43	22540-22542	T1	_	
121-44	22542-22543	.	_	

#Text=Following cannabinoid administration during the T2 scan session, the control group still performed significantly better than the patient group (p<0.01; ηp2 = 0.37), with average scores of 12.33 ± 3.31 and 7.9 ± 2.56 respectively.
122-1	22544-22553	Following	_	
122-2	22554-22565	cannabinoid	_	
122-3	22566-22580	administration	_	
122-4	22581-22587	during	_	
122-5	22588-22591	the	_	
122-6	22592-22594	T2	_	
122-7	22595-22599	scan	_	
122-8	22600-22607	session	_	
122-9	22607-22608	,	_	
122-10	22609-22612	the	_	
122-11	22613-22620	control	_	
122-12	22621-22626	group	_	
122-13	22627-22632	still	_	
122-14	22633-22642	performed	_	
122-15	22643-22656	significantly	_	
122-16	22657-22663	better	_	
122-17	22664-22668	than	_	
122-18	22669-22672	the	_	
122-19	22673-22680	patient	_	
122-20	22681-22686	group	_	
122-21	22687-22688	(	_	
122-22	22688-22689	p	_	
122-23	22689-22690	<	_	
122-24	22690-22694	0.01	_	
122-25	22694-22695	;	_	
122-26	22696-22699	ηp2	_	
122-27	22700-22701	=	_	
122-28	22702-22706	0.37	_	
122-29	22706-22707	)	_	
122-30	22707-22708	,	_	
122-31	22709-22713	with	_	
122-32	22714-22721	average	_	
122-33	22722-22728	scores	_	
122-34	22729-22731	of	_	
122-35	22732-22737	12.33	_	
122-36	22738-22739	±	_	
122-37	22740-22744	3.31	_	
122-38	22745-22748	and	_	
122-39	22749-22752	7.9	_	
122-40	22753-22754	±	_	
122-41	22755-22759	2.56	_	
122-42	22760-22772	respectively	_	
122-43	22772-22773	.	_	

#Text=However post-intervention, the strength of the anticorrelation was directly correlated with WM performance in both the patient (r = −0.62, p <0.05) and control (r = −0.71, p < 0.05) groups (Fig. 5).
123-1	22774-22781	However	_	
123-2	22782-22799	post-intervention	_	
123-3	22799-22800	,	_	
123-4	22801-22804	the	_	
123-5	22805-22813	strength	_	
123-6	22814-22816	of	_	
123-7	22817-22820	the	_	
123-8	22821-22836	anticorrelation	_	
123-9	22837-22840	was	_	
123-10	22841-22849	directly	_	
123-11	22850-22860	correlated	_	
123-12	22861-22865	with	_	
123-13	22866-22868	WM	_	
123-14	22869-22880	performance	_	
123-15	22881-22883	in	_	
123-16	22884-22888	both	_	
123-17	22889-22892	the	_	
123-18	22893-22900	patient	_	
123-19	22901-22902	(	_	
123-20	22902-22903	r	_	
123-21	22904-22905	=	_	
123-22	22906-22907	−	_	
123-23	22907-22911	0.62	_	
123-24	22911-22912	,	_	
123-25	22913-22914	p	_	
123-26	22915-22916	<	_	
123-27	22916-22920	0.05	_	
123-28	22920-22921	)	_	
123-29	22922-22925	and	_	
123-30	22926-22933	control	_	
123-31	22934-22935	(	_	
123-32	22935-22936	r	_	
123-33	22937-22938	=	_	
123-34	22939-22940	−	_	
123-35	22940-22944	0.71	_	
123-36	22944-22945	,	_	
123-37	22946-22947	p	_	
123-38	22948-22949	<	_	
123-39	22950-22954	0.05	_	
123-40	22954-22955	)	_	
123-41	22956-22962	groups	_	
123-42	22963-22964	(	_	
123-43	22964-22967	Fig	_	
123-44	22967-22968	.	_	
123-45	22969-22970	5	_	
123-46	22970-22971	)	_	
123-47	22971-22972	.	_	

#Text=Discussion
#Text=In this pilot study, we investigated functional connectivity of the DMN in patients with SCZ and co-occurring CUD, as well as the effects of cannabinoid adminiatrations on this network.
124-1	22973-22983	Discussion	_	
124-2	22984-22986	In	_	
124-3	22987-22991	this	_	
124-4	22992-22997	pilot	_	
124-5	22998-23003	study	_	
124-6	23003-23004	,	_	
124-7	23005-23007	we	_	
124-8	23008-23020	investigated	_	
124-9	23021-23031	functional	_	
124-10	23032-23044	connectivity	_	
124-11	23045-23047	of	_	
124-12	23048-23051	the	_	
124-13	23052-23055	DMN	_	
124-14	23056-23058	in	_	
124-15	23059-23067	patients	_	
124-16	23068-23072	with	_	
124-17	23073-23076	SCZ	_	
124-18	23077-23080	and	_	
124-19	23081-23093	co-occurring	_	
124-20	23094-23097	CUD	_	
124-21	23097-23098	,	_	
124-22	23099-23101	as	_	
124-23	23102-23106	well	_	
124-24	23107-23109	as	_	
124-25	23110-23113	the	_	
124-26	23114-23121	effects	_	
124-27	23122-23124	of	_	
124-28	23125-23136	cannabinoid	_	
124-29	23137-23152	adminiatrations	_	
124-30	23153-23155	on	_	
124-31	23156-23160	this	_	
124-32	23161-23168	network	_	
124-33	23168-23169	.	_	

#Text=These ‘dual diagnosis’ patients (at T1, baseline) showed DMN hyperconnectivity and reduced anticorrelation between the DMN and the ECN, relative to controls.
125-1	23170-23175	These	_	
125-2	23176-23177	‘	_	
125-3	23177-23181	dual	_	
125-4	23182-23191	diagnosis	_	
125-5	23191-23192	’	_	
125-6	23193-23201	patients	_	
125-7	23202-23203	(	_	
125-8	23203-23205	at	_	
125-9	23206-23208	T1	_	
125-10	23208-23209	,	_	
125-11	23210-23218	baseline	_	
125-12	23218-23219	)	_	
125-13	23220-23226	showed	_	
125-14	23227-23230	DMN	_	
125-15	23231-23248	hyperconnectivity	_	
125-16	23249-23252	and	_	
125-17	23253-23260	reduced	_	
125-18	23261-23276	anticorrelation	_	
125-19	23277-23284	between	_	
125-20	23285-23288	the	_	
125-21	23289-23292	DMN	_	
125-22	23293-23296	and	_	
125-23	23297-23300	the	_	
125-24	23301-23304	ECN	_	
125-25	23304-23305	,	_	
125-26	23306-23314	relative	_	
125-27	23315-23317	to	_	
125-28	23318-23326	controls	_	
125-29	23326-23327	.	_	

#Text=There was a significant association between positive symptom severity and degree of DMN connectivity in the patient group.
126-1	23328-23333	There	_	
126-2	23334-23337	was	_	
126-3	23338-23339	a	_	
126-4	23340-23351	significant	_	
126-5	23352-23363	association	_	
126-6	23364-23371	between	_	
126-7	23372-23380	positive	_	
126-8	23381-23388	symptom	_	
126-9	23389-23397	severity	_	
126-10	23398-23401	and	_	
126-11	23402-23408	degree	_	
126-12	23409-23411	of	_	
126-13	23412-23415	DMN	_	
126-14	23416-23428	connectivity	_	
126-15	23429-23431	in	_	
126-16	23432-23435	the	_	
126-17	23436-23443	patient	_	
126-18	23444-23449	group	_	
126-19	23449-23450	.	_	

#Text=Cannabinoid administration significantly lowered DMN hyperconnectivity and increased the strength of the DMN/ECN anticorrelation.
127-1	23451-23462	Cannabinoid	_	
127-2	23463-23477	administration	_	
127-3	23478-23491	significantly	_	
127-4	23492-23499	lowered	_	
127-5	23500-23503	DMN	_	
127-6	23504-23521	hyperconnectivity	_	
127-7	23522-23525	and	_	
127-8	23526-23535	increased	_	
127-9	23536-23539	the	_	
127-10	23540-23548	strength	_	
127-11	23549-23551	of	_	
127-12	23552-23555	the	_	
127-13	23556-23559	DMN	_	
127-14	23559-23560	/	_	
127-15	23560-23563	ECN	_	
127-16	23564-23579	anticorrelation	_	
127-17	23579-23580	.	_	

#Text=Interestingly, while the strength of the anticorrelation was directly related to WM performance in the healthy control group, this relationship was only present in the patient sample after cannabinoid administration.
128-1	23581-23594	Interestingly	_	
128-2	23594-23595	,	_	
128-3	23596-23601	while	_	
128-4	23602-23605	the	_	
128-5	23606-23614	strength	_	
128-6	23615-23617	of	_	
128-7	23618-23621	the	_	
128-8	23622-23637	anticorrelation	_	
128-9	23638-23641	was	_	
128-10	23642-23650	directly	_	
128-11	23651-23658	related	_	
128-12	23659-23661	to	_	
128-13	23662-23664	WM	_	
128-14	23665-23676	performance	_	
128-15	23677-23679	in	_	
128-16	23680-23683	the	_	
128-17	23684-23691	healthy	_	
128-18	23692-23699	control	_	
128-19	23700-23705	group	_	
128-20	23705-23706	,	_	
128-21	23707-23711	this	_	
128-22	23712-23724	relationship	_	
128-23	23725-23728	was	_	
128-24	23729-23733	only	_	
128-25	23734-23741	present	_	
128-26	23742-23744	in	_	
128-27	23745-23748	the	_	
128-28	23749-23756	patient	_	
128-29	23757-23763	sample	_	
128-30	23764-23769	after	_	
128-31	23770-23781	cannabinoid	_	
128-32	23782-23796	administration	_	
128-33	23796-23797	.	_	

#Text=Cannabinoid administration did not elicit significant changes in psychotic symptom severity, marijuana craving, or cannabis withdrawal symptoms.
129-1	23798-23809	Cannabinoid	_	
129-2	23810-23824	administration	_	
129-3	23825-23828	did	_	
129-4	23829-23832	not	_	
129-5	23833-23839	elicit	_	
129-6	23840-23851	significant	_	
129-7	23852-23859	changes	_	
129-8	23860-23862	in	_	
129-9	23863-23872	psychotic	_	
129-10	23873-23880	symptom	_	
129-11	23881-23889	severity	_	
129-12	23889-23890	,	_	
129-13	23891-23900	marijuana	_	
129-14	23901-23908	craving	_	
129-15	23908-23909	,	_	
129-16	23910-23912	or	_	
129-17	23913-23921	cannabis	_	
129-18	23922-23932	withdrawal	_	
129-19	23933-23941	symptoms	_	
129-20	23941-23942	.	_	

#Text=The DMN hyperconnectivity detected in cannabis-using patients with SCZ is in accordance with abnormalities found in medication-naïve patients with SCZ that do not have CUD, as well as in their first degree relatives.
130-1	23943-23946	The	_	
130-2	23947-23950	DMN	_	
130-3	23951-23968	hyperconnectivity	_	
130-4	23969-23977	detected	_	
130-5	23978-23980	in	_	
130-6	23981-23995	cannabis-using	_	
130-7	23996-24004	patients	_	
130-8	24005-24009	with	_	
130-9	24010-24013	SCZ	_	
130-10	24014-24016	is	_	
130-11	24017-24019	in	_	
130-12	24020-24030	accordance	_	
130-13	24031-24035	with	_	
130-14	24036-24049	abnormalities	_	
130-15	24050-24055	found	_	
130-16	24056-24058	in	_	
130-17	24059-24075	medication-naïve	_	
130-18	24076-24084	patients	_	
130-19	24085-24089	with	_	
130-20	24090-24093	SCZ	_	
130-21	24094-24098	that	_	
130-22	24099-24101	do	_	
130-23	24102-24105	not	_	
130-24	24106-24110	have	_	
130-25	24111-24114	CUD	_	
130-26	24114-24115	,	_	
130-27	24116-24118	as	_	
130-28	24119-24123	well	_	
130-29	24124-24126	as	_	
130-30	24127-24129	in	_	
130-31	24130-24135	their	_	
130-32	24136-24141	first	_	
130-33	24142-24148	degree	_	
130-34	24149-24158	relatives	_	
130-35	24158-24159	.	_	

#Text=Hyperconnectivity of the DMN was also previously reported in patients with SCZ on a stable dose of atypical antipsychotic medication, suggesting that the functional pathology of the DMN appears to be present irrespective of some antipsychotic medication use.
131-1	24160-24177	Hyperconnectivity	_	
131-2	24178-24180	of	_	
131-3	24181-24184	the	_	
131-4	24185-24188	DMN	_	
131-5	24189-24192	was	_	
131-6	24193-24197	also	_	
131-7	24198-24208	previously	_	
131-8	24209-24217	reported	_	
131-9	24218-24220	in	_	
131-10	24221-24229	patients	_	
131-11	24230-24234	with	_	
131-12	24235-24238	SCZ	_	
131-13	24239-24241	on	_	
131-14	24242-24243	a	_	
131-15	24244-24250	stable	_	
131-16	24251-24255	dose	_	
131-17	24256-24258	of	_	
131-18	24259-24267	atypical	_	
131-19	24268-24281	antipsychotic	_	
131-20	24282-24292	medication	_	
131-21	24292-24293	,	_	
131-22	24294-24304	suggesting	_	
131-23	24305-24309	that	_	
131-24	24310-24313	the	_	
131-25	24314-24324	functional	_	
131-26	24325-24334	pathology	_	
131-27	24335-24337	of	_	
131-28	24338-24341	the	_	
131-29	24342-24345	DMN	_	
131-30	24346-24353	appears	_	
131-31	24354-24356	to	_	
131-32	24357-24359	be	_	
131-33	24360-24367	present	_	
131-34	24368-24380	irrespective	_	
131-35	24381-24383	of	_	
131-36	24384-24388	some	_	
131-37	24389-24402	antipsychotic	_	
131-38	24403-24413	medication	_	
131-39	24414-24417	use	_	
131-40	24417-24418	.	_	

#Text=That patients with SCZ, both with and without co-occurring CUD, as well as unaffected first-degree relatives, show the DMN disturbances provides evidence that this may be a core feature of the disorder rather than an epiphenomenon related to medications, substance use, or disease related variables such as chronicity.
132-1	24419-24423	That	_	
132-2	24424-24432	patients	_	
132-3	24433-24437	with	_	
132-4	24438-24441	SCZ	_	
132-5	24441-24442	,	_	
132-6	24443-24447	both	_	
132-7	24448-24452	with	_	
132-8	24453-24456	and	_	
132-9	24457-24464	without	_	
132-10	24465-24477	co-occurring	_	
132-11	24478-24481	CUD	_	
132-12	24481-24482	,	_	
132-13	24483-24485	as	_	
132-14	24486-24490	well	_	
132-15	24491-24493	as	_	
132-16	24494-24504	unaffected	_	
132-17	24505-24517	first-degree	_	
132-18	24518-24527	relatives	_	
132-19	24527-24528	,	_	
132-20	24529-24533	show	_	
132-21	24534-24537	the	_	
132-22	24538-24541	DMN	_	
132-23	24542-24554	disturbances	_	
132-24	24555-24563	provides	_	
132-25	24564-24572	evidence	_	
132-26	24573-24577	that	_	
132-27	24578-24582	this	_	
132-28	24583-24586	may	_	
132-29	24587-24589	be	_	
132-30	24590-24591	a	_	
132-31	24592-24596	core	_	
132-32	24597-24604	feature	_	
132-33	24605-24607	of	_	
132-34	24608-24611	the	_	
132-35	24612-24620	disorder	_	
132-36	24621-24627	rather	_	
132-37	24628-24632	than	_	
132-38	24633-24635	an	_	
132-39	24636-24649	epiphenomenon	_	
132-40	24650-24657	related	_	
132-41	24658-24660	to	_	
132-42	24661-24672	medications	_	
132-43	24672-24673	,	_	
132-44	24674-24683	substance	_	
132-45	24684-24687	use	_	
132-46	24687-24688	,	_	
132-47	24689-24691	or	_	
132-48	24692-24699	disease	_	
132-49	24700-24707	related	_	
132-50	24708-24717	variables	_	
132-51	24718-24722	such	_	
132-52	24723-24725	as	_	
132-53	24726-24736	chronicity	_	
132-54	24736-24737	.	_	

#Text=Patients with SCZ and CUD also demonstrated decreased DMN/ECN anticorrelation relative to controls.
133-1	24738-24746	Patients	_	
133-2	24747-24751	with	_	
133-3	24752-24755	SCZ	_	
133-4	24756-24759	and	_	
133-5	24760-24763	CUD	_	
133-6	24764-24768	also	_	
133-7	24769-24781	demonstrated	_	
133-8	24782-24791	decreased	_	
133-9	24792-24795	DMN	_	
133-10	24795-24796	/	_	
133-11	24796-24799	ECN	_	
133-12	24800-24815	anticorrelation	_	
133-13	24816-24824	relative	_	
133-14	24825-24827	to	_	
133-15	24828-24836	controls	_	
133-16	24836-24837	.	_	

#Text=This finding is consistent with prior studies of non-cannabis using patients with SCZ, both medication naïve and those taking antipsychotic medication.
134-1	24838-24842	This	_	
134-2	24843-24850	finding	_	
134-3	24851-24853	is	_	
134-4	24854-24864	consistent	_	
134-5	24865-24869	with	_	
134-6	24870-24875	prior	_	
134-7	24876-24883	studies	_	
134-8	24884-24886	of	_	
134-9	24887-24899	non-cannabis	_	
134-10	24900-24905	using	_	
134-11	24906-24914	patients	_	
134-12	24915-24919	with	_	
134-13	24920-24923	SCZ	_	
134-14	24923-24924	,	_	
134-15	24925-24929	both	_	
134-16	24930-24940	medication	_	
134-17	24941-24946	naïve	_	
134-18	24947-24950	and	_	
134-19	24951-24956	those	_	
134-20	24957-24963	taking	_	
134-21	24964-24977	antipsychotic	_	
134-22	24978-24988	medication	_	
134-23	24988-24989	.	_	

#Text=Our findings suggest that cannabinoids, at the low doses used, reduce DMN hyperconnectivity.
135-1	24990-24993	Our	_	
135-2	24994-25002	findings	_	
135-3	25003-25010	suggest	_	
135-4	25011-25015	that	_	
135-5	25016-25028	cannabinoids	_	
135-6	25028-25029	,	_	
135-7	25030-25032	at	_	
135-8	25033-25036	the	_	
135-9	25037-25040	low	_	
135-10	25041-25046	doses	_	
135-11	25047-25051	used	_	
135-12	25051-25052	,	_	
135-13	25053-25059	reduce	_	
135-14	25060-25063	DMN	_	
135-15	25064-25081	hyperconnectivity	_	
135-16	25081-25082	.	_	

#Text=DMN hyperconnectivity is theorized to result in a ‘blurring of boundaries’ between internally derived thoughts and external events manifesting as positive symptoms of SCZ such as delusions and hallucinations.
136-1	25083-25086	DMN	_	
136-2	25087-25104	hyperconnectivity	_	
136-3	25105-25107	is	_	
136-4	25108-25117	theorized	_	
136-5	25118-25120	to	_	
136-6	25121-25127	result	_	
136-7	25128-25130	in	_	
136-8	25131-25132	a	_	
136-9	25133-25134	‘	_	
136-10	25134-25142	blurring	_	
136-11	25143-25145	of	_	
136-12	25146-25156	boundaries	_	
136-13	25156-25157	’	_	
136-14	25158-25165	between	_	
136-15	25166-25176	internally	_	
136-16	25177-25184	derived	_	
136-17	25185-25193	thoughts	_	
136-18	25194-25197	and	_	
136-19	25198-25206	external	_	
136-20	25207-25213	events	_	
136-21	25214-25225	manifesting	_	
136-22	25226-25228	as	_	
136-23	25229-25237	positive	_	
136-24	25238-25246	symptoms	_	
136-25	25247-25249	of	_	
136-26	25250-25253	SCZ	_	
136-27	25254-25258	such	_	
136-28	25259-25261	as	_	
136-29	25262-25271	delusions	_	
136-30	25272-25275	and	_	
136-31	25276-25290	hallucinations	_	
136-32	25290-25291	.	_	

#Text=Our data, and those of others, suggest that there may be a dose dependent effect of THC, the primary psychoactive component within cannabis, with low doses improving and high doses worsening hyperconnectivity of this network in association with positive symptoms.
137-1	25292-25295	Our	_	
137-2	25296-25300	data	_	
137-3	25300-25301	,	_	
137-4	25302-25305	and	_	
137-5	25306-25311	those	_	
137-6	25312-25314	of	_	
137-7	25315-25321	others	_	
137-8	25321-25322	,	_	
137-9	25323-25330	suggest	_	
137-10	25331-25335	that	_	
137-11	25336-25341	there	_	
137-12	25342-25345	may	_	
137-13	25346-25348	be	_	
137-14	25349-25350	a	_	
137-15	25351-25355	dose	_	
137-16	25356-25365	dependent	_	
137-17	25366-25372	effect	_	
137-18	25373-25375	of	_	
137-19	25376-25379	THC	_	
137-20	25379-25380	,	_	
137-21	25381-25384	the	_	
137-22	25385-25392	primary	_	
137-23	25393-25405	psychoactive	_	
137-24	25406-25415	component	_	
137-25	25416-25422	within	_	
137-26	25423-25431	cannabis	_	
137-27	25431-25432	,	_	
137-28	25433-25437	with	_	
137-29	25438-25441	low	_	
137-30	25442-25447	doses	_	
137-31	25448-25457	improving	_	
137-32	25458-25461	and	_	
137-33	25462-25466	high	_	
137-34	25467-25472	doses	_	
137-35	25473-25482	worsening	_	
137-36	25483-25500	hyperconnectivity	_	
137-37	25501-25503	of	_	
137-38	25504-25508	this	_	
137-39	25509-25516	network	_	
137-40	25517-25519	in	_	
137-41	25520-25531	association	_	
137-42	25532-25536	with	_	
137-43	25537-25545	positive	_	
137-44	25546-25554	symptoms	_	
137-45	25554-25555	.	_	

#Text=While a significant difference between the effects of smoked cannabis and oral THC was not found in this pilot study, further research is needed to examine possible differential effects of cannabis and THC as well as dose dependent effects on network connectivity and symptomatology.
138-1	25556-25561	While	_	
138-2	25562-25563	a	_	
138-3	25564-25575	significant	_	
138-4	25576-25586	difference	_	
138-5	25587-25594	between	_	
138-6	25595-25598	the	_	
138-7	25599-25606	effects	_	
138-8	25607-25609	of	_	
138-9	25610-25616	smoked	_	
138-10	25617-25625	cannabis	_	
138-11	25626-25629	and	_	
138-12	25630-25634	oral	_	
138-13	25635-25638	THC	_	
138-14	25639-25642	was	_	
138-15	25643-25646	not	_	
138-16	25647-25652	found	_	
138-17	25653-25655	in	_	
138-18	25656-25660	this	_	
138-19	25661-25666	pilot	_	
138-20	25667-25672	study	_	
138-21	25672-25673	,	_	
138-22	25674-25681	further	_	
138-23	25682-25690	research	_	
138-24	25691-25693	is	_	
138-25	25694-25700	needed	_	
138-26	25701-25703	to	_	
138-27	25704-25711	examine	_	
138-28	25712-25720	possible	_	
138-29	25721-25733	differential	_	
138-30	25734-25741	effects	_	
138-31	25742-25744	of	_	
138-32	25745-25753	cannabis	_	
138-33	25754-25757	and	_	
138-34	25758-25761	THC	_	
138-35	25762-25764	as	_	
138-36	25765-25769	well	_	
138-37	25770-25772	as	_	
138-38	25773-25777	dose	_	
138-39	25778-25787	dependent	_	
138-40	25788-25795	effects	_	
138-41	25796-25798	on	_	
138-42	25799-25806	network	_	
138-43	25807-25819	connectivity	_	
138-44	25820-25823	and	_	
138-45	25824-25838	symptomatology	_	
138-46	25838-25839	.	_	

#Text=These preliminary findings also indicated that cannabinoids significantly improve the DMN/ECN anticorrelation.
139-1	25840-25845	These	_	
139-2	25846-25857	preliminary	_	
139-3	25858-25866	findings	_	
139-4	25867-25871	also	_	
139-5	25872-25881	indicated	_	
139-6	25882-25886	that	_	
139-7	25887-25899	cannabinoids	_	
139-8	25900-25913	significantly	_	
139-9	25914-25921	improve	_	
139-10	25922-25925	the	_	
139-11	25926-25929	DMN	_	
139-12	25929-25930	/	_	
139-13	25930-25933	ECN	_	
139-14	25934-25949	anticorrelation	_	
139-15	25949-25950	.	_	

#Text=By improving the strength of anticorrelation between these networks, low dose cannabis (or THC) may allow for more appropriate allocation of attentional resources, thus enhancing the ability to distinguish (and shift) between internal and external modes of processing.
140-1	25951-25953	By	_	
140-2	25954-25963	improving	_	
140-3	25964-25967	the	_	
140-4	25968-25976	strength	_	
140-5	25977-25979	of	_	
140-6	25980-25995	anticorrelation	_	
140-7	25996-26003	between	_	
140-8	26004-26009	these	_	
140-9	26010-26018	networks	_	
140-10	26018-26019	,	_	
140-11	26020-26023	low	_	
140-12	26024-26028	dose	_	
140-13	26029-26037	cannabis	_	
140-14	26038-26039	(	_	
140-15	26039-26041	or	_	
140-16	26042-26045	THC	_	
140-17	26045-26046	)	_	
140-18	26047-26050	may	_	
140-19	26051-26056	allow	_	
140-20	26057-26060	for	_	
140-21	26061-26065	more	_	
140-22	26066-26077	appropriate	_	
140-23	26078-26088	allocation	_	
140-24	26089-26091	of	_	
140-25	26092-26103	attentional	_	
140-26	26104-26113	resources	_	
140-27	26113-26114	,	_	
140-28	26115-26119	thus	_	
140-29	26120-26129	enhancing	_	
140-30	26130-26133	the	_	
140-31	26134-26141	ability	_	
140-32	26142-26144	to	_	
140-33	26145-26156	distinguish	_	
140-34	26157-26158	(	_	
140-35	26158-26161	and	_	
140-36	26162-26167	shift	_	
140-37	26167-26168	)	_	
140-38	26169-26176	between	_	
140-39	26177-26185	internal	_	
140-40	26186-26189	and	_	
140-41	26190-26198	external	_	
140-42	26199-26204	modes	_	
140-43	26205-26207	of	_	
140-44	26208-26218	processing	_	
140-45	26218-26219	.	_	

#Text=Although cannabinoid administration did not improve WM performance in this pilot study, after cannabinoid administration (but not before) we did observe a direct association between the strength of DMN/ECN anticorrelation and WM performance.
141-1	26220-26228	Although	_	
141-2	26229-26240	cannabinoid	_	
141-3	26241-26255	administration	_	
141-4	26256-26259	did	_	
141-5	26260-26263	not	_	
141-6	26264-26271	improve	_	
141-7	26272-26274	WM	_	
141-8	26275-26286	performance	_	
141-9	26287-26289	in	_	
141-10	26290-26294	this	_	
141-11	26295-26300	pilot	_	
141-12	26301-26306	study	_	
141-13	26306-26307	,	_	
141-14	26308-26313	after	_	
141-15	26314-26325	cannabinoid	_	
141-16	26326-26340	administration	_	
141-17	26341-26342	(	_	
141-18	26342-26345	but	_	
141-19	26346-26349	not	_	
141-20	26350-26356	before	_	
141-21	26356-26357	)	_	
141-22	26358-26360	we	_	
141-23	26361-26364	did	_	
141-24	26365-26372	observe	_	
141-25	26373-26374	a	_	
141-26	26375-26381	direct	_	
141-27	26382-26393	association	_	
141-28	26394-26401	between	_	
141-29	26402-26405	the	_	
141-30	26406-26414	strength	_	
141-31	26415-26417	of	_	
141-32	26418-26421	DMN	_	
141-33	26421-26422	/	_	
141-34	26422-26425	ECN	_	
141-35	26426-26441	anticorrelation	_	
141-36	26442-26445	and	_	
141-37	26446-26448	WM	_	
141-38	26449-26460	performance	_	
141-39	26460-26461	.	_	

#Text=In accordance with our findings, Loberg and colleagues found that patients with SCZ who used cannabis showed greater activation of the ECN and deactivation of the DMN during task performance than patients who did not use cannabis.
142-1	26462-26464	In	_	
142-2	26465-26475	accordance	_	
142-3	26476-26480	with	_	
142-4	26481-26484	our	_	
142-5	26485-26493	findings	_	
142-6	26493-26494	,	_	
142-7	26495-26501	Loberg	_	
142-8	26502-26505	and	_	
142-9	26506-26516	colleagues	_	
142-10	26517-26522	found	_	
142-11	26523-26527	that	_	
142-12	26528-26536	patients	_	
142-13	26537-26541	with	_	
142-14	26542-26545	SCZ	_	
142-15	26546-26549	who	_	
142-16	26550-26554	used	_	
142-17	26555-26563	cannabis	_	
142-18	26564-26570	showed	_	
142-19	26571-26578	greater	_	
142-20	26579-26589	activation	_	
142-21	26590-26592	of	_	
142-22	26593-26596	the	_	
142-23	26597-26600	ECN	_	
142-24	26601-26604	and	_	
142-25	26605-26617	deactivation	_	
142-26	26618-26620	of	_	
142-27	26621-26624	the	_	
142-28	26625-26628	DMN	_	
142-29	26629-26635	during	_	
142-30	26636-26640	task	_	
142-31	26641-26652	performance	_	
142-32	26653-26657	than	_	
142-33	26658-26666	patients	_	
142-34	26667-26670	who	_	
142-35	26671-26674	did	_	
142-36	26675-26678	not	_	
142-37	26679-26682	use	_	
142-38	26683-26691	cannabis	_	
142-39	26691-26692	.	_	

#Text=In a previous study, we found a functional dissociation in the DMN pathology in patients with schizophrenia such that MPFC-PCC hyperconnectivity related to positive symptoms (and not working memory capacity) while MPFC-DLPFC anticorrelations related to working memory performance.
143-1	26693-26695	In	_	
143-2	26696-26697	a	_	
143-3	26698-26706	previous	_	
143-4	26707-26712	study	_	
143-5	26712-26713	,	_	
143-6	26714-26716	we	_	
143-7	26717-26722	found	_	
143-8	26723-26724	a	_	
143-9	26725-26735	functional	_	
143-10	26736-26748	dissociation	_	
143-11	26749-26751	in	_	
143-12	26752-26755	the	_	
143-13	26756-26759	DMN	_	
143-14	26760-26769	pathology	_	
143-15	26770-26772	in	_	
143-16	26773-26781	patients	_	
143-17	26782-26786	with	_	
143-18	26787-26800	schizophrenia	_	
143-19	26801-26805	such	_	
143-20	26806-26810	that	_	
143-21	26811-26819	MPFC-PCC	_	
143-22	26820-26837	hyperconnectivity	_	
143-23	26838-26845	related	_	
143-24	26846-26848	to	_	
143-25	26849-26857	positive	_	
143-26	26858-26866	symptoms	_	
143-27	26867-26868	(	_	
143-28	26868-26871	and	_	
143-29	26872-26875	not	_	
143-30	26876-26883	working	_	
143-31	26884-26890	memory	_	
143-32	26891-26899	capacity	_	
143-33	26899-26900	)	_	
143-34	26901-26906	while	_	
143-35	26907-26917	MPFC-DLPFC	_	
143-36	26918-26934	anticorrelations	_	
143-37	26935-26942	related	_	
143-38	26943-26945	to	_	
143-39	26946-26953	working	_	
143-40	26954-26960	memory	_	
143-41	26961-26972	performance	_	
143-42	26972-26973	.	_	

#Text=In addition, there is vast evidence in the literature that DMN/ECN anticorrelations (e.g., MPFC-DLPFC anticorrelations) are related to executive function such as working memory capacity in typical adults.
144-1	26974-26976	In	_	
144-2	26977-26985	addition	_	
144-3	26985-26986	,	_	
144-4	26987-26992	there	_	
144-5	26993-26995	is	_	
144-6	26996-27000	vast	_	
144-7	27001-27009	evidence	_	
144-8	27010-27012	in	_	
144-9	27013-27016	the	_	
144-10	27017-27027	literature	_	
144-11	27028-27032	that	_	
144-12	27033-27036	DMN	_	
144-13	27036-27037	/	_	
144-14	27037-27040	ECN	_	
144-15	27041-27057	anticorrelations	_	
144-16	27058-27059	(	_	
144-17	27059-27062	e.g	_	
144-18	27062-27063	.	_	
144-19	27063-27064	,	_	
144-20	27065-27075	MPFC-DLPFC	_	
144-21	27076-27092	anticorrelations	_	
144-22	27092-27093	)	_	
144-23	27094-27097	are	_	
144-24	27098-27105	related	_	
144-25	27106-27108	to	_	
144-26	27109-27118	executive	_	
144-27	27119-27127	function	_	
144-28	27128-27132	such	_	
144-29	27133-27135	as	_	
144-30	27136-27143	working	_	
144-31	27144-27150	memory	_	
144-32	27151-27159	capacity	_	
144-33	27160-27162	in	_	
144-34	27163-27170	typical	_	
144-35	27171-27177	adults	_	
144-36	27177-27178	.	_	

#Text=Specifically, the magnitude of resting state anticorrelation between DMN/ECN has been linked to superior cognitive control and working memory task performance.
145-1	27179-27191	Specifically	_	
145-2	27191-27192	,	_	
145-3	27193-27196	the	_	
145-4	27197-27206	magnitude	_	
145-5	27207-27209	of	_	
145-6	27210-27217	resting	_	
145-7	27218-27223	state	_	
145-8	27224-27239	anticorrelation	_	
145-9	27240-27247	between	_	
145-10	27248-27251	DMN	_	
145-11	27251-27252	/	_	
145-12	27252-27255	ECN	_	
145-13	27256-27259	has	_	
145-14	27260-27264	been	_	
145-15	27265-27271	linked	_	
145-16	27272-27274	to	_	
145-17	27275-27283	superior	_	
145-18	27284-27293	cognitive	_	
145-19	27294-27301	control	_	
145-20	27302-27305	and	_	
145-21	27306-27313	working	_	
145-22	27314-27320	memory	_	
145-23	27321-27325	task	_	
145-24	27326-27337	performance	_	
145-25	27337-27338	.	_	

#Text=In the present study, we also found a direct association between the strength of the DMN/ECN anticorrelation and WM performance in healthy controls, consistent with prior study findings.
146-1	27339-27341	In	_	
146-2	27342-27345	the	_	
146-3	27346-27353	present	_	
146-4	27354-27359	study	_	
146-5	27359-27360	,	_	
146-6	27361-27363	we	_	
146-7	27364-27368	also	_	
146-8	27369-27374	found	_	
146-9	27375-27376	a	_	
146-10	27377-27383	direct	_	
146-11	27384-27395	association	_	
146-12	27396-27403	between	_	
146-13	27404-27407	the	_	
146-14	27408-27416	strength	_	
146-15	27417-27419	of	_	
146-16	27420-27423	the	_	
146-17	27424-27427	DMN	_	
146-18	27427-27428	/	_	
146-19	27428-27431	ECN	_	
146-20	27432-27447	anticorrelation	_	
146-21	27448-27451	and	_	
146-22	27452-27454	WM	_	
146-23	27455-27466	performance	_	
146-24	27467-27469	in	_	
146-25	27470-27477	healthy	_	
146-26	27478-27486	controls	_	
146-27	27486-27487	,	_	
146-28	27488-27498	consistent	_	
146-29	27499-27503	with	_	
146-30	27504-27509	prior	_	
146-31	27510-27515	study	_	
146-32	27516-27524	findings	_	
146-33	27524-27525	.	_	

#Text=Our findings have implications for establishing the applicability of resting state functional connectivity assessment for use as a measure of circuit-level alteration in inter-regional functional connectivity induced by pharmacologic agents.
147-1	27526-27529	Our	_	
147-2	27530-27538	findings	_	
147-3	27539-27543	have	_	
147-4	27544-27556	implications	_	
147-5	27557-27560	for	_	
147-6	27561-27573	establishing	_	
147-7	27574-27577	the	_	
147-8	27578-27591	applicability	_	
147-9	27592-27594	of	_	
147-10	27595-27602	resting	_	
147-11	27603-27608	state	_	
147-12	27609-27619	functional	_	
147-13	27620-27632	connectivity	_	
147-14	27633-27643	assessment	_	
147-15	27644-27647	for	_	
147-16	27648-27651	use	_	
147-17	27652-27654	as	_	
147-18	27655-27656	a	_	
147-19	27657-27664	measure	_	
147-20	27665-27667	of	_	
147-21	27668-27681	circuit-level	_	
147-22	27682-27692	alteration	_	
147-23	27693-27695	in	_	
147-24	27696-27710	inter-regional	_	
147-25	27711-27721	functional	_	
147-26	27722-27734	connectivity	_	
147-27	27735-27742	induced	_	
147-28	27743-27745	by	_	
147-29	27746-27759	pharmacologic	_	
147-30	27760-27766	agents	_	
147-31	27766-27767	.	_	

#Text=Despite the small sample size, we detected significant alterations in functional connectivity of the DMN induced by cannabinoids between brain regions known to have high CB1 receptor density.
148-1	27768-27775	Despite	_	
148-2	27776-27779	the	_	
148-3	27780-27785	small	_	
148-4	27786-27792	sample	_	
148-5	27793-27797	size	_	
148-6	27797-27798	,	_	
148-7	27799-27801	we	_	
148-8	27802-27810	detected	_	
148-9	27811-27822	significant	_	
148-10	27823-27834	alterations	_	
148-11	27835-27837	in	_	
148-12	27838-27848	functional	_	
148-13	27849-27861	connectivity	_	
148-14	27862-27864	of	_	
148-15	27865-27868	the	_	
148-16	27869-27872	DMN	_	
148-17	27873-27880	induced	_	
148-18	27881-27883	by	_	
148-19	27884-27896	cannabinoids	_	
148-20	27897-27904	between	_	
148-21	27905-27910	brain	_	
148-22	27911-27918	regions	_	
148-23	27919-27924	known	_	
148-24	27925-27927	to	_	
148-25	27928-27932	have	_	
148-26	27933-27937	high	_	
148-27	27938-27941	CB1	_	
148-28	27942-27950	receptor	_	
148-29	27951-27958	density	_	
148-30	27958-27959	.	_	

#Text=Our data may have potential implications for the development of pharmacotherapies that can normalize circuit level function in patients with SCZ.
149-1	27960-27963	Our	_	
149-2	27964-27968	data	_	
149-3	27969-27972	may	_	
149-4	27973-27977	have	_	
149-5	27978-27987	potential	_	
149-6	27988-28000	implications	_	
149-7	28001-28004	for	_	
149-8	28005-28008	the	_	
149-9	28009-28020	development	_	
149-10	28021-28023	of	_	
149-11	28024-28041	pharmacotherapies	_	
149-12	28042-28046	that	_	
149-13	28047-28050	can	_	
149-14	28051-28060	normalize	_	
149-15	28061-28068	circuit	_	
149-16	28069-28074	level	_	
149-17	28075-28083	function	_	
149-18	28084-28086	in	_	
149-19	28087-28095	patients	_	
149-20	28096-28100	with	_	
149-21	28101-28104	SCZ	_	
149-22	28104-28105	.	_	

#Text=The results reported here should be interpreted in light of the study limitations.
150-1	28106-28109	The	_	
150-2	28110-28117	results	_	
150-3	28118-28126	reported	_	
150-4	28127-28131	here	_	
150-5	28132-28138	should	_	
150-6	28139-28141	be	_	
150-7	28142-28153	interpreted	_	
150-8	28154-28156	in	_	
150-9	28157-28162	light	_	
150-10	28163-28165	of	_	
150-11	28166-28169	the	_	
150-12	28170-28175	study	_	
150-13	28176-28187	limitations	_	
150-14	28187-28188	.	_	

#Text=First, this is a pilot study; the small sample size is a significant limitation and results must be replicated in a larger patient sample.
151-1	28189-28194	First	_	
151-2	28194-28195	,	_	
151-3	28196-28200	this	_	
151-4	28201-28203	is	_	
151-5	28204-28205	a	_	
151-6	28206-28211	pilot	_	
151-7	28212-28217	study	_	
151-8	28217-28218	;	_	
151-9	28219-28222	the	_	
151-10	28223-28228	small	_	
151-11	28229-28235	sample	_	
151-12	28236-28240	size	_	
151-13	28241-28243	is	_	
151-14	28244-28245	a	_	
151-15	28246-28257	significant	_	
151-16	28258-28268	limitation	_	
151-17	28269-28272	and	_	
151-18	28273-28280	results	_	
151-19	28281-28285	must	_	
151-20	28286-28288	be	_	
151-21	28289-28299	replicated	_	
151-22	28300-28302	in	_	
151-23	28303-28304	a	_	
151-24	28305-28311	larger	_	
151-25	28312-28319	patient	_	
151-26	28320-28326	sample	_	
151-27	28326-28327	.	_	

#Text=Second, this study did not include a SCZ without CUD subject group for comparison; such a group would be helpful in elucidating pathophysiological differences in SCZ versus ‘dual disorder’ patients.
152-1	28328-28334	Second	_	
152-2	28334-28335	,	_	
152-3	28336-28340	this	_	
152-4	28341-28346	study	_	
152-5	28347-28350	did	_	
152-6	28351-28354	not	_	
152-7	28355-28362	include	_	
152-8	28363-28364	a	_	
152-9	28365-28368	SCZ	_	
152-10	28369-28376	without	_	
152-11	28377-28380	CUD	_	
152-12	28381-28388	subject	_	
152-13	28389-28394	group	_	
152-14	28395-28398	for	_	
152-15	28399-28409	comparison	_	
152-16	28409-28410	;	_	
152-17	28411-28415	such	_	
152-18	28416-28417	a	_	
152-19	28418-28423	group	_	
152-20	28424-28429	would	_	
152-21	28430-28432	be	_	
152-22	28433-28440	helpful	_	
152-23	28441-28443	in	_	
152-24	28444-28455	elucidating	_	
152-25	28456-28474	pathophysiological	_	
152-26	28475-28486	differences	_	
152-27	28487-28489	in	_	
152-28	28490-28493	SCZ	_	
152-29	28494-28500	versus	_	
152-30	28501-28502	‘	_	
152-31	28502-28506	dual	_	
152-32	28507-28515	disorder	_	
152-33	28515-28516	’	_	
152-34	28517-28525	patients	_	
152-35	28525-28526	.	_	

#Text=Third, our sample size was not large enough to distinguish possible differences between cannabis and THC; further investigation is necessary to expand upon these pilot results.
153-1	28527-28532	Third	_	
153-2	28532-28533	,	_	
153-3	28534-28537	our	_	
153-4	28538-28544	sample	_	
153-5	28545-28549	size	_	
153-6	28550-28553	was	_	
153-7	28554-28557	not	_	
153-8	28558-28563	large	_	
153-9	28564-28570	enough	_	
153-10	28571-28573	to	_	
153-11	28574-28585	distinguish	_	
153-12	28586-28594	possible	_	
153-13	28595-28606	differences	_	
153-14	28607-28614	between	_	
153-15	28615-28623	cannabis	_	
153-16	28624-28627	and	_	
153-17	28628-28631	THC	_	
153-18	28631-28632	;	_	
153-19	28633-28640	further	_	
153-20	28641-28654	investigation	_	
153-21	28655-28657	is	_	
153-22	28658-28667	necessary	_	
153-23	28668-28670	to	_	
153-24	28671-28677	expand	_	
153-25	28678-28682	upon	_	
153-26	28683-28688	these	_	
153-27	28689-28694	pilot	_	
153-28	28695-28702	results	_	
153-29	28702-28703	.	_	

#Text=Fourth, because all patients were being treated with antipsychotic medication, the possibility that findings may have been impacted by treatment cannot be ruled out.
154-1	28704-28710	Fourth	_	
154-2	28710-28711	,	_	
154-3	28712-28719	because	_	
154-4	28720-28723	all	_	
154-5	28724-28732	patients	_	
154-6	28733-28737	were	_	
154-7	28738-28743	being	_	
154-8	28744-28751	treated	_	
154-9	28752-28756	with	_	
154-10	28757-28770	antipsychotic	_	
154-11	28771-28781	medication	_	
154-12	28781-28782	,	_	
154-13	28783-28786	the	_	
154-14	28787-28798	possibility	_	
154-15	28799-28803	that	_	
154-16	28804-28812	findings	_	
154-17	28813-28816	may	_	
154-18	28817-28821	have	_	
154-19	28822-28826	been	_	
154-20	28827-28835	impacted	_	
154-21	28836-28838	by	_	
154-22	28839-28848	treatment	_	
154-23	28849-28855	cannot	_	
154-24	28856-28858	be	_	
154-25	28859-28864	ruled	_	
154-26	28865-28868	out	_	
154-27	28868-28869	.	_	

#Text=Similar abnormalities in DMN functional connectivity, however, have been observed in medication-naive patients as well as in first-degree relatives of patients with SCZ.
155-1	28870-28877	Similar	_	
155-2	28878-28891	abnormalities	_	
155-3	28892-28894	in	_	
155-4	28895-28898	DMN	_	
155-5	28899-28909	functional	_	
155-6	28910-28922	connectivity	_	
155-7	28922-28923	,	_	
155-8	28924-28931	however	_	
155-9	28931-28932	,	_	
155-10	28933-28937	have	_	
155-11	28938-28942	been	_	
155-12	28943-28951	observed	_	
155-13	28952-28954	in	_	
155-14	28955-28971	medication-naive	_	
155-15	28972-28980	patients	_	
155-16	28981-28983	as	_	
155-17	28984-28988	well	_	
155-18	28989-28991	as	_	
155-19	28992-28994	in	_	
155-20	28995-29007	first-degree	_	
155-21	29008-29017	relatives	_	
155-22	29018-29020	of	_	
155-23	29021-29029	patients	_	
155-24	29030-29034	with	_	
155-25	29035-29038	SCZ	_	
155-26	29038-29039	.	_	

#Text=Fifth, in the present study, a low dose of THC (3.6% within the smoked cannabis cigarette, or 15mg in the pill) was administered.
156-1	29040-29045	Fifth	_	
156-2	29045-29046	,	_	
156-3	29047-29049	in	_	
156-4	29050-29053	the	_	
156-5	29054-29061	present	_	
156-6	29062-29067	study	_	
156-7	29067-29068	,	_	
156-8	29069-29070	a	_	
156-9	29071-29074	low	_	
156-10	29075-29079	dose	_	
156-11	29080-29082	of	_	
156-12	29083-29086	THC	_	
156-13	29087-29088	(	_	
156-14	29088-29092	3.6%	_	
156-15	29093-29099	within	_	
156-16	29100-29103	the	_	
156-17	29104-29110	smoked	_	
156-18	29111-29119	cannabis	_	
156-19	29120-29129	cigarette	_	
156-20	29129-29130	,	_	
156-21	29131-29133	or	_	
156-22	29134-29138	15mg	_	
156-23	29139-29141	in	_	
156-24	29142-29145	the	_	
156-25	29146-29150	pill	_	
156-26	29150-29151	)	_	
156-27	29152-29155	was	_	
156-28	29156-29168	administered	_	
156-29	29168-29169	.	_	

#Text=This dose is lower than that often seen “on the streets,” where THC percentages can be much higher.
157-1	29170-29174	This	_	
157-2	29175-29179	dose	_	
157-3	29180-29182	is	_	
157-4	29183-29188	lower	_	
157-5	29189-29193	than	_	
157-6	29194-29198	that	_	
157-7	29199-29204	often	_	
157-8	29205-29209	seen	_	
157-9	29210-29211	“	_	
157-10	29211-29213	on	_	
157-11	29214-29217	the	_	
157-12	29218-29225	streets	_	
157-13	29225-29226	,	_	
157-14	29226-29227	”	_	
157-15	29228-29233	where	_	
157-16	29234-29237	THC	_	
157-17	29238-29249	percentages	_	
157-18	29250-29253	can	_	
157-19	29254-29256	be	_	
157-20	29257-29261	much	_	
157-21	29262-29268	higher	_	
157-22	29268-29269	.	_	

#Text=Higher doses of both cannabis and THC, however, might have worsened cognition and psychotic symptom severity that may have impacted the resting state connectivity results.
158-1	29270-29276	Higher	_	
158-2	29277-29282	doses	_	
158-3	29283-29285	of	_	
158-4	29286-29290	both	_	
158-5	29291-29299	cannabis	_	
158-6	29300-29303	and	_	
158-7	29304-29307	THC	_	
158-8	29307-29308	,	_	
158-9	29309-29316	however	_	
158-10	29316-29317	,	_	
158-11	29318-29323	might	_	
158-12	29324-29328	have	_	
158-13	29329-29337	worsened	_	
158-14	29338-29347	cognition	_	
158-15	29348-29351	and	_	
158-16	29352-29361	psychotic	_	
158-17	29362-29369	symptom	_	
158-18	29370-29378	severity	_	
158-19	29379-29383	that	_	
158-20	29384-29387	may	_	
158-21	29388-29392	have	_	
158-22	29393-29401	impacted	_	
158-23	29402-29405	the	_	
158-24	29406-29413	resting	_	
158-25	29414-29419	state	_	
158-26	29420-29432	connectivity	_	
158-27	29433-29440	results	_	
158-28	29440-29441	.	_	

#Text=Sixth, since others have demonstrated that nicotine withdrawal and craving is associated with alterations in the DMN function, future studies should control for levels of nicotine dependence and craving.
159-1	29442-29447	Sixth	_	
159-2	29447-29448	,	_	
159-3	29449-29454	since	_	
159-4	29455-29461	others	_	
159-5	29462-29466	have	_	
159-6	29467-29479	demonstrated	_	
159-7	29480-29484	that	_	
159-8	29485-29493	nicotine	_	
159-9	29494-29504	withdrawal	_	
159-10	29505-29508	and	_	
159-11	29509-29516	craving	_	
159-12	29517-29519	is	_	
159-13	29520-29530	associated	_	
159-14	29531-29535	with	_	
159-15	29536-29547	alterations	_	
159-16	29548-29550	in	_	
159-17	29551-29554	the	_	
159-18	29555-29558	DMN	_	
159-19	29559-29567	function	_	
159-20	29567-29568	,	_	
159-21	29569-29575	future	_	
159-22	29576-29583	studies	_	
159-23	29584-29590	should	_	
159-24	29591-29598	control	_	
159-25	29599-29602	for	_	
159-26	29603-29609	levels	_	
159-27	29610-29612	of	_	
159-28	29613-29621	nicotine	_	
159-29	29622-29632	dependence	_	
159-30	29633-29636	and	_	
159-31	29637-29644	craving	_	
159-32	29644-29645	.	_	

#Text=Lastly, while the investigation of inter-network anticorrelations can provide valuable insight into impairment in intrinsic organization of brain networks in psychiatric patient populations, the introduction of false positives and reporting of spurious anticorrelations in resting state studies have been of particular concern.
160-1	29646-29652	Lastly	_	
160-2	29652-29653	,	_	
160-3	29654-29659	while	_	
160-4	29660-29663	the	_	
160-5	29664-29677	investigation	_	
160-6	29678-29680	of	_	
160-7	29681-29694	inter-network	_	
160-8	29695-29711	anticorrelations	_	
160-9	29712-29715	can	_	
160-10	29716-29723	provide	_	
160-11	29724-29732	valuable	_	
160-12	29733-29740	insight	_	
160-13	29741-29745	into	_	
160-14	29746-29756	impairment	_	
160-15	29757-29759	in	_	
160-16	29760-29769	intrinsic	_	
160-17	29770-29782	organization	_	
160-18	29783-29785	of	_	
160-19	29786-29791	brain	_	
160-20	29792-29800	networks	_	
160-21	29801-29803	in	_	
160-22	29804-29815	psychiatric	_	
160-23	29816-29823	patient	_	
160-24	29824-29835	populations	_	
160-25	29835-29836	,	_	
160-26	29837-29840	the	_	
160-27	29841-29853	introduction	_	
160-28	29854-29856	of	_	
160-29	29857-29862	false	_	
160-30	29863-29872	positives	_	
160-31	29873-29876	and	_	
160-32	29877-29886	reporting	_	
160-33	29887-29889	of	_	
160-34	29890-29898	spurious	_	
160-35	29899-29915	anticorrelations	_	
160-36	29916-29918	in	_	
160-37	29919-29926	resting	_	
160-38	29927-29932	state	_	
160-39	29933-29940	studies	_	
160-40	29941-29945	have	_	
160-41	29946-29950	been	_	
160-42	29951-29953	of	_	
160-43	29954-29964	particular	_	
160-44	29965-29972	concern	_	
160-45	29972-29973	.	_	

#Text=In the present study, however, physiological and other spurious sources of noise were estimated and regressed using the aCompCor method as opposed to global signal regression; doing so allowed interpretation of anticorrelations.
161-1	29974-29976	In	_	
161-2	29977-29980	the	_	
161-3	29981-29988	present	_	
161-4	29989-29994	study	_	
161-5	29994-29995	,	_	
161-6	29996-30003	however	_	
161-7	30003-30004	,	_	
161-8	30005-30018	physiological	_	
161-9	30019-30022	and	_	
161-10	30023-30028	other	_	
161-11	30029-30037	spurious	_	
161-12	30038-30045	sources	_	
161-13	30046-30048	of	_	
161-14	30049-30054	noise	_	
161-15	30055-30059	were	_	
161-16	30060-30069	estimated	_	
161-17	30070-30073	and	_	
161-18	30074-30083	regressed	_	
161-19	30084-30089	using	_	
161-20	30090-30093	the	_	
161-21	30094-30102	aCompCor	_	
161-22	30103-30109	method	_	
161-23	30110-30112	as	_	
161-24	30113-30120	opposed	_	
161-25	30121-30123	to	_	
161-26	30124-30130	global	_	
161-27	30131-30137	signal	_	
161-28	30138-30148	regression	_	
161-29	30148-30149	;	_	
161-30	30150-30155	doing	_	
161-31	30156-30158	so	_	
161-32	30159-30166	allowed	_	
161-33	30167-30181	interpretation	_	
161-34	30182-30184	of	_	
161-35	30185-30201	anticorrelations	_	
161-36	30201-30202	.	_	

#Text=Conclusion
#Text=In this pilot investigation, DMN hyperconnectivity as well as impaired DMN/ECN anticorrelation was found in patients with SCZ and CUD relative to healthy control participants.
162-1	30203-30213	Conclusion	_	
162-2	30214-30216	In	_	
162-3	30217-30221	this	_	
162-4	30222-30227	pilot	_	
162-5	30228-30241	investigation	_	
162-6	30241-30242	,	_	
162-7	30243-30246	DMN	_	
162-8	30247-30264	hyperconnectivity	_	
162-9	30265-30267	as	_	
162-10	30268-30272	well	_	
162-11	30273-30275	as	_	
162-12	30276-30284	impaired	_	
162-13	30285-30288	DMN	_	
162-14	30288-30289	/	_	
162-15	30289-30292	ECN	_	
162-16	30293-30308	anticorrelation	_	
162-17	30309-30312	was	_	
162-18	30313-30318	found	_	
162-19	30319-30321	in	_	
162-20	30322-30330	patients	_	
162-21	30331-30335	with	_	
162-22	30336-30339	SCZ	_	
162-23	30340-30343	and	_	
162-24	30344-30347	CUD	_	
162-25	30348-30356	relative	_	
162-26	30357-30359	to	_	
162-27	30360-30367	healthy	_	
162-28	30368-30375	control	_	
162-29	30376-30388	participants	_	
162-30	30388-30389	.	_	

#Text=Our findings shed light on the effects of cannabinoid administration and suggest that in patients with SCZ and CUD cannabinoids induce alterations in network connectivity of the DMN, and in functional coupling between the DMN and ECN that directly correlates with WM performance.
163-1	30390-30393	Our	_	
163-2	30394-30402	findings	_	
163-3	30403-30407	shed	_	
163-4	30408-30413	light	_	
163-5	30414-30416	on	_	
163-6	30417-30420	the	_	
163-7	30421-30428	effects	_	
163-8	30429-30431	of	_	
163-9	30432-30443	cannabinoid	_	
163-10	30444-30458	administration	_	
163-11	30459-30462	and	_	
163-12	30463-30470	suggest	_	
163-13	30471-30475	that	_	
163-14	30476-30478	in	_	
163-15	30479-30487	patients	_	
163-16	30488-30492	with	_	
163-17	30493-30496	SCZ	_	
163-18	30497-30500	and	_	
163-19	30501-30504	CUD	_	
163-20	30505-30517	cannabinoids	_	
163-21	30518-30524	induce	_	
163-22	30525-30536	alterations	_	
163-23	30537-30539	in	_	
163-24	30540-30547	network	_	
163-25	30548-30560	connectivity	_	
163-26	30561-30563	of	_	
163-27	30564-30567	the	_	
163-28	30568-30571	DMN	_	
163-29	30571-30572	,	_	
163-30	30573-30576	and	_	
163-31	30577-30579	in	_	
163-32	30580-30590	functional	_	
163-33	30591-30599	coupling	_	
163-34	30600-30607	between	_	
163-35	30608-30611	the	_	
163-36	30612-30615	DMN	_	
163-37	30616-30619	and	_	
163-38	30620-30623	ECN	_	
163-39	30624-30628	that	_	
163-40	30629-30637	directly	_	
163-41	30638-30648	correlates	_	
163-42	30649-30653	with	_	
163-43	30654-30656	WM	_	
163-44	30657-30668	performance	_	
163-45	30668-30669	.	_	

#Text=Thus, cannabinoid administration restores circuit function in dual-diagnosis patients close to that seen in normal controls.
164-1	30670-30674	Thus	_	
164-2	30674-30675	,	_	
164-3	30676-30687	cannabinoid	_	
164-4	30688-30702	administration	_	
164-5	30703-30711	restores	_	
164-6	30712-30719	circuit	_	
164-7	30720-30728	function	_	
164-8	30729-30731	in	_	
164-9	30732-30746	dual-diagnosis	_	
164-10	30747-30755	patients	_	
164-11	30756-30761	close	_	
164-12	30762-30764	to	_	
164-13	30765-30769	that	_	
164-14	30770-30774	seen	_	
164-15	30775-30777	in	_	
164-16	30778-30784	normal	_	
164-17	30785-30793	controls	_	
164-18	30793-30794	.	_	

#Text=While further research is needed to elaborate upon the effects of cannabis on functional connectivity of the DMN, plasticity of the DMN induced by cannabinoid administration implies that treatment efficacy could potentially be assessed through the ability to ameliorate underlying circuit-level dysfunction in patients with SCZ and CUD.
165-1	30795-30800	While	_	
165-2	30801-30808	further	_	
165-3	30809-30817	research	_	
165-4	30818-30820	is	_	
165-5	30821-30827	needed	_	
165-6	30828-30830	to	_	
165-7	30831-30840	elaborate	_	
165-8	30841-30845	upon	_	
165-9	30846-30849	the	_	
165-10	30850-30857	effects	_	
165-11	30858-30860	of	_	
165-12	30861-30869	cannabis	_	
165-13	30870-30872	on	_	
165-14	30873-30883	functional	_	
165-15	30884-30896	connectivity	_	
165-16	30897-30899	of	_	
165-17	30900-30903	the	_	
165-18	30904-30907	DMN	_	
165-19	30907-30908	,	_	
165-20	30909-30919	plasticity	_	
165-21	30920-30922	of	_	
165-22	30923-30926	the	_	
165-23	30927-30930	DMN	_	
165-24	30931-30938	induced	_	
165-25	30939-30941	by	_	
165-26	30942-30953	cannabinoid	_	
165-27	30954-30968	administration	_	
165-28	30969-30976	implies	_	
165-29	30977-30981	that	_	
165-30	30982-30991	treatment	_	
165-31	30992-31000	efficacy	_	
165-32	31001-31006	could	_	
165-33	31007-31018	potentially	_	
165-34	31019-31021	be	_	
165-35	31022-31030	assessed	_	
165-36	31031-31038	through	_	
165-37	31039-31042	the	_	
165-38	31043-31050	ability	_	
165-39	31051-31053	to	_	
165-40	31054-31064	ameliorate	_	
165-41	31065-31075	underlying	_	
165-42	31076-31089	circuit-level	_	
165-43	31090-31101	dysfunction	_	
165-44	31102-31104	in	_	
165-45	31105-31113	patients	_	
165-46	31114-31118	with	_	
165-47	31119-31122	SCZ	_	
165-48	31123-31126	and	_	
165-49	31127-31130	CUD	_	
165-50	31130-31131	.	_	

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
166-1	31132-31136	This	_	
166-2	31137-31139	is	_	
166-3	31140-31141	a	_	
166-4	31142-31145	PDF	_	
166-5	31146-31150	file	_	
166-6	31151-31153	of	_	
166-7	31154-31156	an	_	
166-8	31157-31165	unedited	_	
166-9	31166-31176	manuscript	_	
166-10	31177-31181	that	_	
166-11	31182-31185	has	_	
166-12	31186-31190	been	_	
166-13	31191-31199	accepted	_	
166-14	31200-31203	for	_	
166-15	31204-31215	publication	_	
166-16	31215-31216	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
167-1	31217-31219	As	_	
167-2	31220-31221	a	_	
167-3	31222-31229	service	_	
167-4	31230-31232	to	_	
167-5	31233-31236	our	_	
167-6	31237-31246	customers	_	
167-7	31247-31249	we	_	
167-8	31250-31253	are	_	
167-9	31254-31263	providing	_	
167-10	31264-31268	this	_	
167-11	31269-31274	early	_	
167-12	31275-31282	version	_	
167-13	31283-31285	of	_	
167-14	31286-31289	the	_	
167-15	31290-31300	manuscript	_	
167-16	31300-31301	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form.
168-1	31302-31305	The	_	
168-2	31306-31316	manuscript	_	
168-3	31317-31321	will	_	
168-4	31322-31329	undergo	_	
168-5	31330-31341	copyediting	_	
168-6	31341-31342	,	_	
168-7	31343-31354	typesetting	_	
168-8	31354-31355	,	_	
168-9	31356-31359	and	_	
168-10	31360-31366	review	_	
168-11	31367-31369	of	_	
168-12	31370-31373	the	_	
168-13	31374-31383	resulting	_	
168-14	31384-31389	proof	_	
168-15	31390-31396	before	_	
168-16	31397-31399	it	_	
168-17	31400-31402	is	_	
168-18	31403-31412	published	_	
168-19	31413-31415	in	_	
168-20	31416-31419	its	_	
168-21	31420-31425	final	_	
168-22	31426-31430	form	_	
168-23	31430-31431	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
169-1	31432-31438	Please	_	
169-2	31439-31443	note	_	
169-3	31444-31448	that	_	
169-4	31449-31455	during	_	
169-5	31456-31459	the	_	
169-6	31460-31470	production	_	
169-7	31471-31478	process	_	
169-8	31479-31485	errors	_	
169-9	31486-31489	may	_	
169-10	31490-31492	be	_	
169-11	31493-31503	discovered	_	
169-12	31504-31509	which	_	
169-13	31510-31515	could	_	
169-14	31516-31522	affect	_	
169-15	31523-31526	the	_	
169-16	31527-31534	content	_	
169-17	31534-31535	,	_	
169-18	31536-31539	and	_	
169-19	31540-31543	all	_	
169-20	31544-31549	legal	_	
169-21	31550-31561	disclaimers	_	
169-22	31562-31566	that	_	
169-23	31567-31572	apply	_	
169-24	31573-31575	to	_	
169-25	31576-31579	the	_	
169-26	31580-31587	journal	_	
169-27	31588-31595	pertain	_	
169-28	31595-31596	.	_	

#Text=References
#Text=Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia
#Text=Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change
#Text=Developmental changes in within- and between-network connectivity between late childhood and adulthood
#Text=A component based noise correction method (CompCor) for BOLD and perfusion based fMRI
#Text=Functional connectivity in the motor cortex of resting human brain using echo-planar MRI
#Text=Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network
#Text=Psychiatric comorbidities and schizophrenia
#Text=The brain’s default network: anatomy, function, and relevance to disease
#Text=Marijuana withdrawal among adults seeking treatment for marijuana dependence
#Text=Altered functional and anatomical connectivity in schizophrenia
#Text=Anticorrelations in resting state networks without global signal regression
#Text=Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia
#Text=Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics
#Text=Control of goal-directed and stimulus-driven attention in the brain
#Text=Consistent resting-state networks across healthy subjects
#Text=Cannabis use disorders in schizophrenia: effects on cognition and symptoms
#Text=
#Text=Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC
#Text=The human brain is intrinsically organized into dynamic, anticorrelated functional networks
#Text=Endocannabinoid signaling system and brain reward: emphasis on dopamine
#Text=The Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III).
170-1	31597-31607	References	_	
170-2	31608-31626	Psychopathological	_	
170-3	31627-31630	and	_	
170-4	31631-31649	neuropsychological	_	
170-5	31650-31660	correlates	_	
170-6	31661-31663	of	_	
170-7	31664-31670	source	_	
170-8	31671-31681	monitoring	_	
170-9	31682-31692	impairment	_	
170-10	31693-31695	in	_	
170-11	31696-31709	schizophrenia	_	
170-12	31710-31722	Early-course	_	
170-13	31723-31734	unmedicated	_	
170-14	31735-31748	schizophrenia	_	
170-15	31749-31757	patients	_	
170-16	31758-31765	exhibit	_	
170-17	31766-31774	elevated	_	
170-18	31775-31785	prefrontal	_	
170-19	31786-31798	connectivity	_	
170-20	31799-31809	associated	_	
170-21	31810-31814	with	_	
170-22	31815-31827	longitudinal	_	
170-23	31828-31834	change	_	
170-24	31835-31848	Developmental	_	
170-25	31849-31856	changes	_	
170-26	31857-31859	in	_	
170-27	31860-31866	within	_	
170-28	31866-31867	-	_	
170-29	31868-31871	and	_	
170-30	31872-31887	between-network	_	
170-31	31888-31900	connectivity	_	
170-32	31901-31908	between	_	
170-33	31909-31913	late	_	
170-34	31914-31923	childhood	_	
170-35	31924-31927	and	_	
170-36	31928-31937	adulthood	_	
170-37	31938-31939	A	_	
170-38	31940-31949	component	_	
170-39	31950-31955	based	_	
170-40	31956-31961	noise	_	
170-41	31962-31972	correction	_	
170-42	31973-31979	method	_	
170-43	31980-31981	(	_	
170-44	31981-31988	CompCor	_	
170-45	31988-31989	)	_	
170-46	31990-31993	for	_	
170-47	31994-31998	BOLD	_	
170-48	31999-32002	and	_	
170-49	32003-32012	perfusion	_	
170-50	32013-32018	based	_	
170-51	32019-32023	fMRI	_	
170-52	32024-32034	Functional	_	
170-53	32035-32047	connectivity	_	
170-54	32048-32050	in	_	
170-55	32051-32054	the	_	
170-56	32055-32060	motor	_	
170-57	32061-32067	cortex	_	
170-58	32068-32070	of	_	
170-59	32071-32078	resting	_	
170-60	32079-32084	human	_	
170-61	32085-32090	brain	_	
170-62	32091-32096	using	_	
170-63	32097-32108	echo-planar	_	
170-64	32109-32112	MRI	_	
170-65	32113-32124	Spontaneous	_	
170-66	32125-32138	low-frequency	_	
170-67	32139-32151	fluctuations	_	
170-68	32152-32154	in	_	
170-69	32155-32158	the	_	
170-70	32159-32163	BOLD	_	
170-71	32164-32170	signal	_	
170-72	32171-32173	in	_	
170-73	32174-32187	schizophrenic	_	
170-74	32188-32196	patients	_	
170-75	32196-32197	:	_	
170-76	32198-32207	anomalies	_	
170-77	32208-32210	in	_	
170-78	32211-32214	the	_	
170-79	32215-32222	default	_	
170-80	32223-32230	network	_	
170-81	32231-32242	Psychiatric	_	
170-82	32243-32256	comorbidities	_	
170-83	32257-32260	and	_	
170-84	32261-32274	schizophrenia	_	
170-85	32275-32278	The	_	
170-86	32279-32284	brain	_	
170-87	32284-32285	’	_	
170-88	32285-32286	s	_	
170-89	32287-32294	default	_	
170-90	32295-32302	network	_	
170-91	32302-32303	:	_	
170-92	32304-32311	anatomy	_	
170-93	32311-32312	,	_	
170-94	32313-32321	function	_	
170-95	32321-32322	,	_	
170-96	32323-32326	and	_	
170-97	32327-32336	relevance	_	
170-98	32337-32339	to	_	
170-99	32340-32347	disease	_	
170-100	32348-32357	Marijuana	_	
170-101	32358-32368	withdrawal	_	
170-102	32369-32374	among	_	
170-103	32375-32381	adults	_	
170-104	32382-32389	seeking	_	
170-105	32390-32399	treatment	_	
170-106	32400-32403	for	_	
170-107	32404-32413	marijuana	_	
170-108	32414-32424	dependence	_	
170-109	32425-32432	Altered	_	
170-110	32433-32443	functional	_	
170-111	32444-32447	and	_	
170-112	32448-32458	anatomical	_	
170-113	32459-32471	connectivity	_	
170-114	32472-32474	in	_	
170-115	32475-32488	schizophrenia	_	
170-116	32489-32505	Anticorrelations	_	
170-117	32506-32508	in	_	
170-118	32509-32516	resting	_	
170-119	32517-32522	state	_	
170-120	32523-32531	networks	_	
170-121	32532-32539	without	_	
170-122	32540-32546	global	_	
170-123	32547-32553	signal	_	
170-124	32554-32564	regression	_	
170-125	32565-32573	Abnormal	_	
170-126	32574-32580	medial	_	
170-127	32581-32591	prefrontal	_	
170-128	32592-32598	cortex	_	
170-129	32599-32612	resting-state	_	
170-130	32613-32625	connectivity	_	
170-131	32626-32628	in	_	
170-132	32629-32636	bipolar	_	
170-133	32637-32645	disorder	_	
170-134	32646-32649	and	_	
170-135	32650-32663	schizophrenia	_	
170-136	32664-32672	Nicotine	_	
170-137	32673-32684	replacement	_	
170-138	32685-32687	in	_	
170-139	32688-32697	abstinent	_	
170-140	32698-32705	smokers	_	
170-141	32706-32714	improves	_	
170-142	32715-32724	cognitive	_	
170-143	32725-32735	withdrawal	_	
170-144	32736-32744	symptoms	_	
170-145	32745-32749	with	_	
170-146	32750-32760	modulation	_	
170-147	32761-32763	of	_	
170-148	32764-32771	resting	_	
170-149	32772-32777	brain	_	
170-150	32778-32785	network	_	
170-151	32786-32794	dynamics	_	
170-152	32795-32802	Control	_	
170-153	32803-32805	of	_	
170-154	32806-32819	goal-directed	_	
170-155	32820-32823	and	_	
170-156	32824-32839	stimulus-driven	_	
170-157	32840-32849	attention	_	
170-158	32850-32852	in	_	
170-159	32853-32856	the	_	
170-160	32857-32862	brain	_	
170-161	32863-32873	Consistent	_	
170-162	32874-32887	resting-state	_	
170-163	32888-32896	networks	_	
170-164	32897-32903	across	_	
170-165	32904-32911	healthy	_	
170-166	32912-32920	subjects	_	
170-167	32921-32929	Cannabis	_	
170-168	32930-32933	use	_	
170-169	32934-32943	disorders	_	
170-170	32944-32946	in	_	
170-171	32947-32960	schizophrenia	_	
170-172	32960-32961	:	_	
170-173	32962-32969	effects	_	
170-174	32970-32972	on	_	
170-175	32973-32982	cognition	_	
170-176	32983-32986	and	_	
170-177	32987-32995	symptoms	_	
170-178	32997-33005	Impaired	_	
170-179	33006-33016	functional	_	
170-180	33017-33029	connectivity	_	
170-181	33030-33032	of	_	
170-182	33033-33038	brain	_	
170-183	33039-33045	reward	_	
170-184	33046-33055	circuitry	_	
170-185	33056-33058	in	_	
170-186	33059-33067	patients	_	
170-187	33068-33072	with	_	
170-188	33073-33086	schizophrenia	_	
170-189	33087-33090	and	_	
170-190	33091-33099	cannabis	_	
170-191	33100-33103	use	_	
170-192	33104-33112	disorder	_	
170-193	33112-33113	:	_	
170-194	33114-33121	Effects	_	
170-195	33122-33124	of	_	
170-196	33125-33133	cannabis	_	
170-197	33134-33137	and	_	
170-198	33138-33141	THC	_	
170-199	33142-33145	The	_	
170-200	33146-33151	human	_	
170-201	33152-33157	brain	_	
170-202	33158-33160	is	_	
170-203	33161-33174	intrinsically	_	
170-204	33175-33184	organized	_	
170-205	33185-33189	into	_	
170-206	33190-33197	dynamic	_	
170-207	33197-33198	,	_	
170-208	33199-33213	anticorrelated	_	
170-209	33214-33224	functional	_	
170-210	33225-33233	networks	_	
170-211	33234-33249	Endocannabinoid	_	
170-212	33250-33259	signaling	_	
170-213	33260-33266	system	_	
170-214	33267-33270	and	_	
170-215	33271-33276	brain	_	
170-216	33277-33283	reward	_	
170-217	33283-33284	:	_	
170-218	33285-33293	emphasis	_	
170-219	33294-33296	on	_	
170-220	33297-33305	dopamine	_	
170-221	33306-33309	The	_	
170-222	33310-33318	Wechsler	_	
170-223	33319-33328	Preschool	_	
170-224	33329-33332	and	_	
170-225	33333-33340	Primary	_	
170-226	33341-33346	Scale	_	
170-227	33347-33349	of	_	
170-228	33350-33362	Intelligence	_	
170-229	33362-33363	,	_	
170-230	33364-33369	Third	_	
170-231	33370-33377	Edition	_	
170-232	33378-33379	(	_	
170-233	33379-33388	WPPSI-III	_	
170-234	33388-33389	)	_	
170-235	33389-33390	.	_	

#Text=San Antonio, TX: The Psychological Corporation
#Text=Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III
#Text=Substance abuse and schizophrenia: pharmacotherapeutic intervention
#Text=Searching for a baseline: functional imaging and the resting human brain
#Text=Alterations in functional activation in euthymic bipolar disorder and schizophrenia during a working memory task
#Text=Functional connectivity between task-positive and task-negative brain areas and its relation to working memory performance
#Text=Marijuana Craving Questionnaire: development and initial validation of a self-report instrument
#Text=The environment and schizophrenia: the role of cannabis use
#Text=Psychosis reactivity to cannabis use in daily life: an experience sampling study
#Text=Impact of cannabis use on brain function in adolescents
#Text=Co-morbidity of smoking in patients with psychiatric and substance use disorders
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=Resting-state anticorrelations between medial and lateral prefrontal cortex: association with working memory, aging, and individual differences
#Text=Competition between functional brain networks mediates behavioral variability
#Text=Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness
#Text=Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis
#Text=Prefrontal-related functional connectivities within the default network are modulated by COMT val158met in healthy young adults
#Text=Cannabis use and cognition in schizophrenia
#Text=An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
#Text=Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings
#Text=The impact of global signal regression on resting state correlations: are anti-correlated networks introduced?
171-1	33391-33394	San	_	
171-2	33395-33402	Antonio	_	
171-3	33402-33403	,	_	
171-4	33404-33406	TX	_	
171-5	33406-33407	:	_	
171-6	33408-33411	The	_	
171-7	33412-33425	Psychological	_	
171-8	33426-33437	Corporation	_	
171-9	33438-33450	Epidemiology	_	
171-10	33451-33453	of	_	
171-11	33454-33457	DSM	_	
171-12	33457-33458	-	_	
171-13	33458-33459	5	_	
171-14	33460-33464	Drug	_	
171-15	33465-33468	Use	_	
171-16	33469-33477	Disorder	_	
171-17	33477-33478	:	_	
171-18	33479-33486	Results	_	
171-19	33487-33491	From	_	
171-20	33492-33495	the	_	
171-21	33496-33504	National	_	
171-22	33505-33518	Epidemiologic	_	
171-23	33519-33525	Survey	_	
171-24	33526-33528	on	_	
171-25	33529-33536	Alcohol	_	
171-26	33537-33540	and	_	
171-27	33541-33548	Related	_	
171-28	33549-33563	Conditions-III	_	
171-29	33564-33573	Substance	_	
171-30	33574-33579	abuse	_	
171-31	33580-33583	and	_	
171-32	33584-33597	schizophrenia	_	
171-33	33597-33598	:	_	
171-34	33599-33618	pharmacotherapeutic	_	
171-35	33619-33631	intervention	_	
171-36	33632-33641	Searching	_	
171-37	33642-33645	for	_	
171-38	33646-33647	a	_	
171-39	33648-33656	baseline	_	
171-40	33656-33657	:	_	
171-41	33658-33668	functional	_	
171-42	33669-33676	imaging	_	
171-43	33677-33680	and	_	
171-44	33681-33684	the	_	
171-45	33685-33692	resting	_	
171-46	33693-33698	human	_	
171-47	33699-33704	brain	_	
171-48	33705-33716	Alterations	_	
171-49	33717-33719	in	_	
171-50	33720-33730	functional	_	
171-51	33731-33741	activation	_	
171-52	33742-33744	in	_	
171-53	33745-33753	euthymic	_	
171-54	33754-33761	bipolar	_	
171-55	33762-33770	disorder	_	
171-56	33771-33774	and	_	
171-57	33775-33788	schizophrenia	_	
171-58	33789-33795	during	_	
171-59	33796-33797	a	_	
171-60	33798-33805	working	_	
171-61	33806-33812	memory	_	
171-62	33813-33817	task	_	
171-63	33818-33828	Functional	_	
171-64	33829-33841	connectivity	_	
171-65	33842-33849	between	_	
171-66	33850-33863	task-positive	_	
171-67	33864-33867	and	_	
171-68	33868-33881	task-negative	_	
171-69	33882-33887	brain	_	
171-70	33888-33893	areas	_	
171-71	33894-33897	and	_	
171-72	33898-33901	its	_	
171-73	33902-33910	relation	_	
171-74	33911-33913	to	_	
171-75	33914-33921	working	_	
171-76	33922-33928	memory	_	
171-77	33929-33940	performance	_	
171-78	33941-33950	Marijuana	_	
171-79	33951-33958	Craving	_	
171-80	33959-33972	Questionnaire	_	
171-81	33972-33973	:	_	
171-82	33974-33985	development	_	
171-83	33986-33989	and	_	
171-84	33990-33997	initial	_	
171-85	33998-34008	validation	_	
171-86	34009-34011	of	_	
171-87	34012-34013	a	_	
171-88	34014-34025	self-report	_	
171-89	34026-34036	instrument	_	
171-90	34037-34040	The	_	
171-91	34041-34052	environment	_	
171-92	34053-34056	and	_	
171-93	34057-34070	schizophrenia	_	
171-94	34070-34071	:	_	
171-95	34072-34075	the	_	
171-96	34076-34080	role	_	
171-97	34081-34083	of	_	
171-98	34084-34092	cannabis	_	
171-99	34093-34096	use	_	
171-100	34097-34106	Psychosis	_	
171-101	34107-34117	reactivity	_	
171-102	34118-34120	to	_	
171-103	34121-34129	cannabis	_	
171-104	34130-34133	use	_	
171-105	34134-34136	in	_	
171-106	34137-34142	daily	_	
171-107	34143-34147	life	_	
171-108	34147-34148	:	_	
171-109	34149-34151	an	_	
171-110	34152-34162	experience	_	
171-111	34163-34171	sampling	_	
171-112	34172-34177	study	_	
171-113	34178-34184	Impact	_	
171-114	34185-34187	of	_	
171-115	34188-34196	cannabis	_	
171-116	34197-34200	use	_	
171-117	34201-34203	on	_	
171-118	34204-34209	brain	_	
171-119	34210-34218	function	_	
171-120	34219-34221	in	_	
171-121	34222-34233	adolescents	_	
171-122	34234-34246	Co-morbidity	_	
171-123	34247-34249	of	_	
171-124	34250-34257	smoking	_	
171-125	34258-34260	in	_	
171-126	34261-34269	patients	_	
171-127	34270-34274	with	_	
171-128	34275-34286	psychiatric	_	
171-129	34287-34290	and	_	
171-130	34291-34300	substance	_	
171-131	34301-34304	use	_	
171-132	34305-34314	disorders	_	
171-133	34315-34318	The	_	
171-134	34319-34327	positive	_	
171-135	34328-34331	and	_	
171-136	34332-34340	negative	_	
171-137	34341-34349	syndrome	_	
171-138	34350-34355	scale	_	
171-139	34356-34357	(	_	
171-140	34357-34362	PANSS	_	
171-141	34362-34363	)	_	
171-142	34364-34367	for	_	
171-143	34368-34381	schizophrenia	_	
171-144	34382-34395	Resting-state	_	
171-145	34396-34412	anticorrelations	_	
171-146	34413-34420	between	_	
171-147	34421-34427	medial	_	
171-148	34428-34431	and	_	
171-149	34432-34439	lateral	_	
171-150	34440-34450	prefrontal	_	
171-151	34451-34457	cortex	_	
171-152	34457-34458	:	_	
171-153	34459-34470	association	_	
171-154	34471-34475	with	_	
171-155	34476-34483	working	_	
171-156	34484-34490	memory	_	
171-157	34490-34491	,	_	
171-158	34492-34497	aging	_	
171-159	34497-34498	,	_	
171-160	34499-34502	and	_	
171-161	34503-34513	individual	_	
171-162	34514-34525	differences	_	
171-163	34526-34537	Competition	_	
171-164	34538-34545	between	_	
171-165	34546-34556	functional	_	
171-166	34557-34562	brain	_	
171-167	34563-34571	networks	_	
171-168	34572-34580	mediates	_	
171-169	34581-34591	behavioral	_	
171-170	34592-34603	variability	_	
171-171	34604-34616	Disturbances	_	
171-172	34617-34619	of	_	
171-173	34620-34626	visual	_	
171-174	34627-34638	information	_	
171-175	34639-34649	processing	_	
171-176	34650-34652	in	_	
171-177	34653-34658	early	_	
171-178	34659-34665	states	_	
171-179	34666-34668	of	_	
171-180	34669-34678	psychosis	_	
171-181	34679-34682	and	_	
171-182	34683-34695	experimental	_	
171-183	34696-34701	delta	_	
171-184	34701-34702	-	_	
171-185	34702-34703	9	_	
171-186	34703-34704	-	_	
171-187	34704-34724	tetrahydrocannabinol	_	
171-188	34725-34732	altered	_	
171-189	34733-34739	states	_	
171-190	34740-34742	of	_	
171-191	34743-34756	consciousness	_	
171-192	34757-34761	Rate	_	
171-193	34762-34764	of	_	
171-194	34765-34773	cannabis	_	
171-195	34774-34777	use	_	
171-196	34778-34787	disorders	_	
171-197	34788-34790	in	_	
171-198	34791-34799	clinical	_	
171-199	34800-34807	samples	_	
171-200	34808-34810	of	_	
171-201	34811-34819	patients	_	
171-202	34820-34824	with	_	
171-203	34825-34838	schizophrenia	_	
171-204	34838-34839	:	_	
171-205	34840-34841	a	_	
171-206	34842-34855	meta-analysis	_	
171-207	34856-34874	Prefrontal-related	_	
171-208	34875-34885	functional	_	
171-209	34886-34900	connectivities	_	
171-210	34901-34907	within	_	
171-211	34908-34911	the	_	
171-212	34912-34919	default	_	
171-213	34920-34927	network	_	
171-214	34928-34931	are	_	
171-215	34932-34941	modulated	_	
171-216	34942-34944	by	_	
171-217	34945-34949	COMT	_	
171-218	34950-34959	val158met	_	
171-219	34960-34962	in	_	
171-220	34963-34970	healthy	_	
171-221	34971-34976	young	_	
171-222	34977-34983	adults	_	
171-223	34984-34992	Cannabis	_	
171-224	34993-34996	use	_	
171-225	34997-35000	and	_	
171-226	35001-35010	cognition	_	
171-227	35011-35013	in	_	
171-228	35014-35027	schizophrenia	_	
171-229	35028-35030	An	_	
171-230	35031-35035	fMRI	_	
171-231	35036-35041	Study	_	
171-232	35042-35044	of	_	
171-233	35045-35053	Neuronal	_	
171-234	35054-35064	Activation	_	
171-235	35065-35067	in	_	
171-236	35068-35081	Schizophrenia	_	
171-237	35082-35090	Patients	_	
171-238	35091-35095	with	_	
171-239	35096-35099	and	_	
171-240	35100-35107	without	_	
171-241	35108-35116	Previous	_	
171-242	35117-35125	Cannabis	_	
171-243	35126-35129	Use	_	
171-244	35130-35138	Cannabis	_	
171-245	35139-35142	and	_	
171-246	35143-35152	cognitive	_	
171-247	35153-35164	performance	_	
171-248	35165-35167	in	_	
171-249	35168-35177	psychosis	_	
171-250	35177-35178	:	_	
171-251	35179-35180	a	_	
171-252	35181-35196	cross-sectional	_	
171-253	35197-35202	study	_	
171-254	35203-35205	in	_	
171-255	35206-35214	patients	_	
171-256	35215-35219	with	_	
171-257	35220-35233	non-affective	_	
171-258	35234-35243	psychotic	_	
171-259	35244-35251	illness	_	
171-260	35252-35255	and	_	
171-261	35256-35261	their	_	
171-262	35262-35272	unaffected	_	
171-263	35273-35281	siblings	_	
171-264	35282-35285	The	_	
171-265	35286-35292	impact	_	
171-266	35293-35295	of	_	
171-267	35296-35302	global	_	
171-268	35303-35309	signal	_	
171-269	35310-35320	regression	_	
171-270	35321-35323	on	_	
171-271	35324-35331	resting	_	
171-272	35332-35337	state	_	
171-273	35338-35350	correlations	_	
171-274	35350-35351	:	_	
171-275	35352-35355	are	_	
171-276	35356-35371	anti-correlated	_	
171-277	35372-35380	networks	_	
171-278	35381-35391	introduced	_	
171-279	35391-35392	?	_	

#Text=A brain on cannabinoids: the role of dopamine release in reward seeking
#Text=Neural correlates of cognitive impairment in schizophrenia
#Text=Influence of cannabis abuse on schizophrenic psychopathology
#Text=Methods to detect, characterize and remove motion artfifact in resting state fMRI
#Text=Effects of cannabis use status on cognitive function, in males with schizophrenia
#Text=The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis
#Text=A default mode of brain function
#Text=Comorbidity of mental disorders with alcohol and other drug abuse.
172-1	35393-35394	A	_	
172-2	35395-35400	brain	_	
172-3	35401-35403	on	_	
172-4	35404-35416	cannabinoids	_	
172-5	35416-35417	:	_	
172-6	35418-35421	the	_	
172-7	35422-35426	role	_	
172-8	35427-35429	of	_	
172-9	35430-35438	dopamine	_	
172-10	35439-35446	release	_	
172-11	35447-35449	in	_	
172-12	35450-35456	reward	_	
172-13	35457-35464	seeking	_	
172-14	35465-35471	Neural	_	
172-15	35472-35482	correlates	_	
172-16	35483-35485	of	_	
172-17	35486-35495	cognitive	_	
172-18	35496-35506	impairment	_	
172-19	35507-35509	in	_	
172-20	35510-35523	schizophrenia	_	
172-21	35524-35533	Influence	_	
172-22	35534-35536	of	_	
172-23	35537-35545	cannabis	_	
172-24	35546-35551	abuse	_	
172-25	35552-35554	on	_	
172-26	35555-35568	schizophrenic	_	
172-27	35569-35584	psychopathology	_	
172-28	35585-35592	Methods	_	
172-29	35593-35595	to	_	
172-30	35596-35602	detect	_	
172-31	35602-35603	,	_	
172-32	35604-35616	characterize	_	
172-33	35617-35620	and	_	
172-34	35621-35627	remove	_	
172-35	35628-35634	motion	_	
172-36	35635-35644	artfifact	_	
172-37	35645-35647	in	_	
172-38	35648-35655	resting	_	
172-39	35656-35661	state	_	
172-40	35662-35666	fMRI	_	
172-41	35667-35674	Effects	_	
172-42	35675-35677	of	_	
172-43	35678-35686	cannabis	_	
172-44	35687-35690	use	_	
172-45	35691-35697	status	_	
172-46	35698-35700	on	_	
172-47	35701-35710	cognitive	_	
172-48	35711-35719	function	_	
172-49	35719-35720	,	_	
172-50	35721-35723	in	_	
172-51	35724-35729	males	_	
172-52	35730-35734	with	_	
172-53	35735-35748	schizophrenia	_	
172-54	35749-35752	The	_	
172-55	35753-35760	effects	_	
172-56	35761-35763	of	_	
172-57	35764-35772	cannabis	_	
172-58	35773-35776	use	_	
172-59	35777-35779	on	_	
172-60	35780-35794	neurocognition	_	
172-61	35795-35797	in	_	
172-62	35798-35811	schizophrenia	_	
172-63	35811-35812	:	_	
172-64	35813-35814	a	_	
172-65	35815-35828	meta-analysis	_	
172-66	35829-35830	A	_	
172-67	35831-35838	default	_	
172-68	35839-35843	mode	_	
172-69	35844-35846	of	_	
172-70	35847-35852	brain	_	
172-71	35853-35861	function	_	
172-72	35862-35873	Comorbidity	_	
172-73	35874-35876	of	_	
172-74	35877-35883	mental	_	
172-75	35884-35893	disorders	_	
172-76	35894-35898	with	_	
172-77	35899-35906	alcohol	_	
172-78	35907-35910	and	_	
172-79	35911-35916	other	_	
172-80	35917-35921	drug	_	
172-81	35922-35927	abuse	_	
172-82	35927-35928	.	_	

#Text=Results from the Epidemiologic Catchment Area (ECA) Study
#Text=Brain network connectivity in individuals with schizophrenia and their siblings
#Text=Trouble at rest: how correlation patterns and group differences become distorted after global signal regression
#Text=The role of cannabis in cognitive functioning of patients with schizophrenia
#Text=The resting brain: unconstrained yet reliable
#Text=Altered resting-state connectivity in subjects at ultra-high risk for psychosis: an fMRI study
#Text=The reliability of the Alcohol Timeline Followback when administered by telephone and by computer
#Text=Cognitive functioning of long-term heavy cannabis users seeking treatment
#Text=Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia
#Text=Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization
#Text=Default mode network activity and connectivity in psychopathology
#Text=Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=Functional resting-state networks are differentially affected in schizophrenia
#Text=The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample
#Text=Effects of cannabis use on outcomes of psychotic disorders: systematic review
#Text=Functional dysconnectivity of the dorsolateral prefrontal cortex in first-episode schizophrenia using resting-state fMRI
#Text=Smoking apparatus and plasma THC levels.
173-1	35929-35936	Results	_	
173-2	35937-35941	from	_	
173-3	35942-35945	the	_	
173-4	35946-35959	Epidemiologic	_	
173-5	35960-35969	Catchment	_	
173-6	35970-35974	Area	_	
173-7	35975-35976	(	_	
173-8	35976-35979	ECA	_	
173-9	35979-35980	)	_	
173-10	35981-35986	Study	_	
173-11	35987-35992	Brain	_	
173-12	35993-36000	network	_	
173-13	36001-36013	connectivity	_	
173-14	36014-36016	in	_	
173-15	36017-36028	individuals	_	
173-16	36029-36033	with	_	
173-17	36034-36047	schizophrenia	_	
173-18	36048-36051	and	_	
173-19	36052-36057	their	_	
173-20	36058-36066	siblings	_	
173-21	36067-36074	Trouble	_	
173-22	36075-36077	at	_	
173-23	36078-36082	rest	_	
173-24	36082-36083	:	_	
173-25	36084-36087	how	_	
173-26	36088-36099	correlation	_	
173-27	36100-36108	patterns	_	
173-28	36109-36112	and	_	
173-29	36113-36118	group	_	
173-30	36119-36130	differences	_	
173-31	36131-36137	become	_	
173-32	36138-36147	distorted	_	
173-33	36148-36153	after	_	
173-34	36154-36160	global	_	
173-35	36161-36167	signal	_	
173-36	36168-36178	regression	_	
173-37	36179-36182	The	_	
173-38	36183-36187	role	_	
173-39	36188-36190	of	_	
173-40	36191-36199	cannabis	_	
173-41	36200-36202	in	_	
173-42	36203-36212	cognitive	_	
173-43	36213-36224	functioning	_	
173-44	36225-36227	of	_	
173-45	36228-36236	patients	_	
173-46	36237-36241	with	_	
173-47	36242-36255	schizophrenia	_	
173-48	36256-36259	The	_	
173-49	36260-36267	resting	_	
173-50	36268-36273	brain	_	
173-51	36273-36274	:	_	
173-52	36275-36288	unconstrained	_	
173-53	36289-36292	yet	_	
173-54	36293-36301	reliable	_	
173-55	36302-36309	Altered	_	
173-56	36310-36323	resting-state	_	
173-57	36324-36336	connectivity	_	
173-58	36337-36339	in	_	
173-59	36340-36348	subjects	_	
173-60	36349-36351	at	_	
173-61	36352-36362	ultra-high	_	
173-62	36363-36367	risk	_	
173-63	36368-36371	for	_	
173-64	36372-36381	psychosis	_	
173-65	36381-36382	:	_	
173-66	36383-36385	an	_	
173-67	36386-36390	fMRI	_	
173-68	36391-36396	study	_	
173-69	36397-36400	The	_	
173-70	36401-36412	reliability	_	
173-71	36413-36415	of	_	
173-72	36416-36419	the	_	
173-73	36420-36427	Alcohol	_	
173-74	36428-36436	Timeline	_	
173-75	36437-36447	Followback	_	
173-76	36448-36452	when	_	
173-77	36453-36465	administered	_	
173-78	36466-36468	by	_	
173-79	36469-36478	telephone	_	
173-80	36479-36482	and	_	
173-81	36483-36485	by	_	
173-82	36486-36494	computer	_	
173-83	36495-36504	Cognitive	_	
173-84	36505-36516	functioning	_	
173-85	36517-36519	of	_	
173-86	36520-36529	long-term	_	
173-87	36530-36535	heavy	_	
173-88	36536-36544	cannabis	_	
173-89	36545-36550	users	_	
173-90	36551-36558	seeking	_	
173-91	36559-36568	treatment	_	
173-92	36569-36578	Real-time	_	
173-93	36579-36589	electronic	_	
173-94	36590-36600	ambulatory	_	
173-95	36601-36611	monitoring	_	
173-96	36612-36614	of	_	
173-97	36615-36624	substance	_	
173-98	36625-36628	use	_	
173-99	36629-36632	and	_	
173-100	36633-36640	symptom	_	
173-101	36641-36651	expression	_	
173-102	36652-36654	in	_	
173-103	36655-36668	schizophrenia	_	
173-104	36669-36678	Intrinsic	_	
173-105	36679-36689	functional	_	
173-106	36690-36702	connectivity	_	
173-107	36703-36705	as	_	
173-108	36706-36707	a	_	
173-109	36708-36712	tool	_	
173-110	36713-36716	for	_	
173-111	36717-36722	human	_	
173-112	36723-36735	connectomics	_	
173-113	36735-36736	:	_	
173-114	36737-36743	theory	_	
173-115	36743-36744	,	_	
173-116	36745-36755	properties	_	
173-117	36755-36756	,	_	
173-118	36757-36760	and	_	
173-119	36761-36773	optimization	_	
173-120	36774-36781	Default	_	
173-121	36782-36786	mode	_	
173-122	36787-36794	network	_	
173-123	36795-36803	activity	_	
173-124	36804-36807	and	_	
173-125	36808-36820	connectivity	_	
173-126	36821-36823	in	_	
173-127	36824-36839	psychopathology	_	
173-128	36840-36844	Conn	_	
173-129	36844-36845	:	_	
173-130	36846-36847	a	_	
173-131	36848-36858	functional	_	
173-132	36859-36871	connectivity	_	
173-133	36872-36879	toolbox	_	
173-134	36880-36883	for	_	
173-135	36884-36894	correlated	_	
173-136	36895-36898	and	_	
173-137	36899-36913	anticorrelated	_	
173-138	36914-36919	brain	_	
173-139	36920-36928	networks	_	
173-140	36929-36942	Hyperactivity	_	
173-141	36943-36946	and	_	
173-142	36947-36964	hyperconnectivity	_	
173-143	36965-36967	of	_	
173-144	36968-36971	the	_	
173-145	36972-36979	default	_	
173-146	36980-36987	network	_	
173-147	36988-36990	in	_	
173-148	36991-37004	schizophrenia	_	
173-149	37005-37008	and	_	
173-150	37009-37011	in	_	
173-151	37012-37024	first-degree	_	
173-152	37025-37034	relatives	_	
173-153	37035-37037	of	_	
173-154	37038-37045	persons	_	
173-155	37046-37050	with	_	
173-156	37051-37064	schizophrenia	_	
173-157	37065-37075	Functional	_	
173-158	37076-37089	resting-state	_	
173-159	37090-37098	networks	_	
173-160	37099-37102	are	_	
173-161	37103-37117	differentially	_	
173-162	37118-37126	affected	_	
173-163	37127-37129	in	_	
173-164	37130-37143	schizophrenia	_	
173-165	37144-37147	The	_	
173-166	37148-37154	impact	_	
173-167	37155-37157	of	_	
173-168	37158-37166	cannabis	_	
173-169	37167-37170	use	_	
173-170	37171-37173	on	_	
173-171	37174-37183	cognitive	_	
173-172	37184-37195	functioning	_	
173-173	37196-37198	in	_	
173-174	37199-37207	patients	_	
173-175	37208-37212	with	_	
173-176	37213-37226	schizophrenia	_	
173-177	37226-37227	:	_	
173-178	37228-37229	a	_	
173-179	37230-37243	meta-analysis	_	
173-180	37244-37246	of	_	
173-181	37247-37255	existing	_	
173-182	37256-37264	findings	_	
173-183	37265-37268	and	_	
173-184	37269-37272	new	_	
173-185	37273-37277	data	_	
173-186	37278-37280	in	_	
173-187	37281-37282	a	_	
173-188	37283-37296	first-episode	_	
173-189	37297-37303	sample	_	
173-190	37304-37311	Effects	_	
173-191	37312-37314	of	_	
173-192	37315-37323	cannabis	_	
173-193	37324-37327	use	_	
173-194	37328-37330	on	_	
173-195	37331-37339	outcomes	_	
173-196	37340-37342	of	_	
173-197	37343-37352	psychotic	_	
173-198	37353-37362	disorders	_	
173-199	37362-37363	:	_	
173-200	37364-37374	systematic	_	
173-201	37375-37381	review	_	
173-202	37382-37392	Functional	_	
173-203	37393-37408	dysconnectivity	_	
173-204	37409-37411	of	_	
173-205	37412-37415	the	_	
173-206	37416-37428	dorsolateral	_	
173-207	37429-37439	prefrontal	_	
173-208	37440-37446	cortex	_	
173-209	37447-37449	in	_	
173-210	37450-37463	first-episode	_	
173-211	37464-37477	schizophrenia	_	
173-212	37478-37483	using	_	
173-213	37484-37497	resting-state	_	
173-214	37498-37502	fMRI	_	
173-215	37503-37510	Smoking	_	
173-216	37511-37520	apparatus	_	
173-217	37521-37524	and	_	
173-218	37525-37531	plasma	_	
173-219	37532-37535	THC	_	
173-220	37536-37542	levels	_	
173-221	37542-37543	.	_	

#Text=(a) Smoking apparatus consisting of a transparent chamber into which joint was inserted.
174-1	37544-37545	(	_	
174-2	37545-37546	a	_	
174-3	37546-37547	)	_	
174-4	37548-37555	Smoking	_	
174-5	37556-37565	apparatus	_	
174-6	37566-37576	consisting	_	
174-7	37577-37579	of	_	
174-8	37580-37581	a	_	
174-9	37582-37593	transparent	_	
174-10	37594-37601	chamber	_	
174-11	37602-37606	into	_	
174-12	37607-37612	which	_	
174-13	37613-37618	joint	_	
174-14	37619-37622	was	_	
174-15	37623-37631	inserted	_	
174-16	37631-37632	.	_	

#Text=Patients smoked a placebo or active cannabis cigarette immediately prior to scanning (note: photo taken of member of research team, not study participant).
175-1	37633-37641	Patients	_	
175-2	37642-37648	smoked	_	
175-3	37649-37650	a	_	
175-4	37651-37658	placebo	_	
175-5	37659-37661	or	_	
175-6	37662-37668	active	_	
175-7	37669-37677	cannabis	_	
175-8	37678-37687	cigarette	_	
175-9	37688-37699	immediately	_	
175-10	37700-37705	prior	_	
175-11	37706-37708	to	_	
175-12	37709-37717	scanning	_	
175-13	37718-37719	(	_	
175-14	37719-37723	note	_	
175-15	37723-37724	:	_	
175-16	37725-37730	photo	_	
175-17	37731-37736	taken	_	
175-18	37737-37739	of	_	
175-19	37740-37746	member	_	
175-20	37747-37749	of	_	
175-21	37750-37758	research	_	
175-22	37759-37763	team	_	
175-23	37763-37764	,	_	
175-24	37765-37768	not	_	
175-25	37769-37774	study	_	
175-26	37775-37786	participant	_	
175-27	37786-37787	)	_	
175-28	37787-37788	.	_	

#Text=(b) Plasma THC levels in the patient group showed significant increases immediately prior to scanning as compared to baseline (p<0.05).
176-1	37789-37790	(	_	
176-2	37790-37791	b	_	
176-3	37791-37792	)	_	
176-4	37793-37799	Plasma	_	
176-5	37800-37803	THC	_	
176-6	37804-37810	levels	_	
176-7	37811-37813	in	_	
176-8	37814-37817	the	_	
176-9	37818-37825	patient	_	
176-10	37826-37831	group	_	
176-11	37832-37838	showed	_	
176-12	37839-37850	significant	_	
176-13	37851-37860	increases	_	
176-14	37861-37872	immediately	_	
176-15	37873-37878	prior	_	
176-16	37879-37881	to	_	
176-17	37882-37890	scanning	_	
176-18	37891-37893	as	_	
176-19	37894-37902	compared	_	
176-20	37903-37905	to	_	
176-21	37906-37914	baseline	_	
176-22	37915-37916	(	_	
176-23	37916-37917	p	_	
176-24	37917-37918	<	_	
176-25	37918-37922	0.05	_	
176-26	37922-37923	)	_	
176-27	37923-37924	.	_	

#Text=Immediately prior to WM assessment, approximately 30 minutes post scanning, plasma THC levels were somewhat higher (p = 0.053 as compared to baseline), but showed a significant decline from immediately post-intervention resting scan (p<0.05).
177-1	37925-37936	Immediately	_	
177-2	37937-37942	prior	_	
177-3	37943-37945	to	_	
177-4	37946-37948	WM	_	
177-5	37949-37959	assessment	_	
177-6	37959-37960	,	_	
177-7	37961-37974	approximately	_	
177-8	37975-37977	30	_	
177-9	37978-37985	minutes	_	
177-10	37986-37990	post	_	
177-11	37991-37999	scanning	_	
177-12	37999-38000	,	_	
177-13	38001-38007	plasma	_	
177-14	38008-38011	THC	_	
177-15	38012-38018	levels	_	
177-16	38019-38023	were	_	
177-17	38024-38032	somewhat	_	
177-18	38033-38039	higher	_	
177-19	38040-38041	(	_	
177-20	38041-38042	p	_	
177-21	38043-38044	=	_	
177-22	38045-38050	0.053	_	
177-23	38051-38053	as	_	
177-24	38054-38062	compared	_	
177-25	38063-38065	to	_	
177-26	38066-38074	baseline	_	
177-27	38074-38075	)	_	
177-28	38075-38076	,	_	
177-29	38077-38080	but	_	
177-30	38081-38087	showed	_	
177-31	38088-38089	a	_	
177-32	38090-38101	significant	_	
177-33	38102-38109	decline	_	
177-34	38110-38114	from	_	
177-35	38115-38126	immediately	_	
177-36	38127-38144	post-intervention	_	
177-37	38145-38152	resting	_	
177-38	38153-38157	scan	_	
177-39	38158-38159	(	_	
177-40	38159-38160	p	_	
177-41	38160-38161	<	_	
177-42	38161-38165	0.05	_	
177-43	38165-38166	)	_	
177-44	38166-38167	.	_	

#Text=Functional connectivity of the DMN at baseline (T1) in control participants (left column), patients with SCZ and CUD (middle column), and between group comparison (patients > controls) (right column).
178-1	38168-38178	Functional	_	
178-2	38179-38191	connectivity	_	
178-3	38192-38194	of	_	
178-4	38195-38198	the	_	
178-5	38199-38202	DMN	_	
178-6	38203-38205	at	_	
178-7	38206-38214	baseline	_	
178-8	38215-38216	(	_	
178-9	38216-38218	T1	_	
178-10	38218-38219	)	_	
178-11	38220-38222	in	_	
178-12	38223-38230	control	_	
178-13	38231-38243	participants	_	
178-14	38244-38245	(	_	
178-15	38245-38249	left	_	
178-16	38250-38256	column	_	
178-17	38256-38257	)	_	
178-18	38257-38258	,	_	
178-19	38259-38267	patients	_	
178-20	38268-38272	with	_	
178-21	38273-38276	SCZ	_	
178-22	38277-38280	and	_	
178-23	38281-38284	CUD	_	
178-24	38285-38286	(	_	
178-25	38286-38292	middle	_	
178-26	38293-38299	column	_	
178-27	38299-38300	)	_	
178-28	38300-38301	,	_	
178-29	38302-38305	and	_	
178-30	38306-38313	between	_	
178-31	38314-38319	group	_	
178-32	38320-38330	comparison	_	
178-33	38331-38332	(	_	
178-34	38332-38340	patients	_	
178-35	38341-38342	>	_	
178-36	38343-38351	controls	_	
178-37	38351-38352	)	_	
178-38	38353-38354	(	_	
178-39	38354-38359	right	_	
178-40	38360-38366	column	_	
178-41	38366-38367	)	_	
178-42	38367-38368	.	_	

#Text=(a) Positive connectivity of the DMN (MPFC seed) revealing DMN hyperconnectivity in patients with SCZ and co-occurring CUD relative to controls (L medial view).
179-1	38369-38370	(	_	
179-2	38370-38371	a	_	
179-3	38371-38372	)	_	
179-4	38373-38381	Positive	_	
179-5	38382-38394	connectivity	_	
179-6	38395-38397	of	_	
179-7	38398-38401	the	_	
179-8	38402-38405	DMN	_	
179-9	38406-38407	(	_	
179-10	38407-38411	MPFC	_	
179-11	38412-38416	seed	_	
179-12	38416-38417	)	_	
179-13	38418-38427	revealing	_	
179-14	38428-38431	DMN	_	
179-15	38432-38449	hyperconnectivity	_	
179-16	38450-38452	in	_	
179-17	38453-38461	patients	_	
179-18	38462-38466	with	_	
179-19	38467-38470	SCZ	_	
179-20	38471-38474	and	_	
179-21	38475-38487	co-occurring	_	
179-22	38488-38491	CUD	_	
179-23	38492-38500	relative	_	
179-24	38501-38503	to	_	
179-25	38504-38512	controls	_	
179-26	38513-38514	(	_	
179-27	38514-38515	L	_	
179-28	38516-38522	medial	_	
179-29	38523-38527	view	_	
179-30	38527-38528	)	_	
179-31	38528-38529	.	_	

#Text=(b) Brain regions significantly anticorrelated with the MPFC seed showing significantly greater MPFC-DLPFC anticorrelation in controls relative to patients (R lateral view).
180-1	38530-38531	(	_	
180-2	38531-38532	b	_	
180-3	38532-38533	)	_	
180-4	38534-38539	Brain	_	
180-5	38540-38547	regions	_	
180-6	38548-38561	significantly	_	
180-7	38562-38576	anticorrelated	_	
180-8	38577-38581	with	_	
180-9	38582-38585	the	_	
180-10	38586-38590	MPFC	_	
180-11	38591-38595	seed	_	
180-12	38596-38603	showing	_	
180-13	38604-38617	significantly	_	
180-14	38618-38625	greater	_	
180-15	38626-38636	MPFC-DLPFC	_	
180-16	38637-38652	anticorrelation	_	
180-17	38653-38655	in	_	
180-18	38656-38664	controls	_	
180-19	38665-38673	relative	_	
180-20	38674-38676	to	_	
180-21	38677-38685	patients	_	
180-22	38686-38687	(	_	
180-23	38687-38688	R	_	
180-24	38689-38696	lateral	_	
180-25	38697-38701	view	_	
180-26	38701-38702	)	_	
180-27	38702-38703	.	_	

#Text=Connectivity values, quantified as z scores, are shown in the right-hand column.
181-1	38704-38716	Connectivity	_	
181-2	38717-38723	values	_	
181-3	38723-38724	,	_	
181-4	38725-38735	quantified	_	
181-5	38736-38738	as	_	
181-6	38739-38740	z	_	
181-7	38741-38747	scores	_	
181-8	38747-38748	,	_	
181-9	38749-38752	are	_	
181-10	38753-38758	shown	_	
181-11	38759-38761	in	_	
181-12	38762-38765	the	_	
181-13	38766-38776	right-hand	_	
181-14	38777-38783	column	_	
181-15	38783-38784	.	_	

#Text=DMN connectivity in the patients with SCZ and CUD associated with PANSS positive symptom score.
182-1	38785-38788	DMN	_	
182-2	38789-38801	connectivity	_	
182-3	38802-38804	in	_	
182-4	38805-38808	the	_	
182-5	38809-38817	patients	_	
182-6	38818-38822	with	_	
182-7	38823-38826	SCZ	_	
182-8	38827-38830	and	_	
182-9	38831-38834	CUD	_	
182-10	38835-38845	associated	_	
182-11	38846-38850	with	_	
182-12	38851-38856	PANSS	_	
182-13	38857-38865	positive	_	
182-14	38866-38873	symptom	_	
182-15	38874-38879	score	_	
182-16	38879-38880	.	_	

#Text=Connectivity between (a) the MPFC seed and (b) Precuneus significantly correlated with PANSS total symptom score in the patient group at baseline T1.
183-1	38881-38893	Connectivity	_	
183-2	38894-38901	between	_	
183-3	38902-38903	(	_	
183-4	38903-38904	a	_	
183-5	38904-38905	)	_	
183-6	38906-38909	the	_	
183-7	38910-38914	MPFC	_	
183-8	38915-38919	seed	_	
183-9	38920-38923	and	_	
183-10	38924-38925	(	_	
183-11	38925-38926	b	_	
183-12	38926-38927	)	_	
183-13	38928-38937	Precuneus	_	
183-14	38938-38951	significantly	_	
183-15	38952-38962	correlated	_	
183-16	38963-38967	with	_	
183-17	38968-38973	PANSS	_	
183-18	38974-38979	total	_	
183-19	38980-38987	symptom	_	
183-20	38988-38993	score	_	
183-21	38994-38996	in	_	
183-22	38997-39000	the	_	
183-23	39001-39008	patient	_	
183-24	39009-39014	group	_	
183-25	39015-39017	at	_	
183-26	39018-39026	baseline	_	
183-27	39027-39029	T1	_	
183-28	39029-39030	.	_	

#Text=The x-axis indicates PANSS positive symptoms score and the y-axis shows strength of MPFC-Precuneus connectivity, quantified as z scores (p = 0.04, r= 0.65).
184-1	39031-39034	The	_	
184-2	39035-39041	x-axis	_	
184-3	39042-39051	indicates	_	
184-4	39052-39057	PANSS	_	
184-5	39058-39066	positive	_	
184-6	39067-39075	symptoms	_	
184-7	39076-39081	score	_	
184-8	39082-39085	and	_	
184-9	39086-39089	the	_	
184-10	39090-39096	y-axis	_	
184-11	39097-39102	shows	_	
184-12	39103-39111	strength	_	
184-13	39112-39114	of	_	
184-14	39115-39129	MPFC-Precuneus	_	
184-15	39130-39142	connectivity	_	
184-16	39142-39143	,	_	
184-17	39144-39154	quantified	_	
184-18	39155-39157	as	_	
184-19	39158-39159	z	_	
184-20	39160-39166	scores	_	
184-21	39167-39168	(	_	
184-22	39168-39169	p	_	
184-23	39170-39171	=	_	
184-24	39172-39176	0.04	_	
184-25	39176-39177	,	_	
184-26	39178-39179	r	_	
184-27	39179-39180	=	_	
184-28	39181-39185	0.65	_	
184-29	39185-39186	)	_	
184-30	39186-39187	.	_	

#Text=Change in DMN connectivity in control participants (left column), patients with SCZ and CUD (middle column) from T1 to T2 (expressed as T2-T1), and between group comparison at T2 (patients > controls) (right column).
185-1	39188-39194	Change	_	
185-2	39195-39197	in	_	
185-3	39198-39201	DMN	_	
185-4	39202-39214	connectivity	_	
185-5	39215-39217	in	_	
185-6	39218-39225	control	_	
185-7	39226-39238	participants	_	
185-8	39239-39240	(	_	
185-9	39240-39244	left	_	
185-10	39245-39251	column	_	
185-11	39251-39252	)	_	
185-12	39252-39253	,	_	
185-13	39254-39262	patients	_	
185-14	39263-39267	with	_	
185-15	39268-39271	SCZ	_	
185-16	39272-39275	and	_	
185-17	39276-39279	CUD	_	
185-18	39280-39281	(	_	
185-19	39281-39287	middle	_	
185-20	39288-39294	column	_	
185-21	39294-39295	)	_	
185-22	39296-39300	from	_	
185-23	39301-39303	T1	_	
185-24	39304-39306	to	_	
185-25	39307-39309	T2	_	
185-26	39310-39311	(	_	
185-27	39311-39320	expressed	_	
185-28	39321-39323	as	_	
185-29	39324-39326	T2	_	
185-30	39326-39327	-	_	
185-31	39327-39329	T1	_	
185-32	39329-39330	)	_	
185-33	39330-39331	,	_	
185-34	39332-39335	and	_	
185-35	39336-39343	between	_	
185-36	39344-39349	group	_	
185-37	39350-39360	comparison	_	
185-38	39361-39363	at	_	
185-39	39364-39366	T2	_	
185-40	39367-39368	(	_	
185-41	39368-39376	patients	_	
185-42	39377-39378	>	_	
185-43	39379-39387	controls	_	
185-44	39387-39388	)	_	
185-45	39389-39390	(	_	
185-46	39390-39395	right	_	
185-47	39396-39402	column	_	
185-48	39402-39403	)	_	
185-49	39403-39404	.	_	

#Text=(a) Within group contrast showing no significant within group change in healthy controls (T2-T1; paired t-test), reduction in DMN hyperconnectivity in patients (T2-T1, paired t-test), and ongoing but attenuated hyperconnectivity in patients relative to controls (between group contrast).
186-1	39405-39406	(	_	
186-2	39406-39407	a	_	
186-3	39407-39408	)	_	
186-4	39409-39415	Within	_	
186-5	39416-39421	group	_	
186-6	39422-39430	contrast	_	
186-7	39431-39438	showing	_	
186-8	39439-39441	no	_	
186-9	39442-39453	significant	_	
186-10	39454-39460	within	_	
186-11	39461-39466	group	_	
186-12	39467-39473	change	_	
186-13	39474-39476	in	_	
186-14	39477-39484	healthy	_	
186-15	39485-39493	controls	_	
186-16	39494-39495	(	_	
186-17	39495-39497	T2	_	
186-18	39497-39498	-	_	
186-19	39498-39500	T1	_	
186-20	39500-39501	;	_	
186-21	39502-39508	paired	_	
186-22	39509-39515	t-test	_	
186-23	39515-39516	)	_	
186-24	39516-39517	,	_	
186-25	39518-39527	reduction	_	
186-26	39528-39530	in	_	
186-27	39531-39534	DMN	_	
186-28	39535-39552	hyperconnectivity	_	
186-29	39553-39555	in	_	
186-30	39556-39564	patients	_	
186-31	39565-39566	(	_	
186-32	39566-39568	T2	_	
186-33	39568-39569	-	_	
186-34	39569-39571	T1	_	
186-35	39571-39572	,	_	
186-36	39573-39579	paired	_	
186-37	39580-39586	t-test	_	
186-38	39586-39587	)	_	
186-39	39587-39588	,	_	
186-40	39589-39592	and	_	
186-41	39593-39600	ongoing	_	
186-42	39601-39604	but	_	
186-43	39605-39615	attenuated	_	
186-44	39616-39633	hyperconnectivity	_	
186-45	39634-39636	in	_	
186-46	39637-39645	patients	_	
186-47	39646-39654	relative	_	
186-48	39655-39657	to	_	
186-49	39658-39666	controls	_	
186-50	39667-39668	(	_	
186-51	39668-39675	between	_	
186-52	39676-39681	group	_	
186-53	39682-39690	contrast	_	
186-54	39690-39691	)	_	
186-55	39691-39692	.	_	

#Text=(b) Within group contrast showed no significant change in DMN-DLPFC anticorrelation found in healthy controls (T2-T1; paired t-test), a significant increase in MPFC-DLPFC anticorrelation subsequent to cannabinoid administration (T2-T1; paired t-test) and no significant difference in strength of MPFC-to-DLPFC anticorrelation (controls vs. patients at T2).
187-1	39693-39694	(	_	
187-2	39694-39695	b	_	
187-3	39695-39696	)	_	
187-4	39697-39703	Within	_	
187-5	39704-39709	group	_	
187-6	39710-39718	contrast	_	
187-7	39719-39725	showed	_	
187-8	39726-39728	no	_	
187-9	39729-39740	significant	_	
187-10	39741-39747	change	_	
187-11	39748-39750	in	_	
187-12	39751-39760	DMN-DLPFC	_	
187-13	39761-39776	anticorrelation	_	
187-14	39777-39782	found	_	
187-15	39783-39785	in	_	
187-16	39786-39793	healthy	_	
187-17	39794-39802	controls	_	
187-18	39803-39804	(	_	
187-19	39804-39806	T2	_	
187-20	39806-39807	-	_	
187-21	39807-39809	T1	_	
187-22	39809-39810	;	_	
187-23	39811-39817	paired	_	
187-24	39818-39824	t-test	_	
187-25	39824-39825	)	_	
187-26	39825-39826	,	_	
187-27	39827-39828	a	_	
187-28	39829-39840	significant	_	
187-29	39841-39849	increase	_	
187-30	39850-39852	in	_	
187-31	39853-39863	MPFC-DLPFC	_	
187-32	39864-39879	anticorrelation	_	
187-33	39880-39890	subsequent	_	
187-34	39891-39893	to	_	
187-35	39894-39905	cannabinoid	_	
187-36	39906-39920	administration	_	
187-37	39921-39922	(	_	
187-38	39922-39924	T2	_	
187-39	39924-39925	-	_	
187-40	39925-39927	T1	_	
187-41	39927-39928	;	_	
187-42	39929-39935	paired	_	
187-43	39936-39942	t-test	_	
187-44	39942-39943	)	_	
187-45	39944-39947	and	_	
187-46	39948-39950	no	_	
187-47	39951-39962	significant	_	
187-48	39963-39973	difference	_	
187-49	39974-39976	in	_	
187-50	39977-39985	strength	_	
187-51	39986-39988	of	_	
187-52	39989-40002	MPFC-to-DLPFC	_	
187-53	40003-40018	anticorrelation	_	
187-54	40019-40020	(	_	
187-55	40020-40028	controls	_	
187-56	40029-40031	vs	_	
187-57	40031-40032	.	_	
187-58	40033-40041	patients	_	
187-59	40042-40044	at	_	
187-60	40045-40047	T2	_	
187-61	40047-40048	)	_	
187-62	40048-40049	.	_	

#Text=All results shown were significant at whole brain p<0.001 cluster level, FDR-corrected.
188-1	40050-40053	All	_	
188-2	40054-40061	results	_	
188-3	40062-40067	shown	_	
188-4	40068-40072	were	_	
188-5	40073-40084	significant	_	
188-6	40085-40087	at	_	
188-7	40088-40093	whole	_	
188-8	40094-40099	brain	_	
188-9	40100-40101	p	_	
188-10	40101-40102	<	_	
188-11	40102-40107	0.001	_	
188-12	40108-40115	cluster	_	
188-13	40116-40121	level	_	
188-14	40121-40122	,	_	
188-15	40123-40136	FDR-corrected	_	
188-16	40136-40137	.	_	

#Text=MPFC-DLPFC anticorrelation association with WM performance.
189-1	40138-40148	MPFC-DLPFC	_	
189-2	40149-40164	anticorrelation	_	
189-3	40165-40176	association	_	
189-4	40177-40181	with	_	
189-5	40182-40184	WM	_	
189-6	40185-40196	performance	_	
189-7	40196-40197	.	_	

#Text=The strength of anticorrelation between (a) the MPFC seed and (b) the right DLPFC significantly correlated (p<0.05) with WM performance (p<0.05) in the control group at (c) the initial T1 scan session, (d) the control group at T2, and (e) the patient group at T2 following cannabinoid administration.
190-1	40198-40201	The	_	
190-2	40202-40210	strength	_	
190-3	40211-40213	of	_	
190-4	40214-40229	anticorrelation	_	
190-5	40230-40237	between	_	
190-6	40238-40239	(	_	
190-7	40239-40240	a	_	
190-8	40240-40241	)	_	
190-9	40242-40245	the	_	
190-10	40246-40250	MPFC	_	
190-11	40251-40255	seed	_	
190-12	40256-40259	and	_	
190-13	40260-40261	(	_	
190-14	40261-40262	b	_	
190-15	40262-40263	)	_	
190-16	40264-40267	the	_	
190-17	40268-40273	right	_	
190-18	40274-40279	DLPFC	_	
190-19	40280-40293	significantly	_	
190-20	40294-40304	correlated	_	
190-21	40305-40306	(	_	
190-22	40306-40307	p	_	
190-23	40307-40308	<	_	
190-24	40308-40312	0.05	_	
190-25	40312-40313	)	_	
190-26	40314-40318	with	_	
190-27	40319-40321	WM	_	
190-28	40322-40333	performance	_	
190-29	40334-40335	(	_	
190-30	40335-40336	p	_	
190-31	40336-40337	<	_	
190-32	40337-40341	0.05	_	
190-33	40341-40342	)	_	
190-34	40343-40345	in	_	
190-35	40346-40349	the	_	
190-36	40350-40357	control	_	
190-37	40358-40363	group	_	
190-38	40364-40366	at	_	
190-39	40367-40368	(	_	
190-40	40368-40369	c	_	
190-41	40369-40370	)	_	
190-42	40371-40374	the	_	
190-43	40375-40382	initial	_	
190-44	40383-40385	T1	_	
190-45	40386-40390	scan	_	
190-46	40391-40398	session	_	
190-47	40398-40399	,	_	
190-48	40400-40401	(	_	
190-49	40401-40402	d	_	
190-50	40402-40403	)	_	
190-51	40404-40407	the	_	
190-52	40408-40415	control	_	
190-53	40416-40421	group	_	
190-54	40422-40424	at	_	
190-55	40425-40427	T2	_	
190-56	40427-40428	,	_	
190-57	40429-40432	and	_	
190-58	40433-40434	(	_	
190-59	40434-40435	e	_	
190-60	40435-40436	)	_	
190-61	40437-40440	the	_	
190-62	40441-40448	patient	_	
190-63	40449-40454	group	_	
190-64	40455-40457	at	_	
190-65	40458-40460	T2	_	
190-66	40461-40470	following	_	
190-67	40471-40482	cannabinoid	_	
190-68	40483-40497	administration	_	
190-69	40497-40498	.	_	

#Text=The x-axis indicates performance on the WAIS-III Letter Number Sequencing Test, and the y-axis shows strength of MPFC-DLPFC anticorrelation quantified as z scores.
191-1	40499-40502	The	_	
191-2	40503-40509	x-axis	_	
191-3	40510-40519	indicates	_	
191-4	40520-40531	performance	_	
191-5	40532-40534	on	_	
191-6	40535-40538	the	_	
191-7	40539-40547	WAIS-III	_	
191-8	40548-40554	Letter	_	
191-9	40555-40561	Number	_	
191-10	40562-40572	Sequencing	_	
191-11	40573-40577	Test	_	
191-12	40577-40578	,	_	
191-13	40579-40582	and	_	
191-14	40583-40586	the	_	
191-15	40587-40593	y-axis	_	
191-16	40594-40599	shows	_	
191-17	40600-40608	strength	_	
191-18	40609-40611	of	_	
191-19	40612-40622	MPFC-DLPFC	_	
191-20	40623-40638	anticorrelation	_	
191-21	40639-40649	quantified	_	
191-22	40650-40652	as	_	
191-23	40653-40654	z	_	
191-24	40655-40661	scores	_	
191-25	40661-40662	.	_	

#Text=Participant demographic information.
192-1	40663-40674	Participant	_	
192-2	40675-40686	demographic	_	
192-3	40687-40698	information	_	
192-4	40698-40699	.	_	

#Text=Healthy controls (n = 12)\tCannabis (n = 6)\tTHC (n = 6)\t \tAge* (years)\t33.5 ± 7.8\t36.2 ± 9.60\t32.17 ± 8.32\t \tEducation (years)\t16.1 ± 1.7\t9.6 ± 1.50\t11.83 ± 1.34\t \tMean parental education*\t14.2 ± 2.9\t13 ± 1.41\t12.83 ± 2.19\t \tGender*\t3 F,9 M\t1 F,5 M\t2 F,2 M\t \tHandedness*\t1 L,11 R\t1 L,5 R\t0 L,6 R\t \t
#Text=Abbreviations: F, female; M, male; L, left; R, right.
193-1	40701-40708	Healthy	_	
193-2	40709-40717	controls	_	
193-3	40718-40719	(	_	
193-4	40719-40720	n	_	
193-5	40721-40722	=	_	
193-6	40723-40725	12	_	
193-7	40725-40726	)	_	
193-8	40727-40735	Cannabis	_	
193-9	40736-40737	(	_	
193-10	40737-40738	n	_	
193-11	40739-40740	=	_	
193-12	40741-40742	6	_	
193-13	40742-40743	)	_	
193-14	40744-40747	THC	_	
193-15	40748-40749	(	_	
193-16	40749-40750	n	_	
193-17	40751-40752	=	_	
193-18	40753-40754	6	_	
193-19	40754-40755	)	_	
193-20	40758-40761	Age	_	
193-21	40761-40762	*	_	
193-22	40763-40764	(	_	
193-23	40764-40769	years	_	
193-24	40769-40770	)	_	
193-25	40771-40775	33.5	_	
193-26	40776-40777	±	_	
193-27	40778-40781	7.8	_	
193-28	40782-40786	36.2	_	
193-29	40787-40788	±	_	
193-30	40789-40793	9.60	_	
193-31	40794-40799	32.17	_	
193-32	40800-40801	±	_	
193-33	40802-40806	8.32	_	
193-34	40809-40818	Education	_	
193-35	40819-40820	(	_	
193-36	40820-40825	years	_	
193-37	40825-40826	)	_	
193-38	40827-40831	16.1	_	
193-39	40832-40833	±	_	
193-40	40834-40837	1.7	_	
193-41	40838-40841	9.6	_	
193-42	40842-40843	±	_	
193-43	40844-40848	1.50	_	
193-44	40849-40854	11.83	_	
193-45	40855-40856	±	_	
193-46	40857-40861	1.34	_	
193-47	40864-40868	Mean	_	
193-48	40869-40877	parental	_	
193-49	40878-40887	education	_	
193-50	40887-40888	*	_	
193-51	40889-40893	14.2	_	
193-52	40894-40895	±	_	
193-53	40896-40899	2.9	_	
193-54	40900-40902	13	_	
193-55	40903-40904	±	_	
193-56	40905-40909	1.41	_	
193-57	40910-40915	12.83	_	
193-58	40916-40917	±	_	
193-59	40918-40922	2.19	_	
193-60	40925-40931	Gender	_	
193-61	40931-40932	*	_	
193-62	40933-40934	3	_	
193-63	40935-40936	F	_	
193-64	40936-40937	,	_	
193-65	40937-40938	9	_	
193-66	40939-40940	M	_	
193-67	40941-40942	1	_	
193-68	40943-40944	F	_	
193-69	40944-40945	,	_	
193-70	40945-40946	5	_	
193-71	40947-40948	M	_	
193-72	40949-40950	2	_	
193-73	40951-40952	F	_	
193-74	40952-40953	,	_	
193-75	40953-40954	2	_	
193-76	40955-40956	M	_	
193-77	40959-40969	Handedness	_	
193-78	40969-40970	*	_	
193-79	40971-40972	1	_	
193-80	40973-40974	L	_	
193-81	40974-40975	,	_	
193-82	40975-40977	11	_	
193-83	40978-40979	R	_	
193-84	40980-40981	1	_	
193-85	40982-40983	L	_	
193-86	40983-40984	,	_	
193-87	40984-40985	5	_	
193-88	40986-40987	R	_	
193-89	40988-40989	0	_	
193-90	40990-40991	L	_	
193-91	40991-40992	,	_	
193-92	40992-40993	6	_	
193-93	40994-40995	R	_	
193-94	40999-41012	Abbreviations	_	
193-95	41012-41013	:	_	
193-96	41014-41015	F	_	
193-97	41015-41016	,	_	
193-98	41017-41023	female	_	
193-99	41023-41024	;	_	
193-100	41025-41026	M	_	
193-101	41026-41027	,	_	
193-102	41028-41032	male	_	
193-103	41032-41033	;	_	
193-104	41034-41035	L	_	
193-105	41035-41036	,	_	
193-106	41037-41041	left	_	
193-107	41041-41042	;	_	
193-108	41043-41044	R	_	
193-109	41044-41045	,	_	
193-110	41046-41051	right	_	
193-111	41051-41052	.	_	

#Text=Data are reported as mean ± standard deviation where applicable.
194-1	41053-41057	Data	_	
194-2	41058-41061	are	_	
194-3	41062-41070	reported	_	
194-4	41071-41073	as	_	
194-5	41074-41078	mean	_	
194-6	41079-41080	±	_	
194-7	41081-41089	standard	_	
194-8	41090-41099	deviation	_	
194-9	41100-41105	where	_	
194-10	41106-41116	applicable	_	
194-11	41116-41117	.	_	

#Text=Ethnicity not included as all subjects identified as Caucasian.
195-1	41118-41127	Ethnicity	_	
195-2	41128-41131	not	_	
195-3	41132-41140	included	_	
195-4	41141-41143	as	_	
195-5	41144-41147	all	_	
195-6	41148-41156	subjects	_	
195-7	41157-41167	identified	_	
195-8	41168-41170	as	_	
195-9	41171-41180	Caucasian	_	
195-10	41180-41181	.	_	

#Text=No statistically significant between group difference.
196-1	41182-41184	No	_	
196-2	41185-41198	statistically	_	
196-3	41199-41210	significant	_	
196-4	41211-41218	between	_	
196-5	41219-41224	group	_	
196-6	41225-41235	difference	_	
196-7	41235-41236	.	_	
